Lymphocytes
The Practical Approach Series SERIES EDITOR B. D. HAMES Department of Biochemistry and Molecular Biology University of Leeds, Leeds LS2 9JT, UK
See also the Practical Approach web site at http://www.oup.co.uk/PAS * indicates new and forthcoming titles Affinity Chromatography Affinity Separations Anaerobic Microbiology Animal Cell Culture (2nd edition) Animal Virus Pathogenesis Antibodies I and II Antibody Engineering Antisense Technology * Apoptosis Applied Microbial Physiology Basic Cell Culture Behavioural Neuroscience Bioenergetics Biological Data Analysis Biomechanics—Materials Biomechanics—Structures and Systems Biosensors * C. elegans Carbohydrate Analysis (2nd edition) Cell-Cell Interactions The Cell Cycle
* Cell Growth, Differentiation and Senescence * Cell Separation Cellular Calcium Cellular Interactions in Development Cellular Neurobiology Chrornatin * Chromosome Structural Analysis Clinical Immunology Complement * Crystallization of Nucleic Acids and Proteins (2nd edition) Cytokines (2nd edition) The Cytoskeleton Diagnostic Molecular Pathology I and II DNA and Protein Sequence Analysis DNA Cloning 1: Core Techniques (2nd edition) DNA Cloning 2: Expression Systems (2nd edition)
if *
*
*
*
*
DNA Cloning 3: Complex Genomes (2nd edition) DNA Cloning 4: Mammalian Systems (2nd edition) DNA Microarrays DNA Viruses Drosophila (2nd edition) Electron Microscopy in Biology Electron Microscopy in Molecular Biology Electrophysiology Enzyme Assays Epithelial Cell Culture Essential Developmental Biology Essential Molecular Biology I and II Eukaryotic DNA Replication Experimental Neuroanatomy Extracellular Matrix Flow Cytometry (2nd edition) Free Radicals Gel Electrophoresis of Nucleic Acids (2nd edition) Gel Electrophoresis of Proteins (3rd edition) Gene Probes 1 and 2 Gene Targeting (2nd edition) Gene Transcription Genome Mapping Glycobiology Growth Factors and Receptors Haemopoiesis High Resolution Chromotography Histocompatibility Testing
if if
* *
*
if
HIV Volumes 1 and 2 HPLC of Macromolecules (2nd edition) Human Cytogenetics I and II (2nd edition) Human Genetic Disease Analysis Image Processing and Analysis Immobilized Biomolecules in Analysis Immunochemistry 1 Immunochemistry 2 Immunocytochemistry Imnundiagnostics In Situ Hybridization (2nd edition) lodinated Density Gradient Media Ion Channels Light Microscopy (2nd edition) Lipid Modification of Proteins Lipoprotein Analysis Liposomes Lymphocytes (2nd edition) Mammalian Cell Biotechnology Medical Parasitology Medical Virology MHC Volumes 1 and 2 Molecular Genetic Analysis of Populations (2nd edition) Molecular Genetics of Yeast Molecular Imaging in Neuroscience Molecular Plant Pathology I and II Molecular Virology
Monitoring Neuronal Activity if Mouse Genetics and Transgenics Mutagenicity Testing Mutation Detection Neural Cell Culture Neural Transplantation Neurochemistry (2nd edition) Neuronal Cell Lines NMR of Biological Macromolecules Non-isotopic Methods in Molecular Biology Nucleic Acid Hybridisation * Nuclear Receptors Oligonucleotides and Analogues Oligonucleotide Synthesis PCR 1 PCR 2 *PCR3:PCR In Situ Hybridization Peptide Antigens Photosynthesis: Energy Transduction Plant Cell Biology Plant Cell Culture (2nd edition Plant Molecular Biology Plasmids (2nd edition) Platelets Postimplantation Mammalian Embryos
* Post-translational Processing Preparative Centrifugation Protein Blotting * Protein Expression Protein Engineering Protein Function (2nd edition) * Protein Localization by Fluorescence Microscopy * Protein Phosphorylation (2nd edition) Protein Purification Applications Protein Purification Methods Protein Sequencing Protein Structure (2nd edition) Protein Structure Prediction Protein Targeting Proteolytic Enzymes Pulsed Field Gel Electrophoresis RNA Processing I and II RNA-Protein Interactions Signalling by Inositides * Signal Transduction (2nd edition) Subcellular Fractionation Signal Transduction if Transcription Factors (2nd edition) Tumour Immunobiology if Virus Culture
Lymphocytes A Practical Approach Second edition Edited by
SARAH L. ROWLAND-JONES Human Immunology Unit Institute of Molecular Medicine John Radcliffe Hospital Oxford OX3 9DS
and ANDREW J. McMICHAEL Human Immunology Unit Institute of Molecular Medicine John Radcliffe Hospital Oxford OX3 9DS
OXPORD UNIVERSITY PRESS
OXPORD UNIVERSITY PRESS
Great Clarendon Street, Oxford OX2 6DP Oxford University Press is a department of the University of Oxford and furthers the University's aim of excellence in research, scholarship, and education by publishing worldwide in Oxford New York Athens Auckland Bangkok Bogotd Buenos Aires Calcutta Cape Town Chennai Dar es Salaam Delhi Florence Hong Kong Istanbul Karachi Kuala Lumpur Madrid Melbourne Mexico City Mumbai Nairobi Paris Sao Paulo Singapore Taipei Tokyo Toronto Warsaw and associated companies in Berlin Ibadan Oxford is a registered trade mark of Oxford University Press Published in the United States by Oxford University Press Inc., New York © Oxford University Press, 2000 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press. Within the UK, exceptions are allowed in respect of any fair dealing for the purpose of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms and in other countries should be sent to the Rights Department, Oxford University Press, at the address above. This book is sold subject to the condition that it shall not, by way of trade or otherwise, be lent, re-sold, hired out, or otherwise circulated without the publisher's prior consent in any form of binding or cover other than that in which it is published and without a similar condition including this condition being imposed on the subsequent purchaser Users of books in the Practical Approach Series are advised that prudent laboratory safety procedures should be followed at all times. Oxford University Press makes no representation, express or implied, in respect of the accuracy of the material set forth in books in this series and cannot accept any legal responsibility or liability for any errors or omissions that may be made. A catalogue record for this book is available from the British Library Library of Congress Cataloging in Publication Data (Data available) ISBN 0 19 963817 9 (Hbk) 0 19 963816 0 (Pbk) Typeset by Footnote Graphics, Warminster, Wilts Printed in Great Britain by Information Press, Ltd, Eynsham, Oxon.
Preface In the 12 years since the last edition of Lymphocytes: A Practical Approach, the field of cellular immunology has seen many changes. The crystallization of MHC molecules opened up a new understanding of how these cell-surface proteins present antigenic fragments to lymphocyte surveillance. These structural insights were complemented by studies that illuminated how these antigenic peptides were being generated in the infected cell and how they found their way into complexes with newly synthesised MHC molecules. The intricacies of antigen presentation by MHC molecules has shed some light on the basis for the extraordinary polymorphism of these proteins, underscored by improved methods of HLA typing which have demonstrated the true extent of this polymorphism. The process of T-cell recognition has been elucidated by studies of the selection and structure of T-cell receptors, as well as a greater understanding of those activities that are triggered when lymphocytes meet their cognate antigen. This has led to a much more detailed characterization of lymphocyte subsets based on their secretion of soluble factors and other functions. Critical to these studies has been an appreciation of the many other cellsurface molecules expressed by different cells in the immune system involved in their trafficking and cell-to-cell interactions. The processes that regulate the early generation and selection of T-lymphocytes in the thymus are better understood, and their ultimate fate has been illuminated by studies in the field of apoptosis or programmed cell-death. Finally, the role of different lymphocyte subsets in the immune response to different pathogens and tumours has been clarified by better methods of characterizing and quantifying these cell populations. This new edition aims first to provide an update of some of the most wellestablished methods in lymphocyte biology. The volume opens with a lively summary of the key principles of lymphocyte culture, including such invaluable advice as to which parts of the procedures are so critical that they must take priority when your house is on fire! The basic principles of immunohistochemistry and the characterization of lymphocyte surface antigens are outlined in subsequent chapters. The central features of T-cell culture for both human and murine studies are provided in three detailed chapters. These areas were all featured in the first edition of the book (edited by G. G. B. Klaus), but are now covered in new chapters reflecting some of the important recent developments in these areas, such as intracytoplasmic staining to study the production of different cytokines by lymphocyte populations studied by flow cytometry, and the use of the ELISpot assay to enumerate antigenspecific T-cells. Immortalization of B-lymphocytes was described in the first edition: in this volume the use of other transforming viruses to generate Tlymphocyte lines is also described. The generation and use of T- and B-cell
Preface hybridomas is a new area covered in this edition, as is the application of molecular techniques to HLA typing, an advance which has revolutionized the field. Two methods for the quantification of antigen-specific T-cells (in addition to the ELISpot assay) are described in successive chapters: first, the use of limiting dilution analysis is described and updated, and then the new technique of identifying T-cells specific for a particular peptide-MHC combination, by staining them with tetrameric complexes of that MHC molecule assembled with the relevant peptide, is described. This latter technique has proved particularly fruitful for in vivo dynamic studies of T-cell responses to pathogens and tumours over the past 2 years. The potential therapeutic use of expanded antigen-specific T-cells is described, and the final chapters deal with new methodologies for studying apoptosis and the biology of the thymus. Some of the common methodologies (such as cell freezing and lymphocyte separation) are described more than once, but we have included the protocols as supplied by the authors, since minor variations may be important in reflecting the practices of different laboratories. I would like to take this opportunity to thank all the authors for their excellent contributions to this new edition of Lymphocytes: a practical approach (and for their patience with the editor!). Although a volume such as this cannot hope to provide exhaustive cover of every available technique in the area of lymphocyte biology, the experience in our group was that our experimental work undoubtedly benefited from each new chapter that arrived over the past few months: I hope that others will find it similarly useful. Oxford September 1999
SARAH ROWLAND-JONES ANDREW J. McMICHAEL
viii
Contents List of Contributors Abbreviations 1. Preparation of lymphocytes and identification of lymphocyte subpopulations Magdalena Plebanski 1. Introduction 2. Sources of lymphoid and professional antigen-presenting cells 3. Methods of purification Lymphoid organs Body fluids
4. Principles of lymphocyte handling and culture Short- and long-term storage (freezing) Principles of long- and short-term culture 5. Methods of subfractionation for lymphocytes and antigen-presenting cells Physical properties Cell-surface markers Acknowledgement
2. Immunohistochemistry of lymphoid organs Simon C. Biddolph and Kevin C. Gatter 1. Introduction 2. Preparation of lymphoid cells and tissues for immunohistochemistry Slide adhesive Choice of preparation Transport of specimen Cell smear and cytocentrifuge preparations Cell imprints ('dabs' or 'touch preparations') Frozen sections ('cryostat sections') Paraffin sections
3. Immunohistochemical staining Immunohistochemical methods
xvii xix
1
1 1 3 3
10 14 14 16 18 19 20 26 27
27 27 27 28 29 29 31 31 32 39 39
Contents Labels Considerations in the choice of method and label Multiple antibody methods Quality control The distribution of cell types in lymphoid tissue
41 45 49 52 53
Acknowledgements
53
References
53
3. Viral transformation of lymphocytes
55
Edgar Meinl and Helmut Fickenscher 1. Introduction 2. Transformation of T lymphocytes Growth transformation of human T cells by herpesvirus saimiri Immortalization of human T cells by human T-cell leukaemia virus type 1
55 56 56 68
3. B-cell immortalization EBV-transformation of human B cells Transformation of macaque B cells with herpesvirus papio
69 69 70
Acknowledgements
71
References
71
4. B- and T-cell hybridomas
75
Judy M. Bastin 1. Introduction
75
2. Methods for generating B- and T-cell hybridomas and the principles of hybridoma culture Tissue culture Materials Selection procedures Immunizations Fusion partners Fusion protocol Growth of hybridomas Screening assays Cloning hybridomas Cryopreserving and thawing cells Large-scale production of hybridomas Purification Human hybridomas Antibody production by chemical and genetic engineering
75 76 76 77 77 79 79 81 81 82 83 84 84 85 86
x
Contents Disadvantages of nybridomas Conclusions
87 87
3. Applications of hybridoma technology B-cell hybridomas T-cell hybridomas References
5. Murine T-cell culture
88 88 90 91 95
Kingston H. G. Mills 1. Introduction T-cell subtypes and their role in protective immunity Strategies for the induction of distinct T-cell subtypes Techniques for detecting T-cell responses
95 95 96 98
2. Tissue culture conditions, growth factors, and cell viability Culture medium and serum Cytokines and growth factors for culturing T cells Viable cell count 3. Preparation of T cells and APCs Preparation of cells from lymphoid and non-lymphoid organs Purification of mononuclear cells and removal of dead cells Purification of T cells, B cells, and T-cell subpopulations Preparation of macrophages and APCs
99 99 101 102
4. Generation and detection of antigen-specific CD4+ T cells In vivo priming of CD4+ T cells Generation of CD4+ T-cell lines and clones Antigen-specific T-cell proliferation Detection of Thl/ThO/Th2 responses by cytokine production Assay of helper function of T cells for antibody production by B cell 5. Generation and detection of antigen-specific CD8+ CTLs
111 111 112 115 119 124
In vivo priming of CD8+ CTLs Generation of CD8+ T-cell lines and clones Cytotoxic T-cell assay
103 103 106 107 110
127 127 127 128
6. MHC restriction analysis Acknowledgements References
130
6. Human CD4 culture
135
131 132
Anna Vyakarnam, B. Vyas, M. Vukmanovic-Stejic, P. Gorak-Stolinska, D. Wallace, A. Noble, and D. M. Kemeny 1. Introduction xi
135
Contents 2. General apparatus, media, and reagents for human CD4 culture Apparatus Media Reagents
136 136 137 137
3. The isolation and culture of CD4 T-cell subsets from peripheral 137 blood 140 Principle 140 The generation of CD4+ Thl, Th2, and ThO effectors Generation of antigen-specific and random CD4 clones 142 4. Assays for CD4 function Principle of proliferation assay Activation-induced cell death Measuring cytokine production in culture supernatants by ELISA Enumerating cytokine-producing cells by flow cytometry: intracytoplasmic cytokine staining
147 147 149 151
References
158
7. Human cytotoxic T-lymphocyte (CTL) studies
153
161
Sarah L. Rowland-Jones 1. Introduction 2. General principles of CTL culture Tissue culture reagents and conditions What persuades memory CTLs to grow in vitro?
161 162 162 163
3. Generation of antiviral CTL Influenza-specific CTLs HIV-specific CTLs Using peptides to stimulate CTLs Generating virus-specific CTL clones
163 164 165 166 167
4. Measuring CTL activity The CTL lysis assay Measuring the antigen-specific release of cytokines by CTLs How do different methods of quantifying CTLs compare?
169 169 172 175
5. Conclusions
176
References
176
8. Limiting dilution analysis for the quantitation of antigen-specific T cells
179
Andrew Carmichael 1. Theoretical considerations Quantitation at the clonal level using limiting dilution analysis (LDA) The Poisson distribution
xii
179 179 180
Contents Advantages of LDA in addition to quantitation Limitations of LD A 2. Methodology Responder cells Stimulator cells 3. Calculation and interpretation of results Calculation of cytotoxic activity in individual microcultures Classification of positive and negative wells Estimation of precursor frequency Interpretation References
9. HLA-peptide tetrameric complexes
183 183 183 184 187 190 190 190 191 194 194 197
Graham S. Ogg 1. Introduction
197
2. Cloning of modified HLA heavy chain
198
3. Protein expression Principle Comments
199 199 200
4. Inclusion body purification Principle
200 200
5. Refolding by dilution Principle Comments
201 201 202
6. Enzymatic biotinylation Principle Comments
202 202 203
7. Purification of refolded protein Principle 8. ELISA Principle Comments
203 203 204 204 206
9. Formation of tetramers Principle Comments
206 206 206
10. Flow cytometry Principle Comments
207 207 207
11. Conclusions
207
References
208 xiii
Contents
10. Expansion of human cytotoxic T lymphocytes 209 for immunotherapy Rusung Tan 1. Introduction Adoptive transfer of CTLs in humans
209 210
2. Peptide recognition by CTLs Peptide binding motifs
211 211
3. Establishing CTL lines Establishing CTL clones Expansion of CTL clones Ensuring the safety of CTL infusions
213 213 215 217
References
218
11. HLA typing methods
221
Pete Krausa and Michael Browning 1. Introduction
221
2. The HLA system Polymorphism in relation to structure and function Nomenclature HLA in populations
223 224 226 227
3. Methods of HLA typing
230
4. Serological HLA typing Preparation of components The micro-lymphocytotoxicity assay Discussion on serology 5. Molecular biological approaches to tissue typing
230 232 237 238 239
6. The PCR reaction Reagent composition The PCR
240 240 242
7. Detection by oligonucleotide probing (PCR-SSOP) PCR-SSOP protocols PCR-SSOP discussion
243 245 248
8. HLA typing by PCR-SSP Five-locus determination PCR-SSP—phototyping High-resolution PCR-SSP typing PCR-SSP discussion
249 249 256 257
9. Sequence-based typing SBT strategies HLA SBT protocol
258 259 261
xiv
Contents 10. Discussion
264
Key references
267
Commercial suppliers
267
References
268
12. Biochemical characterization of lymphocyte surface antigens
273
Antony Symons and Marion H. Brown 1. Introduction
273
2. Immunoprecipitation Introduction Labelling cellular antigens Solubilization of membrane proteins Immunoprecipitation
274 274 274 280 281
3. SDS-polyacrylamide gel electrophoresis (PAGE) Introduction Detection of proteins
285 285 288
4. Immunoblotting Introduction Preparation of protein samples Blotting proteins Detection of antigen
289 289 290 291 294
5. Strategies for the identification of new molecules Affinity chromatography Ligand hunting
296 296 297
References
297
13. Measurement of cells undergoing apoptosis
299
Y. Furukawa and C. R. M. Bangham 1. Introduction Definition of apoptosis Importance of apoptosis in lymphocyte biology Recognition of apoptotic cells by phagocytes Recent advances in our understanding of apoptosis
299 299 299 300 300
2. Methods available to assay apoptosis DNA laddering Analysis of light scatter by flow cytometry (size and granularity)
303 305 305
xv
Contents Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling (TUNEL) Annexin V CMXRos and related dyes
References
305 308 309 313
14. Thymic organ culture John J. T. Owen and Deirdre E. J. McLoughlin 1. Introduction 2. Microdissection and organ culture of the murine feta thymus The production of alymphoid thymus lobes
3. Newborn thymic slice culture 4. Reaggregate thymus organ culture References
315
315 316 321 322 324 329
Appendices Al List of suppliers A2 Commonly used lymphonia lines Edgar Meinl and Helmut Fickenscher
Index
331 337
343
xvi
Contributors CHARLES R. M. BANGHAM
Department of Immunology, Imperial College School of Medicine at St Mary's, Norfolk Place, London W2 1PG, UK. JUDY M. BASTIN
Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK. SIMON C. BIDDOLPH
Department of Paediatric Pathology, Womens' Centre, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK. MARION H. BROWN
MRC Cellular Immunology Unit, Sir William Dunn School of Pathology, South Parks Road, Oxford OX1 3RE, UK. MICHAEL BROWNING
Department of Microbiology and Immunology, University of Leicester, Medical Sciences Building, University Road, Leicester LE1 9HN, UK. HELMUT FICKENSCHER
Institut fur Klinische und Molekulare Virologie, Friedrich-AlexanderUniversitat Erlangen-Nuraberg, Schlossgarten 4, D-91054 Erlangen, Germany. Y. FURUKAWA
Department of Immunology, Imperial College School of Medicine at St Mary's, Norfolk Place, London W21PG, UK. KEVIN C. GATTER
University Department of Cellular Sciences, Level 4, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK. ANDREW CARMICHAEL
Department of Medicine, Level 5, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. P. GORAK-STOLINSKA
Department of Immunology, GKT School of Medicine and Dentistry, 125 Coldharbour Lane, London SE5 9NU, UK. PETE KRAUSA
Molecular Genetics Division, Forensic Analytical, 3777 Depot Road, Suite 409, Hayward, CA 94545, USA.
Contributors DEIRDRE E. J. MCLOUGHLIN
Department of Anatomy, University of Birmingham Medical School, Edgbaston, Birmingham, B15 2TT, UK. EDGAR MEINL
Max Planck-Institut fur Neurobiologie, Am klopferspitz 18a, D-82152 Martinsried, Germany. KINGSTON H. G. MILLS
Infection and Immunity Group, Department of Biology, National University of Ireland, Maynooth, County Kildare Ireland. GRAHAM S. OGG
Molecular Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK. JOHN J. T. OWEN
Department of Anatomy, University of Birmingham Medical School, Edgbaston, Birmingham, B15 2TT, UK. MAGDALENA PLEBANSKI
The Austin Research Institute, Studley Road, Heidelberg, Victoria 3084, Australia. SARAH L. ROWLAND-JONES
Molecular Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK. ANTONY SYMONS
The R. W. Johnson Pharmaceutical Research Institute, 3210 Merryfield Row, San Diego, CA 92121, USA. RUSUNGTAN
Department of Pathology and Laboratory Medicine, BC's Childrens' Hospital, 4480 Oak Street, Room 2G5, Vancouver, BC V6H 3VA, Canada. M. VUKMANOVIC-STEJIC
Department of Immunology, GKT School of Medicine and Dentistry, 125 Coldharbour Lane, London SE5 9NU, UK. ANNA VYAKARNAM
Department of Immunology, GKT School of Medicine and Dentistry, 125 Coldharbour Lane, London SE5 9NU, UK. B.VYAS
Department of Immunology, GKT School of Medicine and Dentistry, 125 Coldharbour Lane, London SE5 9NU, UK. D. WALLACE
Edward Jenner Institute for Vaccine Studies, Compton, Berkshire RG20 7NN, UK. xviii
Abbreviations AEC AICD AMV-RT AO AP APAAP APC APCN ARMS ATCC AZT B-LCL (LCL) B2m HALT BMT BSA BSE CD CDR CG CFA Ci CITES CJD CMV CMXRos Con A CPE CTL CTLp CTLL DAB DAPI DcR ddNTP DIG DIG-11-UTP DiOC6 DISC DMEM
3-amino-9-ethylcarbazole activation-induced cell death reverse transcriptase from avian myeloblastosis virus Acridine Orange alkaline phosphatase alkaline phosphatase, anti-alkaline phosphatase antigen-presenting cell allo-phycocyanin amplification refractory mutation system American Type Culture Collection 3'-azido-3'-deoxythymidine (aka zidovudine) B-lymphoblastoid cell line beta-2 microglobulin bronchus-associated lymphoid tissue bone-marrow transplant(ation) bovine serum albumin bovine spongiform encephalitis cluster of differentiation complementarity determining regions cell growth medium complete Freund's adjuvant Curie Convention on International Trade in Endangered Species Creutzfeldt-Jakob disease cytomegalovirus Chloromethyl-X-Rosamine Concanavalin A cytopathic effect cytotoxic T-lymphocyte cytotoxic T-lymphocyte precursor cytotoxic T-lymphocyte cell line 3,3' -diaminobenzidine tetrahydrochloride 4,6-diamidino-2-phenylindoledihydrochloride decoy receptor dideoxynucleotide digoxigenin digoxigenin-11-uridine triphosphate 3,3' -dihexyloxacarbocyanine iodide death-inducing signalling complex Dulbecco's Modified Eagle's Medium
Abbreviations DMF DMSO DNA DNase dNTP DR DTH DTT Avm EB EBV ECL™ EDTA ELISA EndoH EPOS ER FACS FADD FASL FcR PCS FITC FLICE fmk FNA GALT GM-CST GVHD Gy H-CMV HAMA HAT HAU HBV H-DNA HGPRT HHV HIV HLA HMAR HRP HS Hsp
N,N' -dimethyl formamide dimethyl sulfoxide deoxyribonucleic acid deoxyribonuclease deoxynucleotide death receptor delayed type hypersensitivity dithiothreitol mitochondrial transmembrane potential ethidium bromide Epstein-Barr virus enhanced chemiluminescent (detection) ethylenediamine tetraacetic acid enzyme-linked immunosorbent assay endo-B-N-acetylglucosaminidase H enhanced polymer one-step endoplasmic reticulum fluorescence activated cell sorter Fas-associated protein with Death Domain Fas-ligand crystallizable fragment receptor fetal calf serurn fluorescein isothiocyanate FADD-like ICE fluoromethylketone fine-needle aspirate gut-associated lymphoid tissue ganulocyte-macrophage colony-stimulating factor graft versus host disease Gray human cytomegalovirus human anti-mouse antibody hypoxanthine, aminopterin, thymidine haemagglutinating units hepatitis B virus heavy DNA (high GC convert) hypoxanthine guanine phosphoribosyl transferase human herpesvirus human immunodeficiency virus human leucocyte antigen heat-mediated antigen retrieval horseradish peroxidase human serum heat-shock protein xx
Abbreviations HSV-TK HSV2 HTLV-1 HVS i.p. IAA ICAM ICE ICFA IEF IFN--Y Ig IL IPTG ISCOM IU kDa LARD LCMV LDA L-DNA LN LPS m.o.i. mAb mClCCP MHC MIP MVA NAA NHS NK NuMA OCT OMK PAP PAPC PBMC PBS PCR PE PEG PFA PHA
herpes simplex virus thymidine kinase herpes simplex virus type 2 human T-cell leukaemia virus herpesvirus saimiri intraperitoneal iodoacetamide intercellular adhesion molecule IL 1-B converting enzyme incomplete Freund's adjuvant isoelectric focusing interferon gamma immunoglobulin interleukin isopropylthio-B-D-galactosidase immunostimulating complex International Units kilodalton lymphocyte-associated receptor of death lymphocytic choriomeningitis virus limiting dilution analysis Light DNA (low GC convert) lymph node lipopolysaccharide multiplicity of infection (units) monoclonal antibody carbonyl cyanide w-chlorophenylhydrazone major histocompatibility complex macrophage inflammatory protein Modified Vaccinia Ankara non-essential ammo acids N-hydroxysuccinimide natural killer (cell) nuclear mitotic apparatus (protein) optimum cutting temperature owl-monkey kidney peroxidase anti-peroxidase professional antigen-presenting cell peripheral blood mononuclear cell phosphate-buffered saline polymerase chain reaction phycoerythrin polyethylene glycol paraformaldehyde phytohaemagglutinin
xxi
Abbreviations
Pi PI PMA PMSF PNGase F PS R/l R/10 RANTES RBCL RIA RPMI RSV RT RT-PCR rW SBT SDS-PAGI SFC SIV s1 SSOP SSP SSPE TAP TBS TCGF TCR TdT TEMED Th TILS TK Tm TMAC TNF-a TNFR Tr TRAIL TRAMP TRITC TUNEL UV
inorganic phosphate propidium iodide phorbol myristic acetate phenylmethylsulfonyl fluoride peptidyl-Af-acetylglucosaminidaseF phosphatidylserine RPMI medium with 1 % FCS RPMI medium with 10% FCS regulated on activation, normal T, expressed and secreted red blood cell lysis radioimmunoassay Rosewell Park Memorial Institute (medium) respiratory syncytial virus room temperature reverse transcriptase PCR recombinant vaccinia virus sequence-based typing sodium dodecyl sulfate polyacrylamide gel electrophoresis spot-forming cell simian immunodeficiency virus specific lysis sequence-specific oligonucleotide probes sequence-specific primers saline-sodium phosphate-EDTA transporter associated with antigen-processing Tris-buffered saline T-cell growth factor T-cell receptor terminal deoxynucleotidyl transferase N, N,N', N' -tetramethylethylenediamine T-helper cell tumour infiltrating lymphocytes thymidine kinase melting temperature tetramethylammonium chloride tumour necrosis factor alpha TNF receptor regulatory T cell TNF-related apoptosis-inducing ligand TNFR-related apoptosis-mediating protein tetramethylrhodamineisothiocyanate terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling ultraviolet xxii
Abbreviations v-FLIPS zDEVD-fmk zVAD-fmk
viral FLICE inhibitory protein benzyloxycarbonyl-Asp-Glu-Val-Asp(OMe)fluoromethylketone benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone
xxiii
1 Preparation of lymphocytes and identification of lymphocyte subpopulations MAGDALENA PLEBANSKI
1. Introduction This chapter provides the common methods used to isolate lymphocytes and accessory cells from humans and animals (see Section 2), handle them after recovery (see Sections 3 and 4) and, if necessary, subfractionate them (see Sections 5 and 6). It provides general advice as to which methods may be best used for the particular objectives of your experiment, and cross-references to methods throughout the book. It is common when using a new method to follow it precisely. But what if your house is on fire while you are in the middle of purifying a lymphocyte subpopulation? Should you risk leaving your precious cells on the bench? To help avoid some dilemmas, in addition to standard methods, this chapter aims to provide a measure of the adaptability of different experimental procedures.
2. Sources of lymphoid and professional antigenpresenting cells Lymphoid cells (B and T cells) and professional antigen-presenting cells (PAPCs) in mammals are generated mainly in the primary lymphoid organs. During fetal life they are found in the yolk sac. This function is then taken over by the fetal liver and spleen. In adult life their earliest progenitors are found in the bone marrow. These have the potential to generate all the blood cells of the body, including lymphocytes and many PAPCs. Mature granulocytes (neutrophils, eosinophils, and basophils), B lymphocytes, monocytes, and probably natural-killer (NK) cells, leave the bone marrow via the blood. By contrast, the T cells that leave the bone marrow are immature. The immature T cells home for the thymus where they will divide and mature further. The majority of the T cells generated in the thymus die there and only a small
Magdalena Plebanski percentage of mature T cells leave the thymus (10%). Primary lymphoid organs offer a very specialized source of lymphocytes and PAPCs, well suited to the study of early differentiation in the immune system. Chapter 14 details methods to isolate thymic lymphocytes and PAPCs, as well as how to perform cultures where the ultrastructure of the thymus, believed to play a vital role in its function, is left intact. These organs are difficult to process for use as a source of mature lymphocytes and PAPCs, and may, in fact, generate confusing results when attempting to study conventional mature immune responses. Mature lymphocytes can lodge permanently or temporarily in secondary lymphoid organs. These organs are also an abundant source of PAPCs. Secondary lymphoid organs can be encapsulated (spleen and lymph nodes), aggregated (lymphoid follicles such as tonsils, Peyer's patches of the small intestine and the vermiform appendix of the large bowel), or diffuse (lamina propia under the basement membrane of the epithelium of the respiratory and digestive tract). Further expansion and maturation of B cells into plasma cells, naive T cells into memory cells, and resting memory T cells into effector T cells (for example cytotoxic T cells becoming activated to kill) is thought to occur mainly in the secondary lymphoid organs. Many of the gut-associated lymphoid tissue (GALT) and bronchus-associated lymphoid tissue (BALT) lymphocytes recirculate specifically in these tissues, creating a self-contained pattern of reactivity to antigenic stimuli associated with the mucosa. The purification of mucosa-associated lymphocytes and PAPCs is detailed in Sections 3.1.2 and 3.2.2 of this chapter. Peripheral immune responses, arising from infections in non-mucosal tissues, are, in turn, generally reflected in the composition of the spleen and lymph node lymphocytes. In particular, lymph nodes directly draining an area of antigenic stimulation show an early enrichment for antigen-specific lymphocytes. These organs are also a good source of PAPCs, and both the spleen and certain lymph nodes are easy to obtain and process. Section 3.1.1 details how to isolate spleen and lymph node cells. Some of the mature activated cells leave the lymphoid organ to home to other secondary lymphoid organs and to sites of antigenic challenge. Section 3.1.3 discusses how to isolate infiltrating lymphocytes from tissue and tumours. Lymphocytes travel around in lymphatic and blood vessels. Lymphatic vessels are extensively distributed throughout the body. They initially evolved to drain the fluid that seeps out of blood capillaries into tissue. Thus, whereas blood is directly propelled by the action of the heart, lymph moves passively in response to contraction of the body muscles and the seepage of fluid into tissue. All lymphatic vessels begin as thin, blind capillaries with walls consisting of a single layer of flattened endothelial cells. The lymphatics connect to form larger vessels until they either become the right lymphatic duct (draining the upper right part of the body), which empties into the right subclavian vein, or the thoracic duct, which drains everything else and empties into the left subclavian vein. Lymphatics traverse lymph nodes, bringing the 2
1: Preparation of lymphocytes afferent lymph with information about the state of the tissue that it drains and going out in efferent lymph, which, with time, will reflect the response of the lymph node cells to that information. Both afferent and efferent lymph vessels can be cannulated to recover lymphocytes. Unless you are dealing with a species of adequate size this can be technically very demanding (see Section 3.2.1). Most studies of lymphocyte trafficking, where lymphatic cannulation was necessary, have been carried out in sheep. By contrast, blood samples are easy to obtain from a variety of animals and from humans. Section 3.2.1 details how to obtain and process blood samples to maximize the recovery of lymphoid cells and PAPCs.
3. Methods of purification 3.1 Lymphoid organs 3.1.1 Spleen and lymph nodes The spleen is an abundant source of lymphocytes and PAPCs, with 50-100 X 106 cells/mature spleen in mice, and 200-400 X 106 cells/mature spleen in rats. An ongoing in-vivo immune response, due to immunization or infection, can further double the number of cells in the spleen. As well as white cells, mainly lymphocytes (B and T) and PAPCs such as macrophages and dendritic cells, the spleen is plentiful in red cells. Normally, these do not interfere with assays of lymphocyte proliferation (see Chapter 5 and 6) or the in-vitro stimulation of cultures for T-cell cytotoxicity assays (see Chapters 5, 7 and 8). However, they may interfere in assays such as the early IFNfy-release ELISpot assay (see Chapter 7). A protocol is therefore given in this section (see Protocol 3) to lyse red cells and eliminate red-cell contamination of spleen cells. Be certain that your assay really requires this additional step, since it may cause stress to lymphocytes and decrease their viability. Lymph nodes are another abundant source of lymphocytes and these do not have the problem of red-cell contamination. They are, however, quite small and sometimes difficult to find and remove. In some cases you may need to dissect specific lymph nodes, for example if you want to use draining lymphocytes from an area where you have injected an antigen. However, if there are no such restrictions, mesenteric nodes and cervical nodes may be easier to find since they are usually the biggest. The latter are also easily accessible. In addition, axillary, brachial, inguinal, and popliteal nodes may also yield useful numbers of white cells (5-50 X 106 in mice, 20-100 X 106 in rat). Popliteal nodes (behind the knee) are also easily accessible and may be useful to study when antigens have been applied to the lower leg. Thus, an intradermal injection in the footpad leads to a specific expansion of lymphocytes in the popliteal node of that leg. At early time points (before specific cells have migrated to other secondary lymphoid organs in the body) the other popliteal node may be used as a negative control. 3
Magdalena Plebanski t^f
In the United Kingdom work with animals requires valid licences (individual and project licences) from the Home Office, which are obtained after attending a compulsory course where the proper humane methods of working with animals are demonstrated. Do not under any circumstances attempt to work with animals without attending the course and obtaining a licence. Also, think carefully about your experiment, and try to find out if any of your work with animals can be avoided by using a different experimental approach. Protocol 1. Isolation of splenocytes Equipment and reagents • 70% ethanol • 1 pair of non-sterile scissors and forceps • 1 pair of sterile scissors and forceps (bluntended) • R/10 medium: RPMI supplemented with 4 mM L-glutamine, 100 U/ml benzylpenicillin G, 100 ug/ml streptomycin sulfate, 0.05 mM 2-p-mercaptoethanol, and 10% fetal calf serum (PCS)
RPMI 1640 medium Sterile vials Petri dish 10 ml syringe plunger Sterile cell strainer Sterile test tubes Benchtop centrifuge Sterile centrifuge tubes
Method 1. Kill the animal (by cervical dislocation or CO2) and apply 70% alcohol (pour or swab) to the left-hand side of the abdominal fur. 2. Pick up the skin using forceps (can be non-sterile) just below the rib cage on the left side of the abdomen and cut with scissors (these can be non-sterile). Pull the skin back from the incision, both cranially and caudally, exposing the abdominal-wall musculature. 3. Pour 70% alcohol over the exposed musculature and, using sterile (e.g. dipped in 70% alcohol) scissors and forceps, pick up the abdominal wall over the spleen. Locate the spleen (it can be seen through the abdominal wall as a deep red, sausage-shaped organ just under the liver (which is bigger and less brightly coloured) on the lefthand side of the animal). Cut and open the abdomen near the spleen, giving yourself space to grasp it gently in your forceps and draw it out of the abdomen. 4. Holding it gently with the forceps, remove any non-spleen tissue attached to it (connective tissue, vascular stalk, omental connections, gut tissue) with your sterile scissorsa Place each clean spleen into a sterile vial containing sterile RPMI media (or any other physiological buffer), so that it is completely covered.b 5. Transfer the spleen to a Petri dish containing 5 ml of RPMI medium and disaggregate it.c 6. Put a sterile cell strainer on the top of a sterile tube, and pour your cell 4
1: Preparation of lymphocytes suspension through it. Leave any possible cell debris which may not have been strained to settle for 1-3 min, and transfer the debris-free cells to a sterile centrifuge tube.d 7. Centrifuge for 7 minutes at 600 g (1000-2000 r.p.m. in most common tissue-culture laboratory, benchtop centrifuges) at room temperature (RT) (18-22°C). Discard the supernatant. Flick the cell pellet gently and resuspend in 5-10 ml sterile RPMI. Take (sterilely) a 50 ul aliquot of your cell suspension to count cells and assess their viability (see Protocol 2). Centrifuge the cells again. 8. Discard the supernatant, flick the pellet, and resuspend it in the medium appropriate for your experiment at your required cell concentration.e • These tissues are normally easily distinguished from the self-contained, deep-red structure of the spleen. 6 Although it is best to proceed with the rest of the protocol straight away, isolated spleens can be left in media at room temperature for about an hour. If it will take more than an hour, for example if they need to be transported, it is best to put the vial on ice (up to 6 hours) and fill the vial with R/10, "This can be performed in a variety of ways: from crushing with sterile rounded forceps through a sterile metal mesh to careful teasing apart with a pair of sterile needles or forceps. An easy protocol is to use the stop end of a sterile 10 ml syringe plunger and gently push and rub the spleen as it lies in the Petri dish. Small clumps can be further desegregated by taking up the spleen suspension into a syringe through a wide-gauged needle several times (gentlyI). "Use of a strainer is advisable but not essential. Allowing debris to settle out can be done as many times as necessary. " If this is a standard culture medium, e.g. R/10, cells can be left at this stage for 1 hour at room temperature. Leaving cells standing around in a plastic container such as a centrifuge tube for longer, or at 37 °C, may lead to the selective loss of adherent cells, such as macrophages and some dendritic cells and B cells.
The protocol to obtain lymph node cells is virtually identical, except for the initial locating and removal of lymph nodes. When dissecting be careful not to include fatty and connective tissue, which is frequently found in areas surrounding lymph nodes. Lymph nodes are normally rounded, bean-shaped organs with a solid, rubbery consistency and white/yellow in colour. Fatty tissue is white and easily falls apart when pulled by forceps. Connective tissue is white/pink. Lymph nodes are difficult to manage because of their smaller size, so teasing apart with needles may give you better control and thus increased cell recovery than other methods (steel mesh, or the method delineated above). Sterile forceps can be used to hold the lymph node as it is being teased apart. Cell viability can be assessed by counting, under a microscope, cells that take up a dye, most commonly Trypan Blue, after they have lost membrane integrity (see Protocol 2). If more than 25% of the recovered cells are dead, it might be best to remove them from the viable cells. A simple protocol utilizing a one-step density gradient is detailed in Protocol 4. 5
Magdalena Plebanski Protocol 2. Counting cells and assessing cell viability Equipment and reagents • Coulter counting chamber • Microscope (allowing 10-40 x magnification) • 0.5% Trypan Blue in PBS
. PBS: 1.4 M NaCI, 0.3 mM KCI, 7 mM Na2HPO4, 1 mM K2HP04; pH 7.2 for use with murine cells and pH 7.4 for use with human cells
Method 1. Mix 50 ul of the Trypan Blue solution with 50 ul of your cell solution. Dilute further (e.g. make a 3 x dilution by mixing 25 ul of cells with 50 uJ of Trypan Blue) if your cells look very concentrated. 2. Apply to a Coulter counting chamber (normally 10 ul). Make sure the coverslip is firmly attached to the counting chamber by putting moisture (water, not saliva, regardless of what you see other people in the lab. doing!) on the sides of the coverslip and press it firmly on to the counting chamber. Make sure you can see Neubauer rings (coloured diffraction pattern) on the side of the chamber, indicating that the coverslip is properly stuck. 3. Count live lymphocytes and PAPCs (translucent white cells) and dead cells (blue) using 10 X, 20 X, or 40 x magnification. Count at least 50 live cells, and take note of how many areas of the Coulter chamber you need to count to achieve this number. 4. Calculate the viable-cell concentration as follows: (a) if all cells within the triple-line markings on the chamber are counted (in the most commonly employed chambers there are 25 squares marked, each with smaller 16 squares within them to aid counting), your cell concentration is: number of cells counted x dilution X 104 = cells/ml of suspension; (b) if less than 25 squares are counted, simply multiply to compensate, thus: number of cells counted x dilution x multiplier x 104 = cells/ml of suspension. Avoid counting red cells. They can be distinguished as being smaller than lymphocytes, round with dark, well-delineated edges, and slightly reddish in colour. It takes some experience, or a very good microscope, to be confident about counting red cells. It is possible to lyse red cells (see Protocol 3) before counting to avoid this problem. Although this adds an extra step in the procedure, it might be useful while learning to count cells. Alternatively, once viability is assured, cells can be recounted using a crystal violet dye, which will stain purple only nucleated cells. Red cells will remain transparent. Prepare the crystal violet diluent by mixing glacial acetic acid: deionized water: PBS at a 1:12:12 ratio. Add 1-100 mg crystal violet per ml diluent. Mix 10 ul of cell 6
1: Preparation of lymphocytes suspension with 90 ul of the crystal violet solution and count cells under the microscope as described in Protocol 2. Protocol 3. Red blood cell lysis (RBCL) Equipment and reagents . ACK buffer: 0.15 M NH4CI, 1 mM KHCO3, 0.1 mM Na2EDTA pH 7.2 • Benchtop centrifuge
. PCS . RPMI or PBS
Method 1. Centrifuge the cell preparation containing the red cells you want to lyse for 7 min at 600 g. 2. Discard the supernatant and flick the pellet. Add 10 ml of the RBCL solution (ACK buffer) and mix gently. Leave at room temperature for 5 minutes. 3. Dilute with 25 ml of physiological buffer (e.g. RPMI or PBS). 4. Use 2 ml of fetal calf serum (FCS) to underlay the cells in the RBCL solution. 5. Centrifuge at 600 g for 7 min at room temperature.a,b 6. Discard the supernatant, including the FCS. Flick the pellet and resuspend in 5 ml RPMI. Wash once by centrifuging at 600 g for 7 min at room temperature. Discard the supernatant. 7. Look at the pellet: if the cells are sufficiently clean of red cells (the pellet should look white) proceed to flick the pellet and wash the cells again in RPMI. Then resuspend them in the medium you wish to use for your experiment. Otherwise, repeat steps 1-5 to lyse residual red cells. • Red cell membranes generated during red cell lysis should float at the FCS/RBCL interface, whereas lymphocytes just pellet as normal. "This FCS gradient is only necessary if red cell membranes can interfere with your assay. For eliminating red cells before counting under the microscope, this step is unnecessary, and cells can be pelleted straight away from ACK.
Dead cells are also a common contamination problem. In particular, they may be increased when recovering infiltrating lymphocytes from tissue treated with collagenase, or when using thawed cryopreserved cells. The simple method delineated below can eliminate most dead cells (see Protocol 4). It is also useful if you have a precious but yeast-contaminated culture. Normally such a culture should be immediately discarded to avoid contaminating other cultures in your incubator. In critical cases, the Ficoll gradient technique described in Protocol 4 can be applied. This will not eliminate contamination, but it will reduce it, as yeast will pellet to the bottom of the Ficoll gradient and cells will remain floating on top of the Ficoll/medium interface. 7
Magdalena Plebanski Protocol 4.
Elimination of dead cells
Equipment and reagents • Metrizoite-Ficoll solution (1.077 g/ml) • Sterile centrifuge tubes • Sterile pastettes or 1-10 ml plastic pipettes
• Benchtop centrifuge • RPMI medium
Method 1. Add 5 ml of the metrizoite-Ficoll solution at room temperature to a sterile centrifuge tube. Gently layer your cell suspension (1-10 ml) on to the Ficoll. Avoid making swirls in the Ficoll. You can apply the cells with a sterile pipette, allowing the suspension to slide gently down the sides of the tube.3 2. Centrifuge at 600-800 g for 15 min at room temperature. Make sure no brake is applied to stop the centrifuge spin. 3. Collect the cells at the Ficoll/medium interface (they should look like a cloudy white band). Try to aspirate them from the top with a pipette or pastette about 1 mm away, this helps to minimize Ficoll contamination of your cells. Dead cells will have pelleted straight to the bottom. 4. Wash your cells twice in RPMI. Count as described in Protocol 3 during the last spin. Resuspend in the medium of your choice. • If using thawed cells it is best to rest them for at least 1 h in R/10 medium (see Protocol 1) at 37°C to eliminate residual dimethylsulfoxide (DMSO) before layering.
3.1.2 Tonsils and Peyer's patches These organs are tougher to dissociate and need an additional collagenase treatment step. Peyer's patches are an integral component of the gutassociated lymphoid tissue (GALT), and in the mouse approximately 30 of them are embedded along the length of the small intestine. About 1.0 X 106 cells can be recovered from each patch. Maintaining sterility is difficult due to the proximity of the gut contents, even if those are flushed prior to dissection. Plan your experiments accordingly. Protocol 5. Isolation of cells from Peyer's patches Equipment and reagents • As for Protocol 1 • Collagenase • Sterile, wide-bore, 5-10 ml plastic pipette or a 3 ml pastette
• Ice-cold saline • 2 U/ml dispase and 0.1 mg/ml DNase I (if needed)
8
1: Preparation of lymphocytes Method 1. Kill the animal (cervical dislocation or CO2), put on the dissecting board, belly up, and apply 70% alcohol (pour or swab) to the abdominal fur. 2. Pick up the skin just under the jaw and cut towards the pubis with scissors (these can be non-sterile). Pull the skin back from the incision, to both sides, exposing the abdominal wall musculature. 3. Pour 70% alcohol over the exposed musculature and, using sterile (e.g. dipped in 70% alcohol) scissors and forceps, pick up the abdominal wall over the gut and cut to give yourself enough space to remove the whole of the small intestine. Transfer this into a vial containing sterile medium (e.g. RPMI). 4. Transfer into a Petri dish containing sterile medium. Cut the gut into 15 cm lengths and flush the contents with ice-cold saline. Cut around each Peyer's patch (white, round protuberances) using sterile sharp scissors and sterile forceps. 5. Transfer the patch to another dish and rinse with medium. 6. Transfer to a tube containing 1 ml of medium (e.g. RPMI) and collagenase (1-8 ug/ml)a, and incubate for 30 min. During this time take the suspension up and down the wide-bore pipette or pastette about 10 times, every 10 minutes, to help to further dissociate the tissue. Add neutral protease (e.g. 2 U/ml of dispase) and DNase I (0.1 mg/ml) if needed. 7. Transfer the suspension to a sterile tube, allow the debris to settle, and transfer the debris-free cell suspension to a 50 ml sterile centrifuge tube. Top up with cold medium (e.g. RPMI) and centrifuge at 800 g for 10 min at 4°C. 8. Remove the supernatant, flick the pellet, and resuspend it in 10 ml of cold medium. Centrifuge at 600 g for 7 min at 4°C. Repeat this step twice. Count the cells and during the last centrifuge spin assess viability as described in Protocol 2. Resuspend in the right volume of culture medium to give the cell concentration appropriate to your experiment. "Check the collagenase you purchase for details of its specific activity and recommended dose.
For tonsils the protocol is the same, except of course for finding and dissecting the tonsils. For collagenase dissection of any tissue, small fragments of tissue, ideally 2 mm3, will assist efficient digestion. Where significant cell death is expected during the digestion process, it will be necessary to add DNase (50 kU/ml). 9
Magdalena Plebanski 3.1.3 Infiltrating lymphocytes Lymphocytes specifically associated with a local inflammatory, delayed-type hypersensitivity (DTH) or autoimmune response may be enriched in tissue. Their characterization can provide vital information about the local targets of the immune reaction. This approach has been particularly rewarding in the study of solid tumours, where tumour infiltrating lymphocytes (TILs) specific for tumour-associated antigens have been isolated by cloning, thereby providing new targets for the immunotherapy of cancer. However, the numbers of cells isolated can be small, thousands rather than millions, and an early cloning (see Chapter 6), immortalization (see Chapter 4, 5), or optimized culture protocol (see Chapters 6-9) must be in place to use them efficiently. Most tissues can be dissected by adapting Protocol 5 and adding the appropriate density gradients (Percoll (see Protocol 8) or Ficoll (see Protocols 2 and 6) are commonly used) to further isolate lymphocytes away from tissue-derived cells. T cell-specific magnetic beads (see Section 5.2.4) can be also used to positively select for TILs. Isolation of lymphocytes from tumours, rather than tissue, carries the problem of tumour cell proliferation in culture, which can easily outgrow the TILs. Early cloning (see Chapter 6) or limiting-dilution analysis assays (see Chapter 9) may be used to separate TILs from tumour cells.
3.2 Body fluids 3.2.1 Blood and lymph A blood sample is easy to obtain from human volunteers. It can also be taken from animals. In smaller species, such as the mouse, the volume recovered (if all the blood was taken this would be 4 ml, up to 0.4 ml can be taken without causing distress) means that only limited numbers of lymphocytes and PAPCs are available for immunoassays. Registered human blood donors give up to 500 ml of blood, and are allowed to do so every 6 months. It is good practice not to take more than 50 ml at a time from each volunteer for experimental purposes, and not to bleed them again until their blood composition has had time to recover (2 weeks). Volunteers should be fully informed and give written consent to give blood for your particular experimental purpose. If trained and allowed to do so, you can take the blood sample yourself. Hospitals run courses. Otherwise use the assistance of trained staff. Recoveries using standard methods (see Protocol 6) yield an average of 0.5-2 X 106 peripheral blood mononuclear cells (PBMCs) per ml of blood taken. The PBMC composition in a normal healthy adult human averages 60% T cells (CD3+ cells, of which 70% are CD4+ and 30% CD8+), 15% monocytes/macrophages (CD14+), 10% B cells (CD22+), and 15% natural killer (NK) cells (CD56+/CD16+). The frequency of these cells may vary dramatically due to a number of factors including disease, diet, age, genetic predisposition, and pregnancy. 10
1: Preparation of lymphocytes Lymph can be obtained by cannulating the lymphatic ducts. The easiest to cannulate, and also the one containing the most representative lymph sample, since it contains lymph drained from the whole body, is the thoracic duct. The procedure for cannulation is intricate and beyond the practical experience of this author. It is, however, excellently described in the previous edition of Lymphocytes: a practical approach, and in a video made by Dr Simon Hunt (Keble College, Oxford University). Copies of this video may be requested (
[email protected]). Protocol 6. Isolation of human peripheral blood mononuclear cells (PMBCs) Equipment and reagents • Standard implements for taking blood: tourniquet, sterile swab (can be 70% alcohol on cotton wool), dry sterile cotton wool, plaster, sterile syringe and needle/ butterfly, and a sterile tube containing anticoagulant" (usually 10 U of preservativefree heparin/ml blood taken)
. • • •
Metrizoite-Ficoll (1.077 g/ml) RPMI medium Sterile centrifuge tubes Benchtop centrifuge
Method 1. Find a clean safe environment in which to take blood from your human volunteer. Have all the necessary implements ready. 2. Take the blood into a sterile plastic syringe (see notes in the introduction to this Section) and transfer to a sterile centrifuge tube of appropriate size containing anticoagulant.a 3. Close the lid of the tube and gently invert to mix the anticoagulant with the blood.b Continue with the next steps if you require a sample of plasma as well as PBMCs from your donor; otherwise go to step 6. 4. Pellet the cells by centrifuging the blood at 800 g (2000-3000 r.p.m. in most benchtop centrifuges found in tissue-culture laboratories) for 20 min at room temperature (18-22°C), with no brake.c Avoid taking all the plasma and try to leave at least 2 cm of it on top of your cells, then top up to the original volume of blood with medium (e.g. RPMI) at room temperature. 5. Mix your cells gently with the remaining plasma and medium by inverting the tube several times.d 6. Layer your cell suspension on to Ficoll using a 1:1 ratio of Ficolkblood, but down to 1:1.5 is still acceptable. Overlay the cell suspension either using a pipette and applying the sample gently to the sides of a sterile centrifuge tube already containing the right amount of Ficoll, or Ficoll can be underplayed by gently eluting the Ficoll at the bottom of the cell suspension. In either case try to avoid
11
Magdalena Plebanski Protocol 6. Continued
7.
8.
9.
10. 11.
swirls. Make sure that the Ficoll and the blood are at room temperature, because (a) the density of Ficoll changes with temperature, and (b) cells clump and are inappropriately separated at 4°C. Keep the Ficoll solution in a dark place or covered with aluminium foil (it is light sensitive) at room temperature at all times, so that it is always ready for use. Don't be surprised if, as you layer, you observe red-cell aggregates falling down through the Ficoll, this is to be expected. Centrifuge at 800 g for 30 min at room temperature without a brake. Make sure the last person to use the centrifuge before you has not changed the temperature setting (!). Look for the milky-white PBMC band at the interface between the Ficoll (transparent) and the remaining plasma (yellow). (Note that the red cells (and neutrophils) will have pelleted through the Ficoll to the bottom.) Collect this PMBC band by aspirating it gently from the top with a sterile pipette or pastette, about 1 mm away from it is best. Start by aspirating the sides as some cells will stick to the sides of the tube. Try to take as little Ficoll as possible with your cells. Do not leave cells uncollected as the PBMC band diffuses with time. Centrifuge the cells that you have collected (800 g, 15 min, room temperature, no brake). Discard the supernatant and flick the pellet before resuspending it in RPMI (normally 10-20 ml are used for the following washing steps). Do not leave cells standing around for more than 10 minutes at this stage, or they will clump. Centrifuge at 600 g for 7 min at room temperature, with full brake. Discard the supernatant, flick the pellet, add RPMI medium. Repeat step 10. Count your cells and assess their viability during this last spin as described in Protocol 2. Resuspend finally in the medium appropriate to your experiment at the cell concentration you require.*
"This is normally heparin (10 U of heparin per ml of blood collected), but other anticoagulants may be used. For example, CDP-adenine is usually employed in blood banks. "At this point blood can be stored for up to 2 hours at room temperature or overnight at 4°C. If it is stored cold then it must be brought back to room temperature before continuing. Failure to do so will provoke clumping and loss of cells during the next protocol steps. "Red cells will pellet first, with an almost invisible layer of white cells on the top, and will normally take up half the volume of your tube. The rest (yellow liquid at the top) is plasma. d Failure to leave some plasma behind may not only cause cell loss by aspirating white blood cells together with the plasma, but will result in clumping of the remaining cells in the next steps. "PBMCs purified in this way can be left in a sterile container in suitable medium (e.g. R/10) overnight at room temperature, or in the 37°C, humid, C02 incubator with the lid of the container slightly loose (to allow C02 exchange, but not contamination) for up to 2 days. However, a proportion of the adherent cells may be lost when they are stored for >1 h, and reactivity may decline, depending on the particular bioassay employed, the longer the cells are left unused. A protocol for the long-term storage of cells by freezing is given in Protocol 8.
12
1: Preparation of lymphocytes 3.2.2 Infiltrates (peritoneum, lungs, synovial fluid) Peritoneal lavage is most commonly performed to obtain macrophages. A peritoneal wash can be taken from an animal by simply rinsing the peritoneal cavity with saline (see Protocol 7). A normal mouse will yield 107 cells, with up to 35% macrophages. The proportion of macrophages may increase up to 65% if thioglycollate is added to the saline and injected intraperitoneally (i.p.) 3-4 days earlier. Even greater numbers of infiltrating macrophages (up to 95%) may be obtained if the animal is immunized i.p. with certain bacterial or parasitic vaccines and cells harvested at day 10 (Propionibacterium acnes (formerly called Corynebacterium parvum) vaccine may be used for this purpose at 0.7 mg vaccine/100 g body weight). Protocol 7. Isolation of peritoneal macrophages Equipment and reagents • 70% ethanol • 22-gauge needle and syringe
• PBS (see Protocol 2) containing 20 U/ml heparin
Method 1. Anaesthetize (ether or CO2) or kill the animal (cervical dislocation) and apply 70% alcohol (pour or swab) to the abdomen. 2. Inject intraperitoneally (i.p.) PBS containing 20 U/ml heparin (5 ml for a mouse, 10 ml for a rat). 3. Massage the abdomen for 1-2 min. 4. Insert a syringe with a 22-gauge needle a short distance (2-4 mm) through the abdominal muscle (peritoneum) at any place where it can avoid touching any organs. Aspirate the fluid while holding the abdominal muscle as high as possible. If the flow stops and the peritoneum is still full, check that your needle is not touching an organ, and readjust if necessary.3 'Animals should recover normally after anaesthesia.
Bronchial lavage will also yield mostly macrophages (up to 90%). The total number recovered is approximately 10s per mouse and 5 X 106 per rat. To do this attach a length of flexible tubing to a syringe and fill the lungs (of anaesthetized animals) with PBS (5-10 ml in mice), flushing the PBS in and out three times. This can be repeated twice more to optimize yields. Synovial fluid cells can be obtained from synovial fluid by treating the fluid with hyaluronidase (50 ug/ml for 30 min at 37 °C, with stirring) to reduce viscosity, and then following Protocol 6, steps 6-12 (described for the separation of blood PBMCs on Ficoll). 13
Magdalena Plebanski
4. Principles of lymphocyte handling and culture 4.1 Short- and long-term storage (freezing) After isolation, lymphocytes and PAPCs can, if necessary, be stored. Human PBMCs can be stored in a constant pH, physiological medium supplemented with nutrients (e.g. R/10) at 37 °C in a humid CO2 incubator for up to 2 days. There is no apparent loss in their ability to secrete lymphokines (such as IL-4 or IFN-y), proliferate, or become activated for lysis by in vitro restimulation. Store them at 106-107/ml, but preferably at 2-5 X 106/ml. Since mouse spleen cells are more sensitive, it is best to use them within 12 h of isolation. Both human and murine cells can normally be left on the bench at room temperature in buffered culture medium containing nutrients (e.g. R/10) for up to 2 h. Inevitably, these steps lead to the loss of adherent cells, particularly if the PBMC or spleen mix is left in a plastic or glass container with a wide surface area. When planning to store cells short term, you should consider whether the lymphocyte or PAPC cell population you are studying may have additional requirements for survival in vitro. Furthermore, some cells may differentiate as soon as they are taken out of their in vivo environment. For example, adherence to plastic quickly leads to monocytes acquiring some of the properties of activated macrophages. For long-term storage (weeks-years) lymphoid and accessory cells can be frozen, and then revived before your experiment. Freezing and defrosting cells, even with an optimized protocol (see Protocols 8 and 9, respectively), may lead to some cell loss. Recoveries after freezing/defrosting differ between cells. Resting cells (>80% PBMCs and spleen cells are normally non-cycling), immortalized T- and B-cell lines (see Chapters 4 and 5) and activated CD4+ T cells are best (see Chapters 6 and 7). Activated cells, particularly those containing lytic granules (neutrophils, cytotoxic T lymphocytes (CTLs), eosinophils, basophils) are worst. It is advisable to freeze between 0.5-5 X 107 cells/vial (in a 1.0 or 0.5 ml volume). In our experience, the smallest number of cells recoverable after freezing is 5 X 104 cells. Storage will also affect recovery. For long-term (>2 weeks), storage in liquid nitrogen (temperature of -120 °C) is advisable. For 1-2 weeks, storage in a -70 °C freezer is normally sufficient. Protocol 8.
Freezing cells
Equipment and reagents • FCS or normal human serum • Dimethylsulfoxide (DMSO) • Cryotubes • Polystyrene rack • Ice and ice-bucket
Centrifuge tubes Benchtop centrifuge Freezer vials (Nunc) -70 °C freezer Liquid-nitrogen storage tank
14
I: Preparation of lymphocytes Method 1. Centrifuge the cells to be frozen at 600 g for 7 min at 4°C. Remove the supernatant and flick the pellet. 2. Remove aggregates from heat-inactivated (30 min at 56°C) FCS or mormal human serum by centrifuging at 800 g for 30 minutes before use. Keep the serum sterile; if in doubt about its sterility, sterilize through a 0.2 (umsterile filter. Resuspend the cells (107-108/ml) in cold (4°C) neat, sterile, heat-inactivated PCS or normal human serum. 3. Incubate on ice for 20 min. While the cells are thus becoming less pinocytically active, make a solution of 20% dimethylsulfoxide (DMSO) in heat-inactivated sterile PCS or normal human serum. Add 0.25 ml of this serum/DMSO solution to each freezer vial (Nunc). Label the vials with a permanent marker pen. 4. Gently resuspend the cells. Add 0.25 ml of the cold cells in serum to each vial containing 0.25 ml of serum and 20% DMSO. 5. Put the vials into a commercially available, gradual freezing chamber, or if you do not have one, push them into a polystyrene rack so that each vial is firmly embedded on three sides and place in a -70°C freezer where the temperature will not be disturbed during storage. 6. For long-term storage (>2 weeks) leave the vials for 24-72 h at -70°C and then transfer them to a liquid nitrogen tank.
Protocol 9. Thawing cryopreserved cells Equipment and reagents • 37 °C water bath • Benchtop centrifuge • Sterile, 15 ml Universal tube • Sterile pastette . RPMI, 10%FCS(R/10 medium, see Protocol 7)
Method 1. Defrost cells from the nitrogen tank by transferring them to -70°C for 24-72 h. 2. Quickly defrost by immersion and gentle shaking in a 37°C water bath. 3. Transfer cells from the vial to a 15 ml sterile Universal tube with a sterile pastette. 4. Immediately add warm (37°C) R/10 medium; initially slowly with gentle shaking, 0.5 ml/min for the first 2 min, followed by 2 ml/min for the next 2 min, and then top up with 5 ml. 5. Centrifuge at 600 g for 7 min at room temperature, with brake. 6. Discard the supernatant, flick the pellet, and add 10 ml of R/10. 15
Magdalena Plebanski Protocol 9. Continued 7. Repeat steps 5 and 6 twice. During the last spin take an aliquot of cells to count and assess viability (see Protocol 2). Follow Protocol 4 if too many dead cells are present (>25%). Otherwise, resuspend the cells at the right concentration in the medium appropriate to your assay.
4.2 Principles of long- and short-term culture Culture media (which determines pH, isotonicity, and nutrients), media supplements (biological factors required for cell survival), the shape and physical properties of the container, and temperature, all affect cell survival and differentiation in culture. A series of conventional culture media have been developed commercially that normally support lymphoid cells and PAPCs in vitro. The most commonly used is RPMI. However, the specialized cell function you may want to study may require a specialized medium, for example the stimulation of naive T cells is normally undetectable in RPMI but is clearly inducible in aMEM media. Most human PBMCs and mouse spleen cell in-vitro cultures and bioassays require supplementation of the media with serum-derived factors. Serum-free media have been developed that provide these factors uniquely, but the simple expedient of adding 10% fetal calf serum (FCS) works for the majority of bioassays. Serum batches are variable in their ability to support assays, and also the level of background responses they induce. Using autologous, or species-specific serum (e.g. normal human serum with human cells) tends to reduce background problems. However, even then, it is advisable to batch-test the serum for your particular culture requirements. The shape of the tissue-culture container and the cell concentration used varies greatly depending on the bioassay and purpose of culturing. Most standard lymphocyte cultures (to assess proliferation, restimulate cells for cytotoxicity assays, or assays of lymphokine production) are carried out in standard tissue-culture plates (Terasaki plates or 96-, 48-, 24-, 12-, or 6-well, flat-bottom plates), with 0.5-5 X 106 cells/ml in the correct volume for the plate being used. Lymphoid cells and PAPCs will change in culture. The longer cells are cultured, the more changes there will be from their initial in-vivo characteristics. This will happen even with clonal cell populations. Although this fact must be kept in mind, many specific questions can only be addressed with long-term cultures. Moreover, in the near future they could be an essential tool not only for the immunologist (see Chapters 4, 5, 6, 7, 8, 9, and 15) but also for the physician (see Chapter 13). 4.2.1 Contamination problems Before deciding on the appropriate level of paranoia it is important to decide whether you are setting up a short-, medium-, or long-term culture. Short 16
1: Preparation of lymphocytes cultures (<24 h) do not require great care for the maintenance of sterility, and can even be performed without it. Media can be supplemented with antibiotics (penicillin and streptomycin or gentamicin, are most commonly used) to minimize possible bacterial contamination. Medium-term cultures (1-7 days) require standard sterility precautions. In other words, all reagents and implements used must be sterile; work in a sterility hood and keep your incubator clean. Fungi and yeasts are particular problems of improperly kept tissue-culture incubators. If you are planning to do long-term cultures (>7 days), fungal or yeast spores may still get into your culture from the air, even if the incubator itself is clean. Contamination usually comes from the air and thus starts in wells at the edges of plates. If using such tissue-culture plates, place your cells in the middle on the plate, and fill the edges with sterile medium. This will not only warn you of contamination in your environment before your cell sample is lost, but will help humidify the immediate area around your cells, decreasing evaporation. Plastic sandwich-boxes, with a small hole left for gas exchange, can also be used to protect plates with cells in long-term culture. Long-term culture always carries the risk of losing your cells. If feasible, consider freezing a sample of your culture as a back-up (see Protocol 8). If, despite your best efforts, contamination has crept in and you have a duplicate clean sample of cells, throw out your contaminated cells. Do it. However, if you have one sample of irretrievably precious cells, you can try rescuing your culture using fungicides or fungostatic agents. Amphotericin B at a 2 (ug/ml final concentration in culture is a common fungostatic, which does not interfere with most lymphocyte functions. It must be maintained in culture (since it prevents growth, but does not kill fungi and yeasts), by adding it every 7 days. The Ficoll gradient delineated in Protocol 4 can be applied to a culture if there is extensive yeast contamination. This will not eliminate contamination, but it will reduce it, as the yeast will pellet to the bottom of the Ficoll gradient and cells will remain floating on top of the Ficoll/medium interface. The recovered cells can be then cultured as normal in the presence of Amphotericin B. Another common contamination problem is mycoplasma. It is not detectable by eye. The first signs of contamination may be a failure of your cells to react normally in functional assays. Specific mycoplasma-detection tests are available commercially. Routine testing (every month) of long-term cultures for mycoplasma contamination is advisable. 4.2.2 Preventing cell proliferation In cases where PAPCs are used to induce the growth and expansion of T cells it may become necessary to stop the former from proliferating. This can be done by irradiating the PAPCs with gamma radiation (normally from a caesium source): 2000 rads prevent the proliferation of human and murine PAPCs and T cells without affecting most of their antigen-presenting cell 17
Magdalena Plebanski functions. If there is no radioactive source available, incubate your PAPCs for 45 min with 50 ug/ml of mitomycin C, followed by extensive washing. However, mitomycin C treatment may lead to a more severe loss in antigenpresenting capacity and should be used with caution.
5. Methods of subfractionation for lymphocytes and antigen-presenting cells The efficient functioning of the immune system depends upon the interaction between different cell types. Table 1 lists the main immune cell types and their characteristics (including cell-surface markers). T cells are central to the Table 1. Main blood-cell types Features
Cell (other names)
Red, small, central indentation
Erythrocyte (red blood Oxygen transport cell or RBC)
Main function
Blood group antigens: ABand rhesus
Very small, irregular shape
Thrombocytes (platelets)
—
Clotting
Surface markers
Medium sized, granular Basophils (similar cell Changes in vessel in tissues is mast cell) permeability
IgE receptor (IgER)
Medium sized, granular Eosinophils
IgG receptor (IgGR), complement receptor (C3bR)
Opsonin targeted killing
Medium sized, granular Natural killer cells (NK) Killing of cells
lgGR(CD16),CD56
Big, granular
Neutrophils
Phagocytosis
IgGR, C3bR, lectins
Big, round in blood, multitude of shapes in tissues
Monocytes (macrophages or histiocytes when in tissue)
Phagocytosis, opsonin targeted killing, fever response, complement production, specific T-cell activation
IgGR, C3bR, lectins (e.g. bacterial lipopolysaccharide receptor or CD1 4)
Veiled cells in blood, long thin arms in tissue
Dendritic cells (Langerhans cells in skin, interdigitating cells in lymph nodes and spleen)
Specific T-cell activation Unusually high levels of MHC molecules, CD38
Medium sized, round in B lymphocyte (terminally blood differentiated B cell is called a plasma cell)
Antibody secretion (as plasma cell), T-cell activation
Medium sized, round in Helper T lymphocyte (Th) blood
Regulates the function CD2, CDS, T-cell of other immune cells receptor (TcR), and CD4
Medium sized, round in Cytotoxic T lymphocyte Killing of cells blood (CTL)
18
Surface immunoglobulin CD19,CD20,CD22
CD2, CDS, TcR, and CDS
3: Preparation of lymphocytes regulation of the specificity, nature, durability, and magnitude of immune responses. The T-cell response is normally activated when PAPCs (B cells, monocytes/macrophages, dendritic cells) partially digest antigen to present its fragments (peptides) to T cells. These are complexed on the PAPC surface with major histocompatibility molecules (MHC). T cells specific for that peptide-MHC complex are then activated. The two main types of T cells, bearing either the CD8 or the CD4 marker, recognize class I- and class II-type MHC complexes, respectively. B-cell activation can occur in the absence or presence of T cells. The latter can regulate B-cell differentiation, and consequently the nature of the antibodies produced to an immune challenge. Markers now exist to distinguish naive and memory T cells, T cells homing to specific tissues, T cells causing suppression or activation of a specific set of immune effector functions. The list grows every day. A similar explosion in cell-surface markers has occurred for PAPCs. Isolating clean PAPC populations and studying their interaction with particular T-cell subsets continues to reveal subtleties in the workings of the immune system.
5.1 Physical properties 5.1.1 Density and size Table 1 provides a comparative idea of the size and granularity of different blood cell types. These apply to cells that are not undergoing an active immune response, since extensive differentiation and changes in shape and size can occur. A density gradient based on Percoll to separate dendritic cells, macrophages, and resting versus activated human T and B cells is described in Protocol 10. Gradients based on the use of albumin have also been described. The most common use of Protocol 10 is the isolation of specific, activated T cells from culture. T-cell blast cells normally appear in a stimulated culture after 48 hours. Cultures can be followed microscopically to allow you to choose the optimal time-point for harvesting blast cells. Several modifications of this method have been proposed to enrich dendritic-cell recovery. In fact, adaptations of this protocol, by modifying the density of the gradient, can be utilized to optimize recoveries of particular cell types in any species. Protocol 10. Isolation of blast T cells on a Percoll gradient Equipment and reagents • Percoll . FCS • 7.5% sodium bicarbonate solution • 10 x RPMI
• Centrifuge tubes • 1-5 ml pastettes, pipettes, or syringes with wide-gauge needle • Benchtop centrifuge
Method
1. Prepare Percoll for cell-use by adding 1.5 M of PBS in a ratio of 1 part PBS to 9 parts of a commercial Percoll solution. Alternatively, dilute 19
Magdalena Plebanski Protocol 10.
2.
3. 4.
5. 6.
7.
Continued
10x RPMI 1640 medium to 1x with dH20 and 7,5% bicarbonate solution. This isotonic Percoll solution is termed 100% Percoll and has a density of 1.1294 g/ml. 10 ul of 10 M Hepes can be added to further maintain physiological pH. Prepare 50%, 40%, and 30% Percoll solutions by diluting the 100% isotonic Percoll with PBS, RPMI, or, for delicate cell types, R/10. Prepare at least 2 ml of each per blast-cell preparation. You will also need a Percoll-free (0%) solution of your chosen medium. Centrifuge the cell preparation containing T-cell blasts at 600 g for 7 min at room temperature, with brake. Discard the supernatant. Flick the pellet and resuspend it in 2 ml of the 100% isotonic Percoll solution. Gently layer on to it 2 ml of each one of the 50%, 40%, 30%, and 0% Percoll solutions. Centrifuge at 600 g for 10 min at room temperature, with no brake. Collect cells at each interface (pipette, pastette, or a syringe with a wide-gauge needle can be used), starting from the 0%-30% interface, 30%-40%, 40%-50% (here are your blast T cells), 50%-100% (here are the resting T cells) and discard the pellet. Wash several times to remove Percoll by centrifuging at 600 g for 7 min at room temperature, with brake. During the last spin assess recovery and viability (see Protocol 2).
5.1.2 Adherence Macrophages, and to a lesser extent dendritic cells and B cells, adhere to glass and plastic. Incubation of human PBMCs in R/10 at 37 °C on a plastic surface, such as a Petri dish, tissue-culture flask, or flat-bottomed tissue-culture wells for more than 1 h is sufficient to cause the adherence of macrophages and dendritic cells, and to some degree, activated B cells. T cells, NK cells, and resting B cells generally do not adhere. If the incubation continues for more than 3 hours, dendritic cells and B cells will detach but macrophages will remain adhered to plastic. Adherence can thus be used to significantly enrich or deplete particular PAPCs. Firmly attached adherent cells can be recovered by gentle rubbing with a cell scraper. Incubation with Ca2+- and Mg2+-free PBS with 0.1-3 mM EDTA (PBS-EDTA) for 20 min at 4°C facilitates detachment.
5.2 Cell-surface markers 5.2.1 Binding of antibodies to specific surface markers Monoclonal antibody (mAb) technology has been coupled with an explosion in the characterization and understanding of different surface molecules on lymphoid cells and PAPCs. Some common markers are listed on Table 1. 20
1: Preparation of lymphocytes Methods have been developed based on the separation of cells that have bound a specific mAb. The main, commonly used protocols are detailed in the following sections. There are two main types of selection: negative, where the cell type which bound the mAb is removed and discarded, and positive where it is recovered. For ease in isolation, select abundantly expressed markers and antibodies with well-characterized binding properties. Remember that the markers we use are also functional molecules for the cell. Thus the interaction of the mAb with the marker could alter subsequent functional activity. When separating cells it is necessary to first consider the scale of preparation. A method suitable for isolating 106 cells may become unwieldy or prohibitively expensive if used to isolate 108 cells. Similarly, methods suitable for large-scale purification may result in excessive cell loss if used with small cell numbers. In general, complement-mediated lysis (see Section 5.2.2) and panning and columns (see Section 5.2.3) are better suited to large-scale preparations (>5 X 107 cells). Magnetic beads (see Section 5.2.4), and particularly cell sorting (see Section 5.2.5), are well suited to smaller preparations (<5 X 107). Perform all steps with sterile reagents if cell subpopulations are required for subsequent culturing. 5.2.2 Complement-mediated lysis This method used to be extensively employed for negative selection. In brief, cells that have bound antibody are killed by the action of complement. It is relatively cheap, and if optimal conditions are followed, gives good depletion. Its limitations are that the mAb employed needs to be able to fix complement, and a good source of complement (batch-testing is advisable) with low non-specific lysis and high specific activity is required. Lysis is time-dependent, and may vary for specific markers and complement batches. Lysis will release the cell contents into the environment which contains your negatively selected cells. Protocol 11. Negative cell selection by complement-mediated cell lysis Equipment and reagents • Monoclonal antibodies of choice (must be of complement-fixing isotype) • Complement source (rabbit or guinea-pig serum) . RPMI
• Centrifuge tubes • Benchtop centrifuge • Equipment and reagents analysis (see Chapter 2)
for FACScan
Method NB: Timing in this protocol is strict. 1. Incubate cells in centrifuge tubes at 2.5 x 106/ml in your medium of choice (e.g. RPMI) with the mAb at a saturating concentration (in most cases 1 ug/ml is sufficient) for 5 min at 37°C.
21
Magdalena Plebanski Protocol 11. Continued 2. Add fresh rabbit or guinea-pig serum as the complement source, 1 volume per 9 volumes of cells (i.e. 1/10 dilution) is usually appropriate. If known, use the optimal dilution titrated for your serum batch. Incubate for 45 min at 37°C. 3. Take an aliquot to assess cell viability (see Protocol 2) and to give a measure of lysis efficiency. 4. Centrifuge the cells at 600 g for 7 min at room temperature, with brake. Remove the supernatant, flick the pellet, and resuspend in RPMI. Repeat. 5. Take an aliquot to assess cell viability (see Protocol 2).a 6. Confirm the efficiency of your depletion by FACScan analysis with the appropriate markers (see Chapter 2). Remember, for the planning and interpretation of your FACScan analysis, that an antibody-binding step has already been performed on your cells. "Some dead cells will have been lost during washing in step 4. However, if too many dead cells for your experimental purpose are still present, eliminate them by Ficoll separation (see Protocol 4).
5.2.3 Panning and columns Adherence to antibody-coated plates or columns is also extensively used, particularly for negative selection. Depletion with optimized protocols is good (up to 90%) and may be enhanced to 100% by additional cycles. Some adherent cells may be non-specifically lost by binding to plastic or glass when following these protocols. The protocol described here assumes the separation of an adherent cell-free population, such as T cells. Protocol 12. Negative selection of human PBMCs by panning Equipment and reagents • Selected murine IgG mAb to a human cellsurface marker • 50 or 90 mm bacteriological-grade Petri dishes » PBS (see Protocol 2)
• Anti-mouse IgG . RPMI • RPMI 10% heat-inactivated FCS (R/10 medium, see Protocol 7) • Benchtop centrifuge and tubes
Method 1. Cover the bottom surface of the Petri dishes with 50 ug/ml anti-mouse antibody in PBS and incubate overnight (4°C or room temperature).3 2. Rinse the plates three times, gently, with medium (e.g. RPMI). 3. Discard the antibody solution and block non-specific binding sites by incubating for 1 h with R/10 medium, or block overnight at 4°C. 22
1: Preparation of lymphocytes 4. Incubate 2-10 x 106 cells/ml) with the specific mAb (normally 1 ug/ml) in R/10 or PBS with 10% heat-inactivated FCS at 4°C for 30 min. 5. Wash three times by centrifuging at 600 g for 7 min at room temperature, with brake. Resuspend in cold R/10 to give a cell concentration of 5-10 x 106/ml. 6. Discard the R/10 from plate and add mAb-coated cells at 5-10 x 106/ml. Add cells in the minimal volume that will still safely cover the surface of the Petri dish (for 90 mm Petri dishes this is 3.5 ml, and for 50 mm it is 2 ml). 7. Incubate at 4°C on a flat surface for 1-2 h. 8. Recover cells which have not bound to the antibody-coated plate. Swirl and gently tip the plate and collect the floating cells with a pastette. Additional cells can be recovered by adding (gently) more R/10 to the plate and repeating this procedure. 9. Wash the negatively selected cells at 600 g for 7 min at room temperature, no brake. Resuspend in the appropriate tissue-culture medium. Viability can be assessed by following Protocol 2 and phenotype confirmed by FACScan analysis (see Chapter 2). "You can leave such prepared plates for up to 7 days in the fridge in a humidified container.
Commercially available columns pre-coated with m Abs of the appropriate specificity, which deplete a variety of common lymphoid and PAPC populations, work on the same principle and are usually simple and reliable. However, they are expensive. Nylon-wool columns for the isolation of T cells may provide a cheaper alternative. This classic empirical method relies on the adherence of B cells, pre-B cells, monocytes/macrophages, and dendritic cells, as well as dead cells to the nylon wool. NK and T cells will not bind, and may thus be enriched compared to other cell types. Minor contaminating cells not removed by the column may be subsequently depleted by magnetic beads (see Section 5.2.4). Protocol 13. T-cell purification by a nylon-wool column Equipment and reagents • Nylon wool • 10 ml plastic syringe
. RPMI with 10%FCS(R/10 medium, see Protocol 7)
Method 1. Wash the nylon wool by boiling it for 5-10 min in four changes of distilled water. 2. Pack it into 10 ml plastic syringe up to the 5 ml mark (0.6 g wool/ syringe). 23
Magdalena Plebanski Protocol 13. Continued 3. Pass 20 ml R/10 medium through the nylon wool. Leave for 15 min at 37°C in R/10. 4. Load the column with 108 cells in 1 ml R/10 (e.g. PBMCs or spleen cells) and incubate at 37°C for 30 min. 5. Elute the T cells and NK cells by flushing through with warm R/10.
5.2.4 Magnetic beads Cell resetting with ferric oxide beads containing maghemite (magnetic beads), which can be attracted by a magnet, allows for the quick and efficient recovery of cell subpopulations. Selective binding of beads occurs if they have a specific mAb coupled to them (direct method). Alternatively, the mAb may be allowed to bind first to the cells, and then beads are applied which bind to the mAb (anti-murine IgG coupled beads are generally used) (indirect method). Positive selection with ferric beads can be performed by following the standard protocol and then eluting the cells from the beads. Purchasing beads for large-scale fractionation can be very expensive. Making your own beads is possible, but laborious. They are thus not a good option for largescale cell depletions (>5 X 107 cells), but they are an excellent choice for the quick recovery or depletion of low numbers of cells. Commercially available beads (Dynabeads M-450 from Dynal) come in a standard size of 4 uM in diameter and thus are individually visible under 10 X magnification. Magnets are also available with holders for Eppendorf tubes, or 5-15 ml laboratory plastic tubes, but any magnet can be used. Choose reagents according to the scale of your purification. Protocol 14 gives the method for indirect negative (steps 1-6) and positive selection (steps 1-9). Steps 3-9 can be used for the direct method. Protocol 14. Positive and negative cell selection using magnetic beads Equipment and reagents • Monoclonal antibody (mAb) to the cellsurface marker of choice (unmodified or biotinylated) • Magnet • Tubes to fit the magnet • Detachabeads (Dynal)"
• Maghemite beads (Dynabeads, Dynal) conjugated with anti-lg (recognizing your mAb of choice) or conjugated to streptavidin if your first mAb is biotinylated . RPMI with 10%FCS(R/10 medium, see Protocol 7)
Method 1. Incubate cells (106-107/ml in R/10) with a saturating concentration of the mAb antibody (1 (ug/ml is usually sufficient) for 30 minutes at 4°C.
24
1: Preparation of lymphocytes 2. Wash unbound antibody off the cells by centrifuging at 600 g for 7 min, at 4°C, with brake. Discard the supernatant (in some cases this mAb solution can be kept to restain cells). Flick the pellet, then resuspend the cells in R/10 and wash again. Finally resuspend at 107-5 x 107/ml in a transparent tube, which will then be easily applied to the magnet. 3. Wash the appropriate number of immunomagnetic beads (5 beads per cell you wish to select or deplete).b To do this transfer the beads to a transparent tube (e.g. Eppendorf or FACScan Falcon tube) and apply to a magnet for 1-2 min. Remove the supernatant with a pastette, taking care not to remove the beads that are being held by the magnet. Top the tube up with R/10, take off the magnet, close the tube, and mix the beads by inversion. Repeat twice. Resuspend in R/10 at 108 beads/ml. 4. Add the beads to the cells. Keep to a small total volume (0.5-1 ml) and, if necessary, use more than one tube. Incubate at 4°C for 45 min with gentle shaking or rotation (enough to prevent the beads and cells from settling to the bottom of the tube by gravity and thus encourage cell-bead interaction, but not strong enough to disrupt this interaction). 5. Apply the bead/cell mixture to the magnet for 2-3 minutes. Beads and bead-bound cells will be held by the magnet on the side of the tube. Transfer the unbound cells to a fresh tube, and apply again to the magnet. Repeat this process a further time with the unbound cells in another fresh tube in order to eliminate beads and bead-bound cells (negatively selected cells). 6. To recover cells bound to beads wash them first from unbound cells by resuspending them in cold R/10 and applying another two times to the magnet. 7. Resuspend the bound cells at a concentration of 107-5 x 107/ml in R/10 at room temperature, either by estimating this concentration or counting an aliquot of your bead/cell mix under the microscope (40 x magnification). 8. Add Detachabeads" at 100 (ul/ml to the cell/bead mix and incubate for 45 min at room temperature with gentle mixing. 9. Apply to the magnet and recover the unbound cells as in step 5. 10. Assess cell numbers and viability (see Protocol 2), and surface phenotype by FACScan analysis (see Chapter 2). " Detachabeads is an antibody to IgG which changes its conformation causing it to release the cells. " If the mAb used with the cells is murine IgG use anti-mouse IgG-coupled beads. If your mAb is biotinylated, you can use streptavidin-coated beads.
25
Magdalena Plebanski 5.2.5 Cell sorting The fluorescence-activated cell sorter (FACS) can be used for the analysis of lymphocyte subpopulations (as outlined in Chapters 6 and 9). This machine electronically detects and quantifies cells with specific fluorescence. The FACS can also be used for the isolation of cell subpopulations bearing a particular surface marker. Thus, cells are stained with a fluorochromelabelled mAb and are then applied to the FACS machine as if for analysis. Currently, up to five different fluorescent markers can be used. Particularly precise selection criteria can thus be employed. Changes in polarity influence the direction of a stream of cells contained in electronically charged droplets. Cells of the required staining characteristics can be selected using appropriate software and are given appropriate charges automatically. Droplets with positively charged cells will be diverted to one tube and those with negatively charged cells into another. Depending on the software, intricate selection criteria can be used on the basis of this simple principle. Isolation of a particular subpopulation may be slow, since cells are selected one by one. It can take 2-8 hours to recover 107 cells. To maintain sterility it is possible, in most sorters, to fit a 0.2 um Millipore filter into the sheath fluidsupply line and then flush through this filter with 10 ml of absolute ethanol (taking care that no alcohol gets into the sheath reservoir by clamping it off beforehand). Then the alcohol is washed off by extensive washing with sterile sheath fluid. Cell sterility during staining is maintained conventionally, using sterile reagents and a tissue-culture hood. Sterile tubes are used for collecting FACS-derived cell fractions. When using FACS to isolate cell subpopulations from culture, note that debris, particularly aggregated dead cells, may block the orifice of the nozzle that takes up the input cells. This will stop the sorting process. Dead-cell aggregates can be allowed to settle to the bottom of a tube and transferred to a fresh tube for sorting. If cell death is extensive consider removing them with a Ficoll gradient (see Protocol 4). When rare cells are being isolated the infrequent droplets collected may dry out. To prevent this, collect the deflected droplets directly into an appropriate fluid (e.g. pH-controlled medium). The presence of 10% serum will help to minimize cell loss through non-specific adherence to the collecting tube. Before attempting to use the FACS machine for cell sorting it is advisable to familiarize yourself with the use of the FACS machine and software for analysis.
Acknowledgement The author wishes to thank Carolyn Hannan for her helpful comments on this chapter. 26
2
Immunohistochemistry of lymphoid organs SIMON C. BIDDOLPH and KEVIN C. GATTER
1. Introduction Immunohistochemistry is a technique for localizing and identifying cellular or tissue components (antigens) by means of an antigen-antibody interaction, the site of the interaction being identified by the application of an appropriate labelling system. This technique plays an important part in diagnostic cellular pathology and biomedical research, and this chapter describes in detail the preparation of lymphoid cells and tissues for immunohistochemistry. It outlines the most frequently used labelling systems, and gives full details of the systems we find most useful in our laboratory. The distribution of different lymphocyte subpopulations in lymphoid tissue is also described.
2. Preparation of lymphoid cells and tissues for immunohistochemistry Immunohistochemical procedures can be applied to cytological preparations (cell smears, cytocentrifuge preparations, and cell imprints), frozen sections, paraffin sections, and resin sections. Procedures used on resin sections using light microscopy are adequately documented elsewhere (1), as are all those used in electron microscopy (2).
2.1 Slide adhesive Whichever type of preparation is made, the cells and tissues will be supported on a glass slide, but the very nature of the immunohistochemical procedure greatly increases the chance of the specimen being lost from the slide. Before one embarks on any of the subsequent preparative techniques, it is essential that there is an available supply of slides treated with adhesive, as described in Protocol 1. Coated slides are available commercially (Speci-Microsystems Ltd., UK).
Simon C. Biddolph and Kevin C. Gatter Protocol 1. Coating slides with adhesivea Equipment and reagents • VECTABOND™ reagent (Vector Laboratories Ltd) in 350 ml acetoneb
• 2% Decon (Decon Ltd) in distilled water
Method 1. Arrange the slides in a slide-rack and wash in 2% Decon for 5 min at room temperature. 2. Wash the slides in running tap water for 5 min. 3. Wash the slides in distilled water for 5 min at room temperature. 4. Place the slides in acetone for 5 min at room temperature. 5. Place the slides in the VECTABOND™ mixture for 5 min at room temperature. 6. Wash the slides in running tap water for 5 min. 7. Wash the slides in distilled water for 5 min at room temperature. 8. Shake the slides dry and incubate at 37°C overnight. When cool, place slides in boxes and store indefinitely at room temperature. ' Modified from the manufacturer's instructions, with permission. "This mixture is sufficient to coat 500 slides.
2.2 Choice of preparation A major consideration concerns the processing of preparations; i.e. to preserve the antigens which are to be demonstrated, whilst simultaneously preserving the cell and tissue morphology to allow an accurate interpretation of the results. From a morphological view, it is better to fix and process tissues through to paraffin sections. However, the range of antigens that can be demonstrated in paraffin sections is restricted when compared to that achieved in frozen sections and cytological preparations. Ultimately, the decision to use a particular preparation rests on which antigen one is hoping to demonstrate, and on which type of preparation the antibody, against that antigen, has been used successfully. Commercial antibody suppliers should ideally give this information. If developing or assessing an antibody, all the different types of preparation must be examined in order to establish what type of preparative technique can be used on a particular specimen type (see Table 1). Fresh tissue is best for demonstrating the broadest spectrum of antigens (see Table 1). After imprints have been taken (see Section 2.5), a portion can be taken for frozen sections (see Section 2.6), and the remainder placed in fixative for processing to produce paraffin sections (see Section 2.7). 28
2: Immunohistochemistry oflymphoid organs Table 1. Permissible preparative techniques
Fresh tissue Fixed tissue Cellular fluid"
FNA"
Cell smear
Cytocentrifuge
Imprint
Frozen section
Paraffin section
No No Yes Yes
No No Yes Yes
Yes No No No
Yes" No
Yesb Yesc Yesf Yesf
Yese Yese
" After subsequent freezing. * After subsequent fixation and processing to paraffin wax. c After subsequent processing to paraffin wax. d This term covers cell-lines in vitro and body fluids. "After subsequent centrifugation and freezing. 'After subsequent centrifugation, fixation, and processing to paraffin wax. 9 Fine-needle aspirate.
Thus, arrangements should be made to receive a specimen in an optimal state (see Section 2.3), so that the appropriate study can be carried out for a particular antigen.
2.3 Transport of specimen Under ideal circumstances, the specimen will arrive in the laboratory without delay. In the event of a delay of a few hours, there is no appreciable deterioration if the specimen is kept refrigerated at 4°C. Any longer than this and autolysis will lead to antigen loss or diffusion, and morphology will be compromised. Various transport media can be used to delay this deterioration: • saline-moistened gauze, Carmichael's medium (3), and Michel's transport medium (4) for fresh tissue; • fixative of choice for fixed tissue; • RPMI-1640 tissue culture medium (Gibco BRL) for cellular fluids and fineneedle aspirates (FNAs).
2.4 Cell smear and cytocentrifuge preparations These preparations can be made from cellular fluids (in vitro cell lines and body fluids) and FNAs. Cytocentrifuge preparations are preferred to cell smears, because a larger number can be made from any one specimen and the concentration of cells into a smaller area makes the subsequent staining more economical and the analysis quicker. If the specimen is rich in cells, it can be advantageous to prepare cell blocks for frozen and paraffin sections (see steps 2 (c) and (d), Protocol 2). 29
Simon C. Biddolph and Kevin C. Gatter Protocol 2. Cell smear and cytocentrifuge preparations from cellular fluids and fine-needle aspirates Equipment and reagents • Centrifuge and plastic centrifuge tubes • Cytocentrifuge and cuvettes (Shandon Scientific Ltd.) • Haemocytometer . VECTABOND-coated slide (see Protocol 1) • 10% (v/v) fetal calf serum (FCS) in RPMI1640 cell culture medium (Gibco BRL)
. DAKO pen (DAKO) • Neutral-buffered formalin: 10% (v/v) formaldehyde, 29 mM NaH2PO4H2O, 46 mM Na2HP04 • 4% agarose • Acetonea
Method 1. Transfer the specimen to a plastic centrifuge tube and centrifuge at 120 g for 10 min. 2. Drain off the supernatant and: (a) For cytocentrifuge preparations, resuspend the pellet in 2 ml 10% PCS in RPMI-1640 medium. Using the haemocytometer, determine the cellularity and adjust the concentration of cells to between 5 x 105 and 106 cells/ml with FCS/RPMI medium. Proceed to step 3. (b) For cell smears, place a pea-sized amount of the specimen on to a coated slide, and with a second slide apply pressure to the specimen to spread it evenly and quickly over both slides. Proceed to step 4. (c) For frozen sections, proceed to Section 2.6. (d) For paraffin sections, fix the cells in neutral-buffered formalin (see Section 2.7.1) for 12 h, centrifuge at 120 g for 10 min, drain off the fixative, and pour molten 4% agarose on to the pellet. Centrifuge at 120 g for 10 min and allow the agarose to set. Remove the agarose pellet and proceed to Section 2.7.3. 3. Place 250 ul of the resuspended cells into each of 12 cytocentrifuge cuvettes and centrifuge at 120 g for 10 min. 4. Air-dry the cell smears and the cytocentrifuge preparations at room temperature for 2 h.b 5. Fix for 10 min in acetonea at room temperature, air-dry for a further 10 min, circle the area of interest with the DAKO pen,c and proceed with immunostainingd(see Section 3). •Acetone is our fixative of choice for the subsequent immunostaining of cytological preparations. Better morphology is seen if preparations are fixed for 2 min in acetone:methanol:40% formaldehyde (19/19/2 by vol.) or acetone:PBS:formalin (5). bLymphoid markers are best shown in cytological preparations that have been air-dried (6). 'This applies a limiting line around the area of interest which prevents the spread of aqueous solutions. d lf immunostaining is not to be performed immediately, wrap the slides in foil after fixation and store at -20°C. Prior to staining, allow the slides to reach room temperature before removing the foil. This prevents condensation forming, which can lead to antigen diffusion.
30
2: Immunohistochemistry of lymphoid organs
2.5 Cell imprints ('dabs' or 'touch preparations') On receipt of a fresh lymphoid specimen, making an imprint is the first preparation that can be carried out. It involves the direct transfer of cells from a freshly cut surface of the tissue on to a slide, and is a quick and simple method involving no specialized equipment. Individual cells or clumps of cells will be seen and the preparation is similar in nature to a cell smear. Immunohistochemistry can be successfully carried out and individual cellular morphology is well preserved, but tissue morphology is better seen in frozen and paraffin sections. The freshly cut surface is lightly blotted with soft and absorbent paper. It is best to grasp the back of the specimen with forceps and lightly, and squarely, touch the specimen on to a coated slide (see Protocol 1). Avoid any sideways movement as this will disrupt the cells. The slides should be dried at room temperature and fixed with acetone prior to immunostaining (see Protocol 2, step 5).
2.6 Frozen sections ('cryostat sections') Freezing tissue provides a hardened specimen for sectioning, excellent preservation of antigens, and moderately good morphological preservation. Ideally, an extremely rapid cooling rate should be used to limit cellular damage caused by ice-crystal formation. The sample size and choice of freezing process are the most important considerations. We freeze specimens no larger than 10 X 10 X 5 mm, using liquid nitrogen at a temperature of -196 °C. Once frozen the specimen can be either sectioned immediately in a cryostat, or stored in a -70 °C freezer (or liquid nitrogen) for sectioning at a later date. To limit the desiccant effects of these cold storage temperatures, we entirely cover the specimen in OCT (Optimum Cutting Temperature compound, Miles Scientific), and wrap it in cold foil or place it in a polyethylene storage tube suited to extreme cold temperatures. OCT should also be used to surround and support the specimen for sectioning in the cryostat. Frozen sections can also be made from highly cellular fluids and FNAs. After centrifugation, the pellet of cells can be carefully frozen and treated in a similar way to tissue (see Protocol 2, step 2 (c) ). 2.6.1 Considerations in the sectioning and fixing of frozen sections To produce high-quality frozen sections safely from lymphoid tissues, several points should be considered: (a) Frozen sections should not be prepared until a risk assessment into the presence of infective agents has been carried out. Betapropriolactone destroys the infectivity of human immunodeficiency virus without compromising the antigenicity (7), but cutting tuberculous specimens may have to be prohibited if suitable containment procedures are unavailable. 31
Simon C. Biddolph and Kevin C. Garter (b) The optimal temperature for cutting different tissues varies; -20 °C is best for bone-marrow because of the need to cool any bone running through the sample, although it is advisable to remove any obvious bone prior to sectioning. Gut-associated lymphoid tissue (GALT), lymph node, thymus, and tonsil are best at -15 °C. Liver and spleen will shatter unless the temperature is raised to -10 °C within the cryostat. (c) Sections should be cut at 6 u.m on to coated slides (see Protocol 1), and air-dried for 6-12 h. Sections should be fixed in acetone for 10 min at room temperature, and circled with a DAKO pen prior to immunostaining or storage (see Protocol 2, step 5).
2.7 Paraffin sections Fixing and processing tissues for paraffin-wax sections gives the best morphological preservation when compared to cytological preparations and frozen sections. Paraffin acts as a support for tissue, thus allowing thin sections to be cut and viewed under the microscope. Unfortunately, the processes used to produce paraffin sections can lead to the masking or destruction of antigens. Nevertheless, a wide range of antigens is still detectable, and commercial antibody suppliers are constantly striving to produce antibodies for use in fixedand paraffin-processed tissue (see Table 2), Numerous techniques have been developed to enable us to 'retrieve' antigens that previously were believed to have been lost entirely in the fixing and processing stages (see Section 2.7.7). 2.7.1 Fixation The primary objective in the fixation of tissue destined for paraffin sections is to stabilize the cell contents and tissues in as near a life-like state as possible through all the processing stages, whereby water is removed and paraffin wax is infiltrated into the specimen. A large variety of fixatives is available, but no single fixative can preserve every single tissue component. Formaldehydebased fixatives are the most widely used and, although the exact mechanism of their fixation effect is not known, it is thought that methylene bridges are formed between amino groups on cellular proteins. This, in effect, creates a gel that holds the cellular constituents in place. We use formol acetic acid for the fixation of bone-marrow trephines—as it has a decalcifying effect that does not compromise antigenicity (see Section 2.7.2)—and neutral-buffered formalin for the fixation of all other lymphoid tissues prior to the production of paraffin sections: • Formol acetic acid—(10% (v/v) formaldehyde, 0.15 M NaCl, 2% (v/v) glacial acetic acid). The bone-marrow trephine should be placed in at least 20 times its own volume of fixative. Large spicules of bone in the specimen should be carefully removed (see Section 2.6.1 (b) ).The solution should be changed three times over 2 days to allow proper fixation and decalcification to occur. 32
2: Immunohistochemistry oflymphoid organs • Neutral-buffered formalin—(10% (v/v) formaldehyde, 29 mM NaH2PO4.H2O, 46 mM Na2HPO4).Tissue should be cut into slices 3 mm thick and placed in at least 20 times its own volume of fixative. Optimal fixation occurs between 12 and 24 h (8), but tissue can be kept in this solution for many years. 2.7.2 Decalcification Areas of calcification in tissue can cause problems when sectioning. Large areas of bone should be excised away, after fixation, from the area of interest. Smaller foci can be decalcified by fixation in formol acetic acid (see Section 2.7.1). 2.7.3 Processing After fixation, the tissue, or cells supported by solid agarose (see Protocol 2, step 2 (d)), must be taken through a graded series of alcohols and an intermediate agent (xylene) to allow infiltration by paraffin wax. This is most conveniently carried out on an automatic tissue processor (e.g. Shandon Scientific Ltd.) using 1.5 h for each of the 12 steps. Increasing the processing temperature from ambient to 45 °C for all stages up to that of wax infiltration benefits immunohistochemical staining (8). The immunoreactivity of tissue in paraffin wax is unaffected by long-term storage, therefore enabling retrospective studies to be carried out. 2.7.4 Sectioning, section drying, and storage Paraffin blocks should be cut at 4-5 |xm on a microtome, by an experienced histologist. The sections must be put on to coated slides (see Protocol 1) and dried overnight at 37 °C. The sections can be heated in a 60 °C oven for 1 h if they need to be stained quickly. The use of a hot-plate is not recommended because of the uneven temperatures across the plate (8). Our experience is that unstained sections can be stored at room temperatures for many years without losing immunoreactivity. 2.7.5 Rehydrating sections The paraffin wax must be completely removed from the section prior to staining. We use three changes of xylene, each of 5 min. The xylene is removed using a graded series of alcohols followed by a thorough wash in cold, running tap water and then transferred to distilled water to await staining. Less toxic alternatives to xylene are available, e.g. Citroclear (HD Supplies). 2.7.6 Blocking endogenous enzymes Enzymes are commonly used as labels, either attached directly or indirectly to the antibody being applied to detect the antigen (see Section 3.2). If enzymes exist in the cells or tissues that are the same or similar to those used as the label in the staining technique, they must be removed—otherwise they will act on the substrate used to locate the enzyme label and a false-positive result will 33
Simon C. Biddolph and Kevin C. Gatter be produced. This is important at this stage because we have found that the best time to remove endogenous peroxidases (pseudoperoxidase, myeloperoxidase, and peroxidase in erythrocytes, granulocytes, and eosinophils, respectively (9)), when using horseradish peroxidase as a label (see Section 3.2.1), is after paraffin section rehydration and before any subsequent stages. We expose the rehydrated sections to 0.5% (2 vol.) hydrogen peroxide in methanol for 20 min at room temperature (see Protocol 3, step 3), or 3% (10 vol.) hydrogen peroxide in distilled water for 20 min at room temperature. This treatment is too harsh for frozen sections and, although alternative treatments are available (9), we either ignore the more granular falsepositivity and carefully compare the test section to a negative control section, or use a different enzyme label such as alkaline phosphatase (see Section 3.1.3). 2.7.7 Antigen retrieval Some antigens were thought to be hidden by, or even destroyed, by formaldehyde-based fixatives and/or paraffin processing. However, methods have been devised to unmask, or retrieve, some antigens using proteolytic enzyme digestion. The use of many antibodies on paraffin sections continued to be limited until the arrival, in the early 1990s, of the heat-mediated antigen retrieval technique (10). Both methods of retrieval are used today, but the latter proves to be the most effective over a broad range of antigens. Some antigens do not need to be retrieved as they are unaffected by fixation or processing, and some, to date, can only be detected in cytological preparations or in frozen sections. Commercial antibody suppliers give information in their catalogues as to whether their products are suitable for different types of preparation. Table 2 shows the antibodies we use in formalin-fixed, paraffin-embedded sections, with our preferred choice of pre-treatment. i. Proteolytic enzyme digestion With formalin fixation, methylene bridges are formed between amino groups. Digestion with proteolytic enzymes can remove this cross-linking, which prevents access to the antigenic sites by the antibody. The time for digestion varies with the nature and time of fixation used, and the antigen being retrieved. The antigen itself can be digested if the times and conditions are not carefully controlled. Unfortunately, there is no one enzyme and time of digestion that can be universally applied. Protocol 3 gives details for using the two most useful proteolytic enzymes. ii. Heat-mediated antigen retrieval (HMAR) This method involves the exposure of paraffin sections to high temperatures in aqueous salt or protein denaturant solutions. Although the exact mechanism of HMAR is unclear, it is believed that the combination of high temperature and exposure to a salt solution may chelate or precipitate 34
2: Immunohistochemistry oflymphoid organs calcium or other divalent metal cations, which otherwise mask antigenic sites by complexing with proteins during formaldehyde fixation (11). Different solutions have been investigated and, although no single solution has been found to be universally optimal, we use either a sodium citrate solution or—most regularly—a Tris-EDTA disodium salt solution (pH 9.0) depending on the antigen we are retrieving or the antibody we are using (see Table 2). Protocol 3. Proteolytic enzyme digestion of formalin-fixed and paraffin-processed sections Equipment and reagents • 0.5% (2 vol.) H2O2 in methanol (for a peroxidase-based labelling system) • Trypsin solution: 0.1% (w/v) trypsin type II, crude from porcine pancreas (ICN Biochemicals) in 0.1% CaCI2 (w/v) pH 7.8, at 37 °C'
• TBS (Tris-buffered saline): 50 mM Trisbase pH 7.6, 0.15 M NaCI • Protease solution: 0.0125% (w/v) protease type XXIV, bacterial (Sigma) in TBSa
Method 1. Cut 4 um paraffin sections on to coated slides (see Protocol 1) and dry overnight at 37°C. De-wax and rehydrate to running tap water and place in distilled water. 2. If using a peroxidase-based labelling system, place sections in 0.5% (2 vol.) H202 in methanol for 20 min at room temperature (see Section 2.7.6). Wash the slides in running tap water and place in distilled water at room temperature. Otherwise omit this step. 3. Pre-warm the slides by immersion in distilled water at 37°C for 30 min. 4. Place the slides in the pre-warmed proteolytic enzyme solution.6 5. Halt the digestion by washing the slides in running tap water for 5 min, and place in distilled water at room temperature. " Pre-warm this solution to 37 °C. "The optimum time for immersion in this solution differs between antigens, antibodies, and the length of fixation Times range from 5 to 30 min and must be determined by trial and error.
HMAR has the following advantages over proteolytic enzyme digestion: • Uniform heating times can be used to retrieve antigens, regardless of the length of time in fixative, whereas enzyme digestion has to be matched to fixation time. • A much greater number of antigens are retrieved. • Some antigens once thought to be completely lost can now be retrieved. 35
Simon C. Biddolph and Kevin C. Garter • The staining of many antigens can be enhanced over and above that obtained post-digestion. • The detection threshold is lowered. This increased sensitivity means that antibodies can be used in a more dilute form. • Non-specific background staining is reduced. However, not all antigens are retrieved optimally using HMAR, so that proteolytic enzyme digestion can still play a part. Also, when using a biotinylated labelling system (see Section 3.1.4), one should bear in mind that the exposure of endogenous biotin is enhanced by HMAR (12). A microwave oven was first used for antigen retrieval (10) and is ideal for a small number of slides (see Protocol 4), but it may give inconsistent results because of its hot and cold spots: for large numbers of slides and more consistent retrieval, we prefer to use a pressure-cooker (13), as shown in Protocol 5, which is also more gentle to the sections. Protocol 4. Heat-mediated antigen retrieval using a microwave oven Equipment and reagents • 850 W domestic microwave oven • Sodium citrate antigen-retrieval solution: 10 mM trisodium citrate dihydrate pH 6.0 • Tris-EDTA antigen-retrieval solution: 50 mM Tris, 2 mM EDTA disodium salt, pH 9.0
• 700 ml microwave-proof container* (Sealtight foodsaver, ADDIS) • Microwave-proof cling-film • Two glass slide-racks, each with 10 slots, enough to hold 20 slides back-to-back
Method 1. Follow Protocol 3, steps 1 and 2. 2. Place the slides back-to-back in the glass slide-racks6 and add enough antigen-retrieval solution of choice to cover the slides. Cover the container with microwave-proof cling-film and pierce the film. 3. Microwave for 5 min at 90% power,3 and check the fluid level. Top up the solution if necessary. 4. Microwave for a further 5 min at 90% power,3 and remove the container from the microwave. Carefully flush out the retrieval solution with cold, running tap water and transfer the slides to distilled water at room temperature. "Different size containers can be used, but the volumes of retrieval solution will then differ. Consequently, the optimal time and power levels should be performance-tested for optima! retrieval. ''The slide-racks should be full of slides at all times. Use blank slides to fill any gaps.
36
2: Immunohistochemistry of lymphoid organs Protocol 5. Heat-mediated antigen retrieval using a pressurecooker Equipment and reagents • Sodium citrate antigen-retrieval solution (see Protocol 4) • Tris-EDTA antigen-retrieval solution (see Protocol 4)
• Stainless-steel pressure-cookera (e.g. Prestige 'Rise n timer' model 6189. Operating pressure of 103 kPa/15 p.s.i.)
Method 1. Follow Protocol 3, steps 1 and 2. 2. Pour 2 litres of the antigen-retrieval solution into the pressure-cooker, place the lid loosely on the body of the pan and heat to boiling point. 3. Place the slidesb into the boiling buffer and seal the cooker. 4. Bring the cooker to pressure.a Heat at full pressure for 90 sec. 5. Remove the cooker from the heat source and place in a sink of cold water. Rinse the exterior of the cooker with cold, running tap water until the pressure has been released. 6. Remove the cooker lid and fill the cooker with cold, running tap water. Remove the slides and place in distilled water. "Follow the manufacturer's instructions for use of the pressure-cooker. b We use four slide racks at one time, 24 slides in each rack. Unlike with microwave retrieval, empty gaps in the rack do not need to be filled.
Table 2. Primary antibodiesa and antigen-retrieval method of choice for formalin-fixed and paraffin-processed specimens Antigen/CD"
No. clone
Supplier
Antigen-retrieval method
CD1a CD2 CD3 CD4 CD5 CD8 CD9 CD15 CD16 CD20 CD21 CD22 CD23 CD30 CD31 CD34
O10 MT910 PCa 1F6 4C7 C8/144B 72F6 C3D1 DJ130C L26 1F8 FPC1 MHM6 BerH2 JC/70A QBend10
Coulter DAKO DAKO NCf NC DAKO NC DAKO DAKO DAKO DAKO NC DAKO DAKO DAKO DAKO
HMAR Citrc HMAR TrEdd HMARTrEd HMAR TrEd HMAR Citr HMARTrEd HMAR TrEd HMAR TrEd HMARTrEd HMAR TrEd HMARTrEd HMARTrEd HMARTrEd HMAR TrEd HMAR TrEd HMAR TrEd
37
Simon C. Biddolph and Kevin C. Gutter Table 2. Continued Antigen/CDb CD35 CD41 CD42b CD43 CD44 CD45 CD45RA CD45RB CD45RO CD50 CD56 CD61 CD66 CD68
No. clone
BerMac-DRC 5B12 MM2/174 DF-T.1 DF1485 2B11 4KB5 PD7/26 UCHL1 KS128 1B6 Y2/51 Kat4c KP1 PGM1 CD71 H68.4 LN-2 CD74 CD75 LN-1 JCB117 CD79a 12E7 CD99 IgA 6E2C1 lgD26 IgD A57H - IgG IgM R1/69 bcl-2/124 bcl-2 Glycophorin A JC159 Glycophorin C Ret40f HLA class II CR3/43 Kappa A8B5 PC Lambda N10/2 PC Ki67 Ki67 PC Lysozyme Myeloperoxidase PC NP57 N'philh Elastase Plasma cell Vs38c S100 PC V. W.ifactor F8/86
Supplier
Antigen-retrieval method
DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO NC DAKO DAKO DAKO DAKO BioGenex DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO DAKO
ProtEnz9 ProtEnz HMAR Citr HMAR TrEd HMARTrEd Nil Nil Nil Nil HMARTrEd HMAR Citr HMAR TrEd HMARTrEd HMARTrEd HMARTrEd HMAR Citr HMAR TrEd HMAR TrEd HMAR TrEd HMARTrEd ProtEnz HMAR TrEd ProtEnz HMAR TrEd HMARTrEd Nil HMAR TrEd HMARTrEd HMARTrEd HMARTrEd HMARTrEd HMARTrEd HMAR TrEd HMARTrEd Nil Nil HMAR TrEd HMAR TrEd HMARTrEd
a Concentrated and lyophilized antibodies, once reconstituted, should be stored as 0.1 ml aliquots at -70°C. Pre-diluted antibodies and kits should be stored at 4°C. Avoid repeated thawing and freezing. * Cluster of differentiation. c Heat-mediated antigen retrieval in sodium citrate solution (see Protocol 4). d Heat-mediated antigen retrieval in Tris-EDTA solution (see Protocol 4). "Polyclonal antibody. 'Novocastra Laboratories Ltd. g Proteolytic enzyme (see Protocol 3). 'hNeutrophil. iVon Willebrand.
38
2: Immunohistochemistry of lymphoid organs
3. Immunohistochemical staining The aim of all immunohistochemical staining methods is to visualize accurately a particular antigen. This is achieved by using a specific antibody to the antigen, then visualizing the antibody. Many methods have been developed over the years, each with their own advantages and disadvantages. This section will look at these methods, the commonly used labels and their visualization, and the considerations in choosing a suitable combination of method and label when staining a particular preparation with a single antibody. Staining a preparation with multiple antibodies will also be considered. All the reagents involved in these methods are commercially available.
3.1 Immunohistochemical methods 3.1.1 Direct method This is the simplest and quickest of all the methods. It involves a one-step procedure whereby a label is conjugated directly to the antibody used against a given antigen, and the conjugate is applied to the specimen. However, this is the least sensitive of all the methods available, and the least versatile because the antibody cannot be used in other methods. A more sensitive variant, known as EPOS (enhanced polymer one-step— from DAKO), is available commercially and is gaining in popularity. However, not all antibodies are available in EPOS form, and it also suffers from a lack of versatility. 3.1.2 Indirect method Increased sensitivity and versatility is achieved in this method over the direct method. Unlabelled antibody (primary antibody) against a given antigen is applied to the preparation. A labelled secondary antibody, raised against the species of the primary one, is then applied. If using a large number of primaries of the same species, a single labelled secondary antibody can be used. This is the two-stage indirect method. Sensitivity is enhanced in the threestage method by the further application of a labelled antibody raised against the species in which the labelled secondary was raised. 3.1.3 Unlabelled antibody-enzyme complex method An enzyme label (horseradish peroxidase or alkaline phosphatase—see Section 3.2) and an antibody against the enzyme form a complex (peroxidase anti-peroxidase—PAP, and alkaline phosphatase anti-alkaline phosphatase— APAAP (14)). The antibody in the complex must be raised in the same species as that of the primary. A bridging antibody forms a link between the primary antibody and the complex. Sensitivity is considerably improved by repeating the bridging layer and the enzyme complex, particularly in the 39
Simon C, Biddolph and Kevin C. Gatter APAAP method. It is particularly useful for using on preparations where the endogenous peroxidase content is high, e.g. bone marrow and spleen, and also where the blocking methods (see Section 2.7.6) may destroy the specimen. However, we prefer not to use the APAAP method with primaries directed against nuclear antigens. Results are poor, which we hypothesize relates to poor penetration by the relatively large complexes (unpublished observations). 3.1.4 Avidin-biotin and streptavidin-biotin systems Avidin and streptavidin have a natural affinity for biotin, which is easily conjugated to antibodies and labels. The unlabelled primary is applied, followed by incubation with a biotinylated secondary antibody raised against the species in which the primary antibody was raised. Finally, labelled avidin or streptavidin are allowed to bind with the biotinylated secondary. Alternatively, avidin or streptavidin are allowed to complex with the biotinylated label, and this complex binds to the biotinylated secondary. Both systems are highly sensitive and the most popular methods in use today. The one disadvantage is the problem of endogenous biotin, which is most noticeable in frozen sections and paraffin sections treated with HMAR (see Section 2.7.7 («')). Liver, kidney, breast, and adipose tissue, as well as cells/tissues with high numbers of mitochondria (11), have high levels of endogenous biotin. The biotin can be effectively blocked using commercially available kits (DAKO and Vector Laboratories), which use incubations in 0.1% avidin followed by 0.01% biotin. 3.1.5 Biotinylated tyramine method This method, first used for enhancing ELISA and Western blotting (15) and subsequently adapted for immunohistochemistry (16), produces significantly increased sensitivity when compared to the avidin/streptavidin-biotin systems. The method uses horseradish peroxidase-labelled streptavidin, or the streptavidin-biotin complex, as the third step after the application of primary and biotinylated secondary antibodies (see Section 3.1.4), followed by the application of biotinylated tyramine. The horseradish peroxidase catalyses the deposition of biotinylated tyramine at the sites of immunoreactivity, allowing the increased amounts of biotin to be detected by further addition of labelled avidin or streptavidin. The method allows the detection of some antigens thought to be undetectable in paraffin sections, even after the use of HMAR (17), and also the extensive dilution of primary antibodies. Commercial kits are available— TSA (Du Pont) and CSA (DAKO)—or the biotinylated tyramine can be made in the laboratory (16,17). To date, we have limited experience of this method, but it will certainly be used more in the future unless new primary antibodies and antigen-retrieval solutions are developed. 40
2: Immunohistochemistry oflymphoid organs
3.2 Labels It is essential in all immunohistochemical staining methods to use labels to visualize the antigen-antibody reaction. Enzymes are the most widely used labels because, with the addition of a substrate and a chromogen, different coloured and stable reaction products are visible using light microscopy. Fluorescent labels are also used, but they require more specialized instrumentation to be seen (see Section 3.2.3).
3.2.1 Horseradish peroxidase (HRP) This is the most widely used enzyme label. Hydrogen peroxide acts as the substrate, and different chromogens can be used to produce a variety of different coloured reaction products: • 3,3'-Diaminobenzidine tetrahydrochloride (DAB) yields a dark-brown reaction product, insoluble in organic solvents. See Protocol 6, Method A and Figures 1 A-F, H, and /. The colour can be intensified (see Protocol 6, step 2). • 3-Amino-9-ethylcarbazole (AEC) yields a red reaction product, which is soluble in organic solvents and must be mounted in an aqueous mountant. See Protocol 6, Method B. • Hanker-Yates reagent (18) yields a blue end product, insoluble in organic solvents. Protocol B. Demonstration of horseradish peroxidase Equipment and reagents • TBS (see Protocol 3) . 0.05% DABa (w/v) (3,3'-diaminobenzidine tetrahydrochloride} in TBS • AEC (3-amino 9-ethyl carbazole) • DMF (N,N'-dimethyl formamide) • 0.2 M acetate buffer pH 5.0
« 3% (10 vol.) hydrogen peroxide in distilled water • Mayer's haematoxylin • Xylene-based mountant (e.g. DePeX, BDH) • Aqueous mountant (e.g. Aquamount, BDH)
A. Brown reaction product 1. After immunostaining, wash the sections in two changes of TBS over 5 min. 2. Immediately prior to use, add 160 ul 3% hydrogen peroxide to 50 ml of the DAB solution and incubate the slides in this solution for 4 min at room temperature.b 3. Wash the slides in cold, running tap water for 5 min. 4. Counterstain in Mayer's haematoxylin.c 5. Dehydrate, clear, and mount the slides in a xylene-based mountant. 41
Simon C. Biddolph and Kevin C. Gatter Protocol 6.
Continued
B. Red reaction product 1. After immunostaining, wash the sections in two changes of acetate buffer over 5 min. 2. Immediately prior to use, add 10 mg AEC to 2.5 ml DMF in a glass tube and mix well. 3. In a separate tube, add 0.2 ml 3% (10 vol.) hydrogen peroxide to 50 ml acetate buffer. Mix well and add to the solution made in step 2. Mix well. 4. Filter the mixture on to the sections and incubate at room temperature for 15-20 min.c 5. Wash the slides in cold, running tap water for 5 min. 6. Counterstain in Mayer's haematoxylin.c 7. Wash the slides in distilled water and mount the sections in an aqueous mountant. aWear gloves when handling DAB. To lessen the need to handle the powder, add 0.48 g DAB to 20 ml TBS. Divide into 1 ml aliquots and freeze. To use, thaw out an aliquot, add 49 ml TBS and 160 ul of 3% (10 vol.) hydrogen peroxide. Alternatively, DAB tablets are commercially available (Sigma). bThe strength of the end product can be intensified directly after this stage by incubating the slides in a 0.5% (w/v) copper sulfate in 1% (w/v) sodium chloride solution for 5 min. The end product turns black. Proceed from step 3. c Observe and control the staining microscopically.
3.2.2 Alkaline phosphatase This is the most widely used, alternative enzyme label to HRP. The major advantage is in its use as a label on preparations high in endogenous peroxidase or where blocking methods are harmful to the preparation. Thus, it is our method of choice for cytological specimens, bone-marrow aspirates/ trephines, spleen, and frozen sections. Endogenous alkaline phosphatase in bone, liver, and kidney is easily blocked by the addition of levamisole at the visualization stage. Intestinal and placental alkaline phosphatase are more resistant. Napthol phosphate esters act as substrates for this enzyme. They are hydrolysed to form phosphates, and phenolic compounds that couple with diazonium salts (used as chromogens) to produce coloured azo dyes. Various combinations of substrate and chromogen can be used to yield different coloured reaction products: • Napthol AS-BI phosphate and New Fuchsin yield a red reaction product that is soluble in alcohol, but preparations can be mounted in a xylenebased mountant. See Protocol 7, Method A, and Figure 1G. This is a particularly intense reaction product and is ideal for photography. 42
2: Immunohistochemistry of lymphoid organs • Napthol AS-MX phosphate and Fast-Blue BB yield a blue reaction product that must be mounted in an aqueous mountant. See Protocol 7, Method B. (Substituting Fast-Red TR for Fast-Blue BB yields a soluble, red reaction product.) Protocol 7. Demonstration of alkaline phosphatase Equipment and reagents TBS (see Protocol 3) 5% New Fuchsin in 2 M HCI 4% sodium nitrite in distilled water—freshly prepared Napthol AS-BI phosphate-sodium salt Napthol AS-MX phosphate DMF (see Protocol 6)
Tris buffer: 0.05 M Trisbase pH 8.5 1 M levamisole (in distilled water) Mayer's haematoxylin 1% Neutral Red Xylene-based mountant (e.g. DePeX, BDH) Aqueous mountant (e.g. Aquamount, BDH)
A. Red reaction product 1. After immunostaining, wash the sections in two changes of TBS over 5 min. 2. In a glass tube add 50 mg of Napthol AS-BI phosphate to 0.6 ml of DMF and mix well. 3. In a separate tube, add 0.2 ml of 5% New Fuchsin in 2 M HCI to 0.5 ml of freshly prepared 4% (w/v) sodium nitrite. Mix well for 1 min. 4. Add 100 ul of levamisole to 100 ml Tris buffer pH 8.5. Mix well. 5. Add the mixture in step 3 to that in step 4. Mix well. Add the mixture in step 2, mix well, and filter on to the sections. Incubate for 10-30 mina at room temperature. 6. Wash the slides well in distilled water. 7. Counterstain with Mayer's haematoxylin.a 8. Shake the slides dry and lay the slides on a 60°C hot-plate until the sections are dry. 9. Mount the slides in a xylene-based mountant. B. Blue reaction product 1. After immunostaining, wash the sections in two changes of TBS over 5 min. 2. Add 10 ul levamisole to 9.8 ml of Tris buffer pH 8.5. 3. In a glass tube, add 2 mg of Napthol AS-MX phosphate to 0.2 ml of DMF. Mix well. 4. Add the mixture in step 3 to that in step 2. Mix well. Add 10 mg of FastBlue BB.b Filter on to the sections and incubate for 10-20 mina at room temperature. 43
Simon C. Biddolph and Kevin C. Gatter Protocol 7. Continued 5. Wash the slides well in distilled water. 6. Counterstain with 1% Neutral Red.c 7. Wash the slides in distilled water and mount the sections in an aqueous mountant. "Observe and control the staining microscopically. bTo give a red reaction product, substitute 2 mg of Fast-Red TR for 2 mg of Fast-Blue BB. c lf using Fast-Red TR, counterstain with Mayer's haematoxylin as in step 7, Method A.
3.2.3 Fluorescent labels To be visualized these require more specialized equipment than enzyme labels. The preparations also fade with time and, for these reasons, they are not highly favoured. However, they play an important part in multipleantibody staining, particularly for the simultaneous visualization of more than one antigen in the same cell (see Section 3.4). The fluorescent label, or fluorochrome, absorbs a particular wavelength radiation and emits radiation of a longer wavelength within the visible spectrum as a colour. Each fluorochrome has specific absorption and emission maxima, which allow the choice to be made of a suitable light source for excitation at the absorption maximum, and the most appropriate filter system or sets of filters that allow a simple changeover to be made in order to look for each fluorochrome in turn. The fluorochromes we regularly use are: •fluoresceinisothiocyanate (FITC)—apple-green fluorescence; • Texas Red™ (TR)—red fluorescence • tetramethylrhodamine isothiocyanate (TRITC)—orange-red fluorescence The following points should be noted: (a) The fluorochromes are available commercially, conjugated to species, class, or subclass specific immunoglobulins (ams Biotechnology). This is of particular relevance to multiple-antibody staining (see Section 3.4.1). (b) A problem associated with fluorescent labels was the difficulty in relating staining to morphology. This is overcome in our laboratory by the use of a fluorescent nuclear counterstain (see Protocols). (c) Special mounting media must be used to inhibit fading of sections (see Protocols). Examples of staining with fluorochromes are shown in Section 3.4.
44
2: Immunohistochemistry oflymphoid organs Protocol 8. Counterstaining, mounting, and examining the fluorochrome-labelled preparations Equipment and reagents • Fluorescent microscope equipped with a Ploem-type illuminator containing filter sets for fluorochromes being used in an epiillumination system (e.g. Zeiss Axioskop microscope with Omega Optical filters) • Mercury vapour lamp
. TBS (see Protocol 3) • Nuclear counterstain: DAPI (4',6-diamidino2-phenylindole dihydrochloride, Boehringer Mannheim)8 • Fluorescence mounting medium (Dako)b
Method 1. Proceed from the staining method using fluorochrome-labelled antibodies (see Protocols 10 and 72). 2. Wash over 5 min in two changes of TBS. 3. Incubate in DAPI for 10 min at room temperature in the dark. 4. Wash over 5 min in two changes of TBS. 5. Place the sections in distilled water and mount in a fluorescent mounting medium.b 6. View under fluorescent microscopy using the relevant filter system and photograph the results, or store the images on computer for a permanent record. 'This is available commercially as 10 mg aliquots in 10 ml distilled water. Freeze in 200 ul aliquots and make up to 10 ml with absolute alcohol before use. bStore the sections at 4°C. They should resist fading for several months.
3.3 Considerations in the choice of method and label All the staining methods and labels described in Sections 3.1 and 3.2 can be applied to all the preparations shown in Table 1 from all lymphoid cell and tissue specimens. There is no single optimal combination of staining method and label. The optimum is determined by a number of important factors that should be considered at an early stage: (a) Blocking endogenous peroxidase in cytological preparations and frozen sections can be damaging. In paraffin sections of bone marrow and spleen, the activity can be difficult to block. (b) More sensitive methods will detect levels of antigen that others miss. (c) A method with fewer steps gives fewer opportunities for error, whilst maintaining reliability, reproducibility, and standardization. (d) Long methods can be expensive in terms of time and money. 45
Simon C. Biddolph and Kevin C. Gatter Table 3. Immunohistochemical staining methods of choice Preparation Cell smear. Imprint, Cytocentrifuge, Frozen sections, and Paraffin sections of bone-marrow/spleen . Other paraffin sections
First choice method
Protocol
Alternative method
Protocol
APAAP
9
2/3 stage Indirect
10
Avidin or streptavidin
11
2/3 stage Indirect
10
Assessing and balancing the criteria can be a difficult task. Table 3 shows the method of choice, and an acceptable alternative, for studying different preparations. Protocols 9-11 give the methods in detail. Protocol 9. Alkaline phosphatase, anti-alkaline phosphatase (APAAP) method Equipment and reagents • TBS (see Protocol 3) • Primary mouse monoclonal or polyclonal (e.g. rabbit) antibody, optimally diluted in TBS • APAAP complex—mouse monoclonal (DAKO) antibody, optimally diluted in TBS
• DAKO pen (see Protocol 2i • Unconjugated rabbit anti-mouse immunoglobulin (DAKO), and unconjugated monoclonal mouse anti-rabbit immunoglobulin (clone MR12/53, DAKO), optimally diluted in TBS
Method 1. • Follow Protocol 2 for cell smears and Cytocentrifuge preparations. • Follow Section 2.5 for cell imprints. • Follow Section 2.6 for frozen sections. • Follow only steps 1 and 2 of Protocol 3 for paraffin sections requiring no antigen retrieval. • Follow Protocol 3 for paraffin sections requiring proteolytic enzyme digestion. • Follow Protocol 4 for paraffin sections requiring antigen retrieval in the microwave. • Follow Protocol 5tor paraffin sections requiring antigen retrieval in the pressure-cooker. 2. Wash the sections well in TBS, and circle the area of interest with a DAKO pen if necessary. 3. Apply the primary antibody and incubate for 30-60 min at room temperature. 46
2: Immunohistochemistry oflymphoid organs 4. Wash, over 5 min, in two changes of TBS. 5. If using mouse monoclonal primary, proceed to step 7. If using rabbit polyclonal primary, apply unconjugated monoclonal mouse anti-rabbit immunoglobulin and incubate for 30 min at room temperature. 6. Wash, over 5 min, in two changes of TBS. 7. Apply unconjugated rabbit anti-mouse immunoglobulins and incubate for 30 min at room temperature. 8. Wash, over 5 min, in two changes of TBS. 9. Apply the APAAP complex and incubate for 30 min at room temperature. 10. Wash, over 5 min, in two changes of TBS. 11. Repeat steps 7-10 once or twice more to increase the sensitivity of the method. Use 10 min per incubation. 12. Demonstrate alkaline phosphatase as the enzyme label. See Protocol 7.
Protocol 10. Indirect method (2-stage)a Equipment and reagents • Goat anti-mouse immunoglobulin or goat anti-rabbit immunoglobulin—conjugated to HRP (horseradish peroxidase),b or AP (alkaline phosphatase),b or fluorescent labels'
• TBS (see Protocol 3) • Dako pen (see Protocol 2) • Primary mouse monoclonal or polyclonal (e.g. rabbit) antibody, optimally diluted in TBS
Method 1. Refer to Protocol 9, step 1. 2. Wash the sections well in TBS, and circle the area of interest with a DAKO pen if necessary. 3. Apply the primary antibody and incubate for 30-60 min at room temperature. 4. Wash, over 5 min, in two changes of TBS. 5. If using a primary mouse monoclonal antibody, apply goat anti-mouse immunoglobulin conjugated to the label of choice and incubate for 30 min at room temperature. If using a primary rabbit polyclonal, apply goat anti-rabbit immunoglobulin conjugated to the label of choice and incubate for 30 min at room temperature. 6. Wash, over 5 min, in two changes of TBS. 47
Simon C. Biddolph and Kevin C. Gatter Protocol 10. Continued 7. Depending on the conjugated label used, refer to Protocols 6, 7, or 8 for demonstration of the label. "To use a more sensitive 3-stage indirect method, apply rabbit anti-goat Ig conjugated to the label of choice between steps 6 and 7. Incubate for 30 min at room temperature. b Available from DAKO. cAvailable from ams Biotechnology.
Protocol 11. Avidin/streptavidin-biotin complex method Equipment and reagents • TBS (see Protocol 3) • DAKO pen (see Protocol 2) • Primary mouse monoclonal or polyclonal (e.g. rabbit) antibody, optimally diluted in TBS • Avidin or streptavidin complexed with biotinylated horseradish peroxidase or alkaline phosphatase(ABComplex/StreptABComplex, DAKO; Vectastain ABC kit. Vector Laboratories)a,b
> Biotinylated goat anti-mouse immunoglobulin or biotinylated goat anti-rabbit immunoglobulin (DAKO), optimally diluted in TBS > Avidin/biotin blocking kit (DAKO and Vector Laboratories)b > Substrates and chromogens for the demonstration of enzyme labels (see Protocols 6 and 7)
Method 1. Refer to Protocol 9, step 1. 2. Wash the sections well in TBS, and circle the area of interest with a DAKO pen if necessary. 3. If necessary (see Section 3.1.4), block endogenous biotin using the blocking kit.b 4. Apply the primary antibody and incubate for 30-60 min at room temperature. 5. Wash, over 5 min, in two changes of TBS. 6. Complex the avidin or streptavidin to the biotinylated label of choice.a 7. If using a primary mouse monoclonal antibody, apply biotinylated goat anti-mouse immunoglobulin and incubate for 30 min at room temperature. If using a primary rabbit polyclonal antibody, apply biotinylated goat anti-rabbit immunoglobulin and incubate for 30 min at room temperature. 8. Wash, over 5 min, in two changes of TBS. 9. Apply the avidin/streptavidin biotin complex, made in step 6, and incubate for 30 min at room temperature. 10. Wash, over 5 min, in two changes of TBS. 48
2: Immunohistochemistry oftymphoid organs 11. Depending on the conjugated label used, refer to Protocols 6 or 7 for demonstration of the label. " It is essential that these complexes are made at least 30 min before use. * Follow the manufacturer's instructions for optimal use.
3.4 Multiple antibody methods A logical progression from visualizing a single antigen in a preparation is the combination of single-antibody methods to visualize two or more antigens in the same preparation, be they in the same or different sites. 3.4.1 Considerations in the combination of methods and labels Any primary antibody can be used, but the choice and sequence of methods depends on various factors: (a) There must be sufficient contrast between the labels. Thus, we can use different fluorochromes, different enzymes, or different substrates and chromogens for the same enzymes. (b) Methods using enzyme labels are better suited to detecting different antigens on different cells in the same preparation, because in the same cell a confusing blend of colours can result, or one colour may mask another if antigen expression is dramatically different. Fluorescent labels are ideal for double or multiple labelling of antigens in the same cell. Because, by switching between the relevant filters, each labelled antigen can be seen in turn, even if there is very weak antigen expression and one is totally masking the other. (c) Counterstaining multiple enzyme-labelled preparations is not recommended for all cases. The choice will depend on the colours produced by the chromogens, and the relative solubilities of the labels and counterstains in the mounting media. (d) Multiple-antibody methods are merely combinations of single-antibody methods, and the same considerations as to the type of preparation and the suitability of the technique must be taken as in Section 3.3. (e) Cross-reactivity between the reagents must be minimized. This can be achieved by: (i) the simultaneous use of primary antibodies from different animal species, followed by the simultaneous use of labelled secondary antibodies directed against each of the animal species. Different fluorochromes can be used together, as can different enzyme labels. (ii) the simultaneous use of primary antibodies from the same animal species, but of a different class or subclass, followed by the simultaneous use of class- or subclass-specific, labelled secondary antibodies. 49
Simon C. Biddolph and Kevin C. Gatter (iii) the sequential use of two indirect methods, both involving primary antibodies from the same animal species. Ideally, the antigen showing the weaker expression should be stained by the first indirect sequence. Preferably, different enzyme labels are used for each secondary antibody, i.e. the application and demonstration of an HRP-conjugated secondary for the first sequence, and the application and demonstration of an AP-conjugated secondary antibody for the second sequence. Alternatively, the same enzyme label, but different chromogens, can be used in both indirect sequences. (iv) triple staining, which can be achieved using, sequentially, three indirect sequences for three different antibodies, e.g. HRP demonstrated using DAB, followed by AP demonstrated by Fast-Blue BB and, finally, AP as visualized by New Fuchsin. For detecting antigens in the same cell, our method of choice is simultaneous staining using fluorescent labels (see Protocol 12). This method can also be used for demonstrating antigens in different cells in the same preparation, but we prefer sequential staining using enzyme labels (see Protocol 13). Protocol 12. Simultaneous staining of different antigens, in the same cell, with multiple antibodies Equipment and reagents • TBS (see Protocol 3) • DAKO pen (see Protocol 2\ • Two secondary antibodies, optimally diluted in an aliquot of TBS; each directed against the species, classes, or subclasses of the primary antibodies, and each labelled with a different fluorochrome (ams Biotechnology)
• Two primary antibodies, optimally diluted in an aliquot of TBS, e.g. two mouse monoclonal antibodies of different class or subclass", or a mouse monoclonal antibody, and a rabbit polyclonal antibody' • Fluorescent microscope and appropriate filters, nuclear counterstain, and mounting medium for fluorescent microscopy (see Protocol 8)
Method 1. Refer to Protocol 9, step 1. 2. Wash sections well in TBS and circle the area of interest with a DAKO pen if necessary. 3. Apply the mixture of primary antibodies and incubate for 30-60 min at room temperature. 4. Wash, over 5 min, in two changes of TBS. 5. Apply the mixture of secondary antibodies and incubate for 30 min at room temperature. 6. Wash, over 5 min, in two changes of TBS. 50
2: Immunohistochemistry oflymphoid organs 7. Proceed to Protocol Sfor demonstration of the label. * Unfortunately, not all commercial antibody suppliers give the class or subclass of their primary antibodies in their catalogues, Dako and Biogenex do.
Protocol 13. Sequential staining of different antigens, in different cells, using multiple antibodies Equipment and reagents • TBS (see Protocol 3) • DAKO pen (see Protocol 21 • Substrates and chromogens for the demonstration of enzyme labels (see Protocols 6 and Ti • Two primary antibodies, each optimally diluted in TBS
• Two secondary antibodies, each optimally diluted in TBS; each directed against the species, classes, or subclasses of the primary antibodies, and each conjugated to a different enzyme label—HRP or AP (see Protocol 10) • Aqueous mountant (e.g. Aquamount, BDH)
Method 1. Refer to Protocol 9, step 1. 2. Wash the sections well in TBS, and circle the area of interest with a DAKO pen if necessary. 3. Apply the first primary antibody and incubate for 30-60 min at room temperature. 4. Wash, over 5 min, in two changes of TBS. 5. Apply the HRP-conjugated secondary antibody and incubate for 30 min at room temperature. 6. Wash, over 5 min, in two changes of TBS. 7. Proceed to Protocol 6for demonstration of HRP, but do not counterstain in Mayer's haematoxylin. The reaction product will be brown or red. 8. Wash the slides in cold, running tap water for 5 min. 9. Apply the second primary antibody and incubate for 30-60 min at room temperature. 10. Wash, over 5 min, in two changes of TBS. 11. Apply the AP-conjugated secondary antibody and incubate for 30 min at room temperature. 12. Wash, over 5 min, in two changes of TBS. 13. Proceed to Protocol 7 for demonstration of AP, but do not counterstain in Mayer's haematoxylin. The reaction product will be red or blue and should contrast with the colour of reaction product in step 7. 14. Wash the slides in cold, running tap water for 5 min. 15. Wash the slides in distilled water and mount the sections in an aqueous mountant. 51
Simon C. Biddolph and Kevin C. Gattvr
3.5 Quality control It is essential in any s t a i n i n g method to use controls t h a t allow the results to he validated (9). We use a positive control in the form of a preparation that is known to contain the antigen in question—this shows t h a t the method has worked. We also include a negative control in the form of a preparation in which the primary antibody has been o m i t t e d — t h i s will show any staining by the secondary antibodies and must be considered to be non-sped lie. A fuller discussion of problems, and remedies, associated w i t h immunohistochemical staining is addressed elsewhere (18),
Figure 1. Staining of lymphoid tissue. (A) B cells stained for the pan B-ceN antigen CD79a. (B) T cells stained for the pan T-cell antigen CD3. (C) Proliferating cells are identified by nuclear staining for Ki67 antigen. (D) Cytotoxic T cells are marked by antibodies against CDS. (E) Macrophages may be seen in both B- and T-cell areas with anti-CD68 antibodies. (F) Plasma cells are easily recognized with a variety of antibodies, such as those against immunoglobulin fragments or endoplasmic reticulum antigens such as pS3, This figure shows kappa light-chain staining. (G) Follicular dendritic cells are restricted to the germinal centre and are easily identified with antibodies against CD21. IH) Germinalcentre cells are unstained for bcl-2 protein, whereas virtually all other B- and T-cells are positive. (I) Interdigitating reticulum cells in the T-dependeni areas of the paracortex may be identified with antibodies against S100 protein.
52
2: Immunohistochemistry oflymphoid organs
3.6 The distribution of cell types in lymphoid tissue Figure 1 shows how many of the different cell types are distributed in lymphoid tissue with particular regard to lymph nodes, although similar patterns occur in tonsils, adenoids, and spleen. B cells are concentrated in follicles in both the germinal centre and the mantle zone. In the interfollicular area their number is much lower. T cells are most numerous in the interfollicular area, though many are found in the germinal centre associated with the centroblasts and centrocytes (which are B cells), proliferating in response to antigenic stimulation. Most of the T cells in the germinal centre are CD4+ helper cells, with cytotoxic CD8+ cells largely restricted to the interfollicular zone. Macrophages are distributed throughout all areas of lymph node, but are particularly numerous and large in the germinal centre where they are phagocytosing apoptotic lymphocytes (so-called 'tingible body macrophages'). Plasma cells, the end stage of B-cell differentiation, are produced in the germinal centres from where they migrate out into the tissues via the lymph node sinuses. There are specialized cells forming an antigen-presenting framework in the germinal centres known as follicular dendritic cells. The special nature of the environment in the germinal centre is further illustrated by the fact that virtually all the cells within it are bcl-2 protein-negative, indicative of an area of intense apoptotic activity. T-cell areas have similar specialized antigen-presenting dendritic cells, which have a different antigen profile to the dendritic cells in the germinal centre.
Acknowledgements To Jackie Cordell and Margaret Jones for the invaluable discussions, and to Tricia for her patience and understanding.
References 1. Germain, J. and Stevens, A. (19%). In Theory and practice of histological techniques (4th edn) (ed. J. D. Bancroft and A. Stevens), p. 555. Churchill Livingstone, Edinburgh. 2. Polak, J. M. and Priestley, J. V. (ed.) (1992). Electron microscopy immunocytochemistry. Principles and practice. Oxford University Press, Oxford. 3. Carmichael, A. and Coghill, G. R. (1992). Med. Lab. Sci., 49, 38. 4. Michel, B., Milner, Y., and David, K. (1972). J. Invest. Dermatol.,59,449. 5. Aratake, Y., Tamura, K., Kotani, T., and Ohtaki, S. (1988). Acta Cytol., 32, 117. 6. Krausz, T., Schofield, J. B., Van Noorden, S., Stamp, G. W. H., and MacLennan, K. A. (1993). In Fine needle aspiration cytopathology (ed. J. A. Young), p. 310. Blackwell Scientific, Oxford. 7. Chaplin, A. J., Heryet, A., Holdsworth, L. N., Eglin, R. P., and Millard, P. R. (1989). 7. CM. Pathol., 42,318. 53
Simon C. Biddolph and Kevin C. Gatter 8. Williams, J. H., Mepham, B. L., and Wright, D. H. (1997). J. Clin. Pathol, 50,422. 9. Rainbow, R. D. (1994). In Laboratory histopathology a complete reference (ed. A. E. Woods and R. C. Ellis), p. 8.2-1. Churchill Livingstone, Edinburgh. 10. Shi, S. R., Key, M. E., and Kabra, K. L. (1991). J. Histochem. Cytochem., 39,741. 11. Morgan, J. M., Navabi, H., Schmid, K. W., and Jasani, B. (1994). J. Pathol, 174, 301. 12. Hollinshead, M., Sanderson, J., and Vaux, D. J. (1997). J. Histochem. Cytochem., 45,1053. 13. Norton, A. J., Jordan, S., and Yeomans, P. (1994). J. Pathol, 173,371. 14. Cordell, J. L., Falini, B., Erber, W. E., Ghosh, A. K., Abdulaziz, Z., Macdonald, S., Pulford, K. A. F., Stein, H., and Mason, D. Y. (1984). J. Histochem. Cytochem., 32, 219. 15. Bobrow, M. N., Harris, T. D., Shaughnessy, K. J., and Litt, G. J. (1989). J. Immunol. Methods, 125,279. 16. Merz, H., Malisius, R., Mannweiler, S., Zhou, R., Hartmann, W., Orscheschek, K., Moubayed, P., and Feller, A. C. (1995). Lab. Invest., 73,149. 17. King, G., Payne, S., Walker, F., and Murray, G. (1997). J. Pathol, 183,237. 18. Hanker, J. S., Yates, P. E., Metz, C. B., and Rustini, A. (1977). J. Histochem., 9, 789. 19. Van Noorden, S. (1993). In Immunocytochemistry: a practical approach (ed. J. E. Beesley), p. 207. IRL Press, Oxford.
54
33
Viral transformation of lymphocytes EDGAR MEINL and HELMUT FICKENSCHER
1. Introduction The main limitations of molecular and biochemical studies of human T lymphocytes are twofold. First, the phenotype of T-lymphoblastic tumour cell lines like Jurkat (1) is significantly altered in comparison to primary cells with respect to signal transduction (2) and gene regulation. Second, primary T-cell cultures are inevitably limited in their lifespan. It is often laborious and frequently impossible to grow primary T lymphocytes to large numbers, and it requires considerable effort to amplify antigen-specific T cells (as described in Chapter 10). The use of irradiated feeder cells may cause difficulties in the interpretation of results derived from T cells expanded in this way. Immortalization of human T cells should be the ideal way to solve such problems. T-cell transformation should ideally lead to permanent growth independent of restimulation procedures, whilst conserving the essential features of the primary, parental T cells. Various approaches for immortalizing human T cells have been tried. The technique of T-cell fusion hybridomas is successful for rodent cells, but is much more difficult to achieve with human T cells where it is hampered by the genomic instability of the clones (as discussed in Chapter 4). Viral transformation of human T lymphocytes was first achieved by infection with Human T-cell leukaemia virus type 1 (HTLV-1) (3-8). This type of transformation with HTLV-1 has proved useful in a number of situations, although it is largely confined to CD4+ T cells. Retrovirus-transformed T lymphocytes contain integrated proviral DNA and regularly produce HTLV1 virions. The cells tend to lose their T-cell receptor (TCR) complex, their cytotoxic activity, and their dependence on interleukin (IL)-2 after prolonged cultivation (9,10). Alternatively, herpesvirus saimiri (HVS), an oncogenic virus of New World monkeys, can be used to transform human T cells for stable growth in culture (11). Human T cells transformed by this virus exhibit the phenotype of activated mature T cells, retain a functionally intact T-cell receptor, can be
Edgar Meinl and Helmut Fickenscher triggered to cytotoxicity, and produce Thl-type cytokines (reviewed in refs 12 and 13). These cells contain multiple episomes of herpesvirus saimiri, but release of infectious virus has not been observed. The cultivation of primary human B cells is still more limited than the culture of primary T cells. However, transformation by Epstein-Barr virus (EBV) (14, 15) is now an established method that is routinely used to obtain permanently growing human B cells. EBV-transformed lymphoblastoid B cells are widely used as antigen-presenting and target cells to study T-cell specificity and cytotoxicity. In this chapter, we summarize the procedures for viral transformation of human and monkey B and T lymphocytes. The main emphasis is laid on using cell-free HVS C488 to transform human T lymphocytes to antigenindependent growth.
2. Transformation of T lymphocytes 2.1 Growth transformation of human T cells by herpesvirus saimiri 2.1.1 Herpesvirus saimiri Herpesvirus saimiri (16) is the prototype of the genus -y2-herpesviruses or rhadinoviruses (17, 18). The closest relative of HVS in humans is human herpesvirus type 8 (HHV-8), which is associated with Kaposi's sarcoma and rare types of B-cell lymphoma (19). Herpesvirus saimiri is not pathogenic in its natural host, the squirrel monkey (Saimiri sciureus), and can easily be isolated from the peripheral blood of most animals (20, 21). In other South American monkeys—such as common marmosets (Callithrix jacchus), cottontop tamarins (Saguinus oedipus), and owl monkeys (Aotus trivirgatus), as well as in some breeds of rabbit—HVS infection causes fulminant polyclonal Tcell lymphomas and acute lymphatic leukaemias (22-27). The various strains of herpesvirus saimiri are assigned into subgroups A, B, and C on the basis of DNA sequence divergence in the transformation associated region (28, 29). Strains of subgroup A and C are highly oncogenic in various species of New World monkeys (genus Callithrix, genus Saguinus) (24). Furthermore, marmoset (30-35) T lymphocytes can be transformed in vitro by herpesvirus saimiri. Subgroup C strains are further capable of growthtransforming macaque and human T cells 11, 36-39. HVS is capable of infecting a broad range of cell types, including B cells, epithelial cells, fibroblasts (40), and fetal cell cultures (41), but it is only able to transform T cells for stable growth. 2.1.2 Virus culture Because HVS is associated with tumours in some animals, it has to be considered a potential human pathogen even though no human disease has been reported. Appropriate biosafety containment conditions must be applied con56
3: Viral transformation of lymphocytes tainment level 2 in most countries). Epithelial owl-monkey kidney (OMK) cells, which are typically used for amplifying HVS, are derived from healthy Aotus trivirgatus (owl monkeys). OMK cells are a non-transformed, primary cell line which has unusually stable properties (42). The American Type Culture Collection (ATCC; Manassas, Virginia) offers strain OMK637-69 in the 16th passage under catalogue number ATCC CRL-1556. This cell line was isolated in 1970 and later submitted to the ATCC by Dr M. D. Daniel, New England Regional Primate Research Center, Harvard Medical School, Southborough, MA, USA. OMK-637 has been used intensively in several laboratories over decades with no hint of viral contamination. The cells are maintained as a monolayer in Earle's Minimal Essential Medium (MEM) or Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heatinactivated fetal calf serum (PCS), glutamine (350 (ug/ml), and antibiotics (100 (ug/ml gentamicin or penicillin/streptomycin at 120 ug/ml each). OMK cell growth does not require CO2 supplementation. The cells are trypsinized and split just once a week on to a doubled area of tissue-culture plasticware. This low ratio maintains the original status of the primary OMK cells and does not enforce selection for fast-growing subtypes, which are no longer fully permissive. The medium is changed on the fourth day after splitting. The cells should not be used for more than 50 passages. OMK cells are the typical propagation system for herpesvirus saimiri, herpesvirus aotus, and herpesvirus ateles. It should be kept in mind that Aotus trivirgatus monkeys are an endangered species. If OMK cells have to pass customs control, appropriate official documentation according to the Convention on International Trade in Endangered Species (CITES) is needed. Traditionally, the tissue-culture medium of freshly confluent, OMK monolayer cultures is removed on days 2-4 after splitting, and an infectious virion suspension is added in a minimal volume (e.g. diluted in 2 ml for a 25 cm2 flask, or in 5 ml for an 80 cm2 flask). Adsorption is allowed to take place at 37 °C for 1-2 h. The monolayer should be covered by the inoculum fluid and should not dry out during this time. Afterwards, medium is added and the incubation is continued. (In our experience this adsorption step may safely be omitted.) After between 1 and 14 days, early cytopathic changes can be observed, typically with focal rounding of cells. Later on, plaques bordered by rounded cells appear, and several days later, the whole cell layer will be lysed by the virus. When high-titre supernatants are to be prepared, it is essential to inoculate at a low multiplicity of infection (0.1-0.5). Ideally, the culture should be maintained for 1-2 weeks, until all the cells have been lysed. Inoculating the cultures at a higher multiplicity of infection (m.o.i.) often results in more dramatic cytopathic effects but yields lower litres of infectious particles, and a high proportion of the virus carry repetitive terminal H-DNA (high GC content) only, without coding L-DNA (low GC content). Once the infected cells have all been lysed, the whole culture (including the OMK cell debris) is used as HVS viral stocks, without any further treatment. The virus 57
Edgar Meinl and Helmut Fickenscher stocks are reasonably stable and can be stored at 4°C for several months without loss of infectivity. Small volumes of supernatant should be frozen in liquid nitrogen or at -80 °C; the titre may decrease by about one order of magnitude upon freezing and thawing. Protocol 1. Preparation of herpesvirus saimiri stocka Equipment and reagents • OMK cells (see above) • Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heatinactivated PCS, 350 ug/ml L-glutamine, and 100 (ug/ml gentamicin (or 120 (ug/ml each of penicillin and streptomycin)
• Virus stock • Equipment and reagents to comply with relevant biosafety containment conditions
Method 1. Grow OMK cells in DMEM supplemented with 10% PCS, glutamine, and gentamicin. Avoid using OMK cells that have been extensively passaged. 2. Trypsinize OMK cells once a week and split them at a ratio of 1:2 per area. Exchange the medium on day 4. 3. One day after a 1:2 split, infect the cells with an appropriate volume of virus stock, e.g. 500 uJ of a routine stock of 105 p.f.u./ml, for inoculation of an OMK monolayer of 175 cm2. 4. Continue the incubation for 1-2 weeks post-infection.b 5. Harvest the tissue culture fluid (including the cell debris) when the cytopathic effect is complete, and store it at 4°C before use.e Alternatively, store aliquots at -80°C, although some loss of efficiency will result from freeze-thawing. "See text for further details "The optimal time-course for the cytopathic effect in the cell culture to reach the point of complete lysis should be between 1 and 2 weeks: longer or shorter time courses will result in poor litres. c
When stored at 4°C, these preparations can be used for T-cell transformation for up to 3 months.
Virus strain C488 (29, 43) was submitted to the ATCC after only a few passages on OMK cells. The virus is available under the catalogue numbers VR-1396 and VR-1414. ATCC also offers virus strain S295C, which belongs to subgroup B, rather than subgroup C as do the other transforming strains. This virus is unable to transform human T cells, but immortalizes marmoset monkey cells with low efficiency (44). 2.1.3 Virus titration The limiting dilution method is the simplest way to estimate virus litres. OMK cells are trypsinized, split into 24-well plates, and incubated at 5% CO2. The 58
3: Viral transformation of lymphocytes cell-free virus suspension is serially diluted in DMEM at KT* to 10-9 and 1 ml of each dilution is added to each well of the 24-well plate the following day. It is important to perform the assay in triplicate at least, and to run control cultures. The plates are observed for a minimum of 14 days and the progress of the cytopathic effect (CPE) should be monitored daily. The more laborious plaque assay is also based on serial dilution. The methyl cellulose solution is prepared as described in Protocol 2, and subconfluent OMK cultures are infected with dilutions of virus stock in 6 cm dishes. After an hour at 37 °C, the supernatant is replaced by the 2% methyl cellulose solution. The medium is poured off carefully after plaque formation has been observed. The plaques are then stained with crystal violet solution and counted. Routine OMK cell cultures should reach litres between 105 and 107 plaque forming units (p.f.u) per ml (42). Protocol 2. Estimation of herpesvirus saimiri titre Equipment and reagents Confluent OMK cells 24-well plates DMEM (see Protocol 7) 15 ml tubes Viral stock PBS 6 cm dishes 1% crystal violet in 20% ethanol/80% water (v/v)
• 2% methyl cellulose syrup: Measure 100 ml H2O into a 500 ml bottle and add 4.4 g methyl cellulose (Methocel MC 4000; Fluka, cat. no. 64630) and autoclave it for 45 min at 121 °C. Add 100 ml 2 x concentrated DMEM, 20 ml PCS, 700 jig/ml L-glutamine, and 200 ug/ml gentamicin. Mix well overnight in the cold room. Add small volumes of PBS in order to achieve a homogeneous sticky syrup.
A. Limiting dilution method 1. Trypsinize confluent OMK cells and split them by 1:5 per area, e.g. into 24-well dishes with 1 ml of the cell suspension in complete DMEM. Let the cells grow overnight. 2. Prepare serial dilutions of the sample in complete DMEM, down to 10~9 as follows. Prepare a panel of 15 ml tubes, each containing 9 ml complete medium, then add 1 ml of viral stock to 9 ml medium and shake vigorously. Take 1 ml of this dilution and transfer it to the next tube, and so on. 3. Aspirate the medium from the well and add 1 ml of the respective dilution of virus. Run the assay with four parallel wells for each dilution. 4. Monitor the development of the cytopathic effect (CPE) for up to 3 weeks, until all the cells have been lysed. Do not feed these cultures during this period. A. Plaque assay 1. Prepare the 2% methyl cellulose syrup. 59
Edgar Meinl and Helmut Fickenscher Protocol 2.
Continued
2. Split confluent OMK cells by 1:5 per area into 6cm dishes. Let the cells grow overnight. 3. Prepare serial dilutions as described above. 4. Aspirate the medium from the well and add 1 ml of the respective dilution. Use three dishes for each dilution. Aspirate the supernatant again after a 1-h incubation at 37°C. 5. Immediately add 5 ml of the methyl cellulose syrup. 6. Observe the CPE for about a week, until the plaques are easily recognized under the microscope. 7. Carefully pour off the medium, wash gently with PBS, and stain with 1% crystal violet in 20% ethanol/80% water (v/v). Remove surplus dye by washing with water and dry the plates. Count the plaques. NB: Vigorous washing may destroy the monolayer and induce artefacts that are indistinguishable from genuine plaques.
2.1.4 Growth-transformation of human T cells Infection of primary human T lymphocytes with HVS subgroup C strains (notably strain C488), but not with strains of subgroups A or B, yields continuously proliferating, mature T-cell lines (11) (reviewed in refs 12 and 13). Permanently growing T-cell lines have been obtained from primary cells of various sources. Polyclonal preparations of mononuclear cells from adult peripheral blood or from cord blood, from thymus or bone marrow, as well as characterized T-cell clones, or flow cytometry-sorted T cells are all suitable for the procedure. The transformation of bulk cultures is polyclonal (25, 45-47), so that a broad variety of V(3 chains are represented. Although TCR 78 cell lines are not usually obtained when large numbers of polyclonal cells are infected, they can be generated using a number of manoeuvres, such as lysis of the ctp T cells, the use of small microtitre cultures, or through the specific differentiation of virus-infected CD34+ thymocytes (49-52). The method requires either freshly isolated quiescent cells or proliferating viable cells with the morphology of activated T lymphocytes. The primary cells may be purified using Ficoll density gradients (1.077 g/ml; Biochrom, Berlin) or the dextran erythrocyte-sedimentation protocol (selective sedimentation of erythrocytes at 37 °C and 1.2% dextran 250000 (w/v)/30 mM Nad for 45 min). Pre-stimulation of fresh primary cells for 24 h with phytohaemagglutinin (PHA) (0.5-10 ug/ml, Murex/Wellcome) or OKT-3 (10-200 ng/ml, Ortho) is only of advantage if the number of available cells is limited. T-cell clones should be restimulated with antigen or mitogen and feeder cells 3-5 days prior to infection. T-cell cultures are kept at a density 60
3: Viral transformation of lymphocytes of about 1 (0.5-1.5) x 106 cells/ml. Most safety committees specifically prohibit the use of the researcher's own cells for transformation experiments, for obvious safety reasons! Different types of cell-culture plasticware can be used. In our experience, the cells best retain viability in 25 cm2 flasks (3-10 ml containing 3-10 x 106 cells), 24-well plates (1-2 ml containing 1-2 X 106 cells) or 96-well, roundbottomed microtitre plates (100-200 ul containing I04-105 cells). The culture flasks should be incubated at a slight angle (of about 15 degrees) to allow close cell-to-cell contacts in the lower edge of the culture flask. Various media formulations have been used. Lines CB-15, PB-W, Lucas (11), and CB-23 (53) were all isolated using a standard medium formulation (80% RPMI-1640, 20% PCS, 50 uM B-mercaptoethanol, L-glutamine (350ug/ml), gentamicin (100ug/ml), without either pre-stimulation or IL-2 supplementation. The quality of fetal calf serum (FCS) batches, even from the same supplier, varies remarkably. In our experience it is very important to compare different serum batches and select a batch with low endotoxin levels. PCS is inactivated at 56 °C for 30 min to avoid problems for both virus and lymphocytes due to complement activation. The addition of IL-2 (at 20-50 U/ml in the culture medium) activates cell proliferation and enhances the transformation frequency. Because usually about one-third of the culture medium is added or replaced twice-weekly, this will result in a final concentration in the culture of less than 20 U/ml IL-2. After studying many different IL-2 batches from different suppliers we found that pre-tested batches of human recombinant IL-2 with low endotoxin levels, purified from E. coli and offered by Roche (cat. nos 1011456 and 1147528) were the most active and provided optimal conditions for transformation efficiency. To save money, the use of this preparation of IL-2 may be limited to the initial transformation procedure and in maintaining small culture volumes. When stable growth is established, or when large cell-culture volumes of transformed lines are required, the lessexpensive and less-active Proleukin™ is recommended (used at 50-100 U/ml in the medium stock). This is human recombinant IL-2 produced for clinical use, which carries 1-des-Ala and 125-Ser amino-acid substitutions and is available from Chiron (Ratingen, Germany). Efforts to enhance transformation efficiencies led to the observation that adding 45% of certain synthetic media was beneficial. Several types of synthetic media were tested as supplements, but only Panserin 401 (PAN, Aidenbach, Germany) and AIM V (Gibco BRL) improved transformation efficiency significantly in our experiments. Panserin 401 medium allows one to judge the metabolic activity of the culture by colour changes, which is not a feature of AIM V medium. Using pre-tested IL-2 (Roche) and medium supplements, about 90% of primary T-cell cultures can be transformed to antigen- and mitogen-independent growth. The failure rate of about 10% can largely be explained on the basis of trivial reasons, such as poor cell viability prior to infection. From our experience, the optimal medium formulation 61
Edgar Meinl and Helmut Fickenscher is: RPMI-1640 45%, CG 45% Panserin 401 or AIM V (45%), PCS 10%, L-glutamine (350 ug/ml), gentamicin (100 rag/ml), and 20-40 U/ml IL-2 (Roche). Protocol 3. Growth-transformation of primary human T cells with herpesvirussaimiri Reagents . 20-40 U/ml IL-2 • Virus supernatant (106 p.f.u./ml)
• Complete medium: RPMI-1640 (45%), Panserin 401 or AIM V (45%), PCS (10%), L-glutamine, and gentamicin
Method 1. Take quiescent primary or rapidly proliferating T-cells in complete medium with IL-2 (2 identical cultures at 5 ml with 5 x 106cells each). 2. Infect one of the cell cultures with virus supernatant (preferably fresh), e.g. 500 uJ of 106 p.f.u./ml) 3. Maintain both infected and uninfected cultures with meticulous care for several months, paying attention to the following points: • keep the cell density high (about 106/ml); • keep flasks at a slight angle (15 degrees) to allow close cell-to-cell contact; • supply fresh medium supplemented with IL-2 twice weekly. • add or change only one-third of the volume. 4. Make sure the following criteria for transformation are fulfilled: • a steady increase in cell numbers; • appropriate T-lymphoblast morphology; • death of control cultures maintained under the same conditions; • persistence of viral episomal DNA; • CD2 hyper-reactivity and non-specific cytotoxicity. 5. Confirm that the transformed T cells do not produce virus particles.
In order to block auto-oxidation of thiol groups and resulting toxicity, the addition of 1 mM sodium pyruvate (Gibco BRL, cat. no. 043-01360, 100 X stock solution at 100 mM), 50 uM a-thioglycerol (Sigma, cat. no. M-6145, 1000 X stock solution at 50 mM), and 20 nM bathocuproine disulfonic acid (Sigma, cat. no. B-1125; 1000 X stock solution at 20 uM) is advantageous, but not essential (M. Falk and G. Bornkamm, personal communication). 62
3: Viral transformation of lymphocytes a-Thioglycerol is a more stable and less odorous alternative to 3-mercaptoethanol. Copper ions, which are relevant for auto-oxidation, are chelated by bathocuproine disulfonic acid. The addition of sodium pyruvate reduces H2O2 concentrations (54). Most experience in T-cell transformation is based on using the HVS strain C488 (11). However, other strains such as C484 (11, 27, 28, 43, 49, 55) and C139 are also able to transform human T cells to some degree. Strain C139 is an isolate from our laboratory and shows several atypical features (49, 50). Overall, HVS strain C488 seems to be the most reliable for transforming human T cells (49), used at 10% (v/v) of infectious OMK supernatant added to a healthy lymphocyte culture, as described in Protocol 3. At least 105 viable cells are necessary for obtaining a transformed culture (49). Good negative controls are uninfected cells and cultures infected with a virus strain of similar titre, such as strain All (subgroup A) or SMHI (subgroup B), which are unable to transform human T cells. During the first weeks of culture, normal T-cell growth is observed in both virus-infected and control cultures, but this normal mitotic phase should not be misinterpreted as transformation. It may take several months before stable growth of virus-infected T cells becomes obvious in comparison with uninfected control cells. Transformation efficiency seems to vary considerably among different donors, but can reach 90% using just a few millions of viable primary cells for infection. Several criteria indicate that transformation has been achieved: • doubling of the cell number constantly once to four times a week over several months, independent of antigen and mitogen; • cell morphology consistent with T lymphoblasts, e.g. enlargement and clumping; • death of identically treated control cultures • persistence of viral non-integrated episomes without virion production (demonstrated by PCR and Gardella gel, as described below, and negative co-cultivation test on OMK cells); • CD2 hyper-reactivity against membrane-bound CD58, or cross-linked CD2 antibodies (see below) (56), and non-specific cytotoxicity against various human or monkey cell lines. Cultures which seem to be growth-transformed can often be subjected to a gradual withdrawal of the medium supplement (Panserin 401 or AIM V). The addition of 10 mM Hepes pH 7.4 (Gibco BRL) helps to avoid cell degeneration caused by low pH. Exogenous IL-2 supplementation can also be gradually reduced, and even suspended altogether for some CD4+ cell cultures. However, CD8+ transformed cell lines are more sensitive to the withdrawal of IL-2. An alternative protocol to obtain HVS-transformed CD4+ and CD8+ Tcell clones from the blood of HIV-1 infected subjects has been described (57). 63
Edgar Meinl and Helmut Fickenscher Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll gradient, and adherent cells removed by plastic adherence for 2 h. These cells were either infected directly or 2 days following activation with 2 u.g/ml of PHA. The HIV-1 protease inhibitor Ro 31-8959 was added to inhibit spreading of HIV during transformation. At 3-5 days after infection, the cells were seeded at 0.5-1 cells per well in round-bottomed, 96-well plates containing 105, irradiated, allogeneic PBMCs in a final volume of 200 (ul, supplemented with IL-2. The protease inhibitor was maintained for 3 weeks. Growing microcultures were expanded in IL-2 without the addition of feeder cells. 2.1.5 Properties of human growth-transformed T cells Human HVS-transformed T cells carry multiple non-integrated viral episomes (11). Release of infectious virus has not been observed, despite numerous attempts to isolate HVS from human transformed T cells. Most viral genes are not expressed in transformed human T-cells, but the viral oncogene stpC/tip and the superantigen-homologous gene ie14/vsag are strongly and inducibly transcribed (33, 48). Although transformed human T cells usually remain IL-2-dependent, they do not need periodic restimulation with either antigen or mitogen. The transformed cells have the phenotype of mature activated CD4+ or CD8+ T cells, retain a structurally and functionally intact TCR, produce Thl-like cytokines, and can be triggered to cytotoxicity (2, 46, 58-60). They also maintain the early signal-transduction patterns of primary cells (2, 59), express surface activation markers, show inducible cytotoxicity (11, 50, 59), secrete Thl-type cytokines with greater IFN-y production than before transformation (56, 58, 60), and are sensitive to a variety of apoptosisinducing treatments (61, 62). Well-characterized CD4+ T-helper cell clones specific for myelin-basic protein (12, 60), tetanus toxoid (2), bovine 70-kDa heat-shock protein (Hsp70), Lolium perenne group I antigen, Toxocara canis excretory antigen, purified protein-derivative from Mycobacterium tuberculosis (58), have all been successfully transformed, with preservation of their antigen-specificity. Growth transformation of CD8+ EBV-reactive T cells by herpesvirus saimiri has also been reported (45). Although HVS-transformed T cells resemble native T cells in many ways, a striking difference lies in their reactivity to CD2 engagement. Whilst activation of native T cells via the alternative pathway requires particular pairs of antibodies directed to different CD2 epitopes (63), HVS-transformed T cells can be activated by cell-bound CD58 or a single anti-CD2 monoclonal antibody (mAb), provided it recognizes the Tll.l epitope on CD2 and is cross-linked by FcR-bearing cells (33,36,56). Their spontaneous proliferation and cytokine production are reduced by treatment with soluble mAbs to either CD2 or its ligand CD58 (56, 60). CD58 is expressed on a variety of cell types, including lymphocytes, and is the most important cellular ligand for 64
3: Viral transformation of lymphocytes CD2 in humans. Although native T cells are not activated upon binding of CD2 to CD58, this interaction is an important stimulus for the autocrine growth of HVS-transformed T cells (56): this can be inhibited using mAbs to CD2 and its ligand CD58, but not mAbs to other surface molecules like HLADR or B7 (56, 60). The transformed T lymphocytes have further been shown to react on engagement of the CD4 and CD26 receptors (2, 59). When peripheral blood mononuclear cells (PBMCs) are used as antigenpresenting cells (APCs) to study the activation of HVS-transformed T cells, antigen-specific activation may be obscured because the transformed T cells are activated by PBMCs through CD2 without antigen. This problem can be overcome by using mouse L cells (stably-transfected with the appropriate HLA molecule) as APCs, since mouse CD58 binds poorly to human CD2: autocrine activation of the T cells can be simultaneously reduced using antibodies to CD2 or CD58 (60). An alternative is to use EBV-transformed B cells as APCs in the presence of mAbs to CD58 (59). T cell-depleted (2) or unseparated PBMCs (58) have also been used as APCs to elicit an antigenspecific response without blocking mAbs. Withdrawal of IL-2 for a few days before culturing with antigen can enhance the antigen-specific response (2). HVS-transformed T cells from Rhesus monkeys (36) and man (unpublished observations) are both effective APCs. Measuring the production of IFN--y, lymphotoxin, granulocyte-macrophage colony-stimulating factor (GM-CSF), or tumour necrosis factor-a (TNF-a) are all more sensitive indicators of an antigen-specific response than is proliferation (2,13,60, 62). 2.1.6 Test for virus production The concentration of infectious virion particles in the culture supernatant is estimated by the lysis of OMK cells (see Section 2.1.3): this assay is also used to verify that HVS-transformed T cells are not producing virus, which has usually ceased within several weeks of the initial culture (11, 13). Typically, about 106 transformed lymphocytes are added to a 25 cm2 flask of fresh confluent OMK cells (in 5 ml MEM or DMEM with 10% PCS, but without IL-2). Co-cultivation allows the infection of OMK cells with small numbers of lymphocyte-associated virions, as close cell contact is achieved. Transformed human T cells may also be activated by OMK cell contact, presumably by the CD2/CD58 interaction (56), which may stimulate transformed CD8+ lymphocytes to lyse the OMK cells directly: this cytotoxic activity will decrease on further passages with fresh OMK cells. If such problems with cytotoxicity occur, large volumes (around 50 ml) of culture supernatant are harvested to screen for virus particles. Contaminating T cells are removed by low-speed centrifugation (approx. 200 g, 10 min), and the remaining supernatant is subjected to high-speed centrifugation (Sorvall centrifuge approx. 50000 g at 4°C for at least 4 h in an SS34 rotor using 35 ml screw-capped tubes (Nalgene)). Any sediment is resuspended in medium and transferred on to fresh OMK cultures. In the past, three passages were used to exclude virus 65
Edgar MeinI and Helmut Fickenscher growth, taking about 6 weeks. In our experience, the exchange of the culture medium every fourth day over 6 weeks without further passage is sufficient to detect small numbers of infectious particles. Possible or weak cytopathic effects (CPE) can be confirmed by transferring an aliquot of sterile-filtered supernatant to a fresh OMK culture, where typical CPE should be visible in a few days. The sensitivity of this co-cultivation method has been estimated to be one virus-producing cell per 106 cells (21). 2.1.7 Demonstration of viral episomes and virion DNA To demonstrate and distinguish persistent non-integrated episomal (slowly migrating) or lytical linear (higher mobility) viral DNA, in situ lysis gel electrophoresis can be used. The method was originally developed by Gardella (64), and a simplified version is now used (modified after ref. 22). Typical examples for 'Gardella gels' are shown in various reports (11, 22, 36, 64, 65). The electrophoresis is done in a vertical 1% agarose gel in 1 X TBE (89 mM Tris, 89 mM boric acid, 20 mM EDTA) with gel size 20 X 20 cm, 0.5 cm thick, at 4°C. The wells have an area of 0.5 cm X 0.5 cm and are 1 cm deep: they are separated by 0.3-0.5 cm agarose teeth. The thick gel has a tendency to slip out from the gel plates during assembly of the gel apparatus, so the gel and the gel plates are rested on a large 3% agarose block in the lower buffer chamber. The gel system is placed in a refrigerator or cold room with no buffer in the upper chamber. TBE (1 X) for the chambers is precooled. Frozen aliquots of buffers A and B (composition listed below) are prepared in advance, as Ficoll is very sticky, and the enzymes (RNase, Proteinase K) are added just before use. About 2 X 106 transformed lymphocytes are washed in PBS, resuspended in 50 |xl blue sample buffer A (200 mg/ml Ficoll 400,1 X TBE, 0.25 mg/ml Bromophenol Blue, 50 (ug/ml RNase A) and loaded into the bottom of the wells. Conventional X-markers (HindllT) and a small number of virions (obtained by centrifuging 1.0 ml virus suspension at approx. 15 000 g in a cooled benchtop centrifuge) are used as controls, also loaded in buffer A. Green buffer B (120 ul per sample; 50 mg/ml Ficoll 400, 1 X TBE, 1% SDS, 0.25 mg/ml xylene cyanole, 1 mg/ml protease K) is laid over the sample, almost filling the wells. Some 1 X TBE buffer is carefully added to fill the wells completely, and more buffer to fill the upper chamber. Electrophoresis is performed slowly at 4°C. Proteins and RNA are initially degraded enzymatically during a period of at least 3 h at 10 V. Subsequently, the gel run is continued for at least 12 h at 100 V, until xylene cyanole (green) reaches the bottom of the gel. The agarose gel is stained in TBE buffer containing ethidium bromide and photographed, but ethidium bromide staining is usually not sufficient to demonstrate episomal bands. The DNA is transferred on to a nylon membrane (e.g. Hybond™, Amersham) using the alkali transfer protocol. Viral DNA bands will be visualized by stringent hybridization and subsequent autoradiography. There are several alternatives to 66
3: Viral transformation of lymphocytes choosing the hybridization probe. If maximal sensitivity is necessary, a cloned H-DNA fragment should be used (66). H-DNA is highly repetitive in the nonintegrated episomes and amplifies the viral signals. If higher specificity is needed, e.g. to prove that the correct virus strain was used, a fragment from the variable transformation-associated genomic L-DNA end should be used (29). If band intensities have to be compared from cultures infected with different virus strains, it might be advantageous to take a probe from a lessvariable genomic region. An alternative method is to use virus-specific oligonucleotide primers to demonstrate the presence of viral DNA in transformed T cells using PCR (25, 33,49).
2.1.8 Herpesvirus saimiri in T cells of non-human primates The use of herpesvirus saimiri has recently been focused on human T cells, but its potential use in various monkey systems should not be overlooked, as, on the one hand, herpesvirus saimiri is a tumour virus of New World monkeys, and, on the other, Old World monkeys like macaques are widely used as a model for human diseases. For many New World primate species HVS establishes a semi-permissive infection in T cells, with both long-lived productive infection and transformation (summarized in ref. 48). Transcription of IL-2 and activity of IL-4 has been shown from such cultures (30). Transformed New World monkey T cells express the whole spectrum of virus genes, whilst they are producing virus particles (48). T lymphocytes from Old World macaque monkeys can be transformed by HVS in a similar manner to human cells (36-39): the IL-2 dependence of these cultures is variable. In many respects, the transformed macaque T cells resemble their human counterparts. The activated T-cell phenotype is preserved, and virus particles are not usually produced. Antigen-specific Tcell lines against myelin-basic protein or streptolysin O retained their activity after transformation. The MHC class II-expressing transformed cells could present antigen to each other in the absence of additional APCs (36). In contrast to their uninfected progenitor cells, the antigen specificity of the transformants was obscured by using increasing concentrations of irradiated autologous PBMCs as APCs. In contrast to human HVS transformed T cells, transformed T cells from Rhesus monkeys are often double-positive for CD4 and CDS. This does not appear to be an effect of transformation, but rather is a peculiarity of T cells from Rhesus monkeys (36). Most Rhesus monkeys in primate centres are infected with foamy virus, reactivation of which considerably hampers studies of primary T cells and their transformation (37): this is not adequately controlled by the addition of zidovudine (AZT) or other agents which may also be cytotoxic. Transfusion of macaque monkeys with autologous HVS-transformed T cells led to no development of leukaemias or lymphomas, and the animals were also protected from disease after intravenous challenge infection with 67
Edgar Meinl and Helmut Fickenscher high-titre, wild-type virus. HVS strain C488 administered intravenously in high-titre causes an acute disease that is lethal within 2 weeks in naive macaques, thought to be due to a form of polyclonal T-cell leukaemia which has not been seen in humans (39,67).
2.2 Immortalization of human T cells by human T-cell leukaemia virus type 1 Human T-cell leukaemia virus type 1 (HTLV-1) has been used extensively for immortalizing human T cells. The method described here is based on an excellent report by Nutman (68). HTLV-transformed T cells do release virus particles, and as HTLV is a human tumour virus it has to be handled under containment level 3 conditions. Never use your own cells for transformation experiments! Protocol 4. Immortalization of human T-cells by HTLV-1 Equipment and reagents • HTLV-1 producer cells like MT-2 or HUT-102 • T-cells to be transformed, showing rapid growth 2-3 days after activation with PHA . Complete medium: RPMI-1640, PCS (10%), or specific antigen 350 ug/ml L-glutamine, and 100 (ig/ml supplemented with 10-100 U/ml • Irradiation source recombinant IL-2 • Equipment and reagents for PCR and flow cytometry • 24-well tissue-culture plates (e.g. Nunc)
Method 1. Seed rapidly proliferating T cells at 106 cells per well into 24-well plates, in complete medium supplemented with IL-2. 2. Irradiate HTLV-1 producer cells at 106 cells/ml with 6000 rads. 3. Add 106 irradiated producer cells to 106 proliferating T cells. 4. Incubate the cultures for several weeks, feeding the cells twice-weekly with IL-2 medium. 5. Wait for the appearance of rapidly growing cells in the cultures. 6. Confirm transformed status, using: HTLV-1 PCR, flow cytometry for CD25 and HLA-DR. NB: HTLV-1-transformed cells frequently lose IL-2 dependence, cytotoxicity, antigen-reactivity, and TCR expression.
HTLV-1 can be used to transform mononuclear cells from cord blood or adult peripheral blood, or T-cell clones. The cells are first activated with mitogen (PHA, Murex/Wellcome), or with their specific antigen, and incubated in 24-well plates for 2-3 days. The activated cells are then seeded at 106 cells/ml in 24-well plates. The irradiated HTLV-1 producer cells (106 cells/ml; e.g. MT68
3: Viral transformation of lymphocytes 2; or HUT-102, available from ATCC as TIB-162) are added to the wells in a 1:1 ratio, and incubated for 2-6 weeks, being fed with IL-2-containing medium twice weekly. After 6 weeks, rapidly growing cells should be observed, which in many cases are already IL-2-independent. Co-cultivation is more efficient and reliable than infection with cell-free supernatants. HTLV-transformed human T cells express CD25/IL2Ra chain and HLA-DR molecules abundantly on their surface, but after few months of culture, they tend to lose IL-2 dependence, cytotoxicity, antigen-reactivity, and TCR expression (9,10). HTLV-1 provided the first reagent for the immortalization of human T lymphocytes (4, 6-8). In most cases the transformed T cells are CD4+/CD8-, but CD4-/CD8+ human T cells can also be immortalized (3, 5). The principal drawbacks are that transformed cells continue to release virus particles in most cases, and many of the functional characteristics of the primary T cells may be lost. In contrast to HVS-transformed T cells, HTLV-1 immortalized lymphocytes do not produce IL-2.
3. B-cell immortalization 3.1 EBV-transformation of human B cells In contrast to viral transformation of human T lymphocytes, B-cell transformation by EBV is a widely used, reliable, and easy procedure (69), which does not require the same degree of attention to the cultures. This protocol is based on our own experience and on the recommendations by Tosato (15). As for the viruses used in the other protocols, EBV should be treated as a human pathogen and handled at the appropriate level of containment (usually P2). One should keep in mind that EBV is easily reactivated from most EBVtransformed, B-lymphoblastoid cell lines (B-LCL). Never use your own cells in your transformation experiments! To generate EBV stocks, exponentially growing cells of the EBV-transformed, marmoset producer cell line B95-8 (ATCC CRL-1612, DSMZ ACC 100, ECACC 85011419) (70) are seeded at 1 X 106 cells/ml in RPMI-1640 with 10% PCS, glutamine, and antibiotics (complete RPMI). After 3 days of culture, the cells are sedimented at low speed (approx. 200 g, 10 min). The supernatant is filter-sterilized and stored in aliquots at -80 °C. Such supernatants contain up to 1000 transforming units/ml. Protocol 5. Immortalization of human B-cells using EBV Equipment and reagents • Exponentially growing B95-8 cells • RPMI-1640 medium supplemented with 10% PCS, 350 ug/ml l-glutamine, and 100 pg/ml gentamicin • Sterile 0.45 M-m filter
• • • •
69
Freshly purified blood mononuclear cells EBV frozen stock Cyclosporin A 24-well plates
Edgar Meinl and Helmut Fickenscher Protocol 5.
Continued
Method 1. Prepare EBV stock as follows: seed exponentially growing B95-8 cells at 106/ml in the supplemented RMPI-1640 medium. After 3 d, spin down the cells. Pass the supernatant through a sterile filter (0.45 (Jim) and store aliquots at -80 °C. 2. Infect freshly purified blood mononuclear cells (107 cells in 2.5 ml) with 2.5 ml of thawed EBV stock. After 2 h at 37 °C, add 5 ml of complete medium containing cyclosporin A (final concentration 0.5 ug/ml). 3. Cultivate infected cells in flasks or 24-well plates for several weeks with occasional exchange of a third of the medium volume. Keep the cell density high. 4. Amplify the transformed B lymphoblast cells by regular passages.
Freshly gradient-purified PBMCs are infected with an aliquot of supernatant from B95-8 cells (as described in Protocol 5), then maintained in tissue culture until transformation occurs. Transformation may be inhibited by the outgrowth of EBV-specific, cytotoxic T lymphocytes, so cyclosporin A is added to cultures to a final concentration of 0.5 (Ug/ml (Novartis, Basel, Switzerland). Over the next 3 weeks, the cultures do not need much attention: it is important to keep the cell density high, and one third of the medium may be changed once a week if necessary. After 3 weeks, and depending on the metabolic activity, the cells can be expanded in complete medium, which usually leads to rapid proliferation. The resulting lymphoblastoid B-cell lines (14) are latently infected by EBV and can often be induced (e.g. using phorbol esters) to produce virus antigens and particles.
3.2 Transformation of macaque B cells with herpesvirus papio B cells from macaques like Rhesus monkeys (Macaco, mulatd) and cynomolgus monkeys (Macaca fascicularis) can be transformed by herpesvirus papio, an EBV-like virus of baboons (Papio hamadryas) (71-73). The herpesvirus papio-producer cells S594 (71) are seeded at 2 X 105/ml in complete RPMI and cultivated for 10 d at 37 °C. The supernatant is then filter-sterilized and stored in aliquots at -80 °C. Transformation of fresh macaque mononuclear cells is performed in the same way as for the human EBV protocol. The success rate seems to be lower than seen with human B cells and EBV (73). In a similar way, the Rhesus lymphoma cell-line LCL 8664 (ATCC CRL-1805) can be used to produce Rhesus-EBV (74). The cells are seeded at 2 X 105/ml in complete RPMI medium and cultivated for 10 d at 37 °C and thereafter for 10 d at 33 °C, before the virus-containing supernatant is harvested. The use of human AB serum instead of PCS when employing Rhesus-EBV for B-cell 70
5: Viral transformation of lymphocytes transformation has been recommended (73). The generation of macaque Bcell lines is hampered by the contamination of the macaque colonies at most primate centres by simian foamy virus. Cultivation of the B cells in presence of 4 uM AZT may suppress virus reactivation and giant cell formation, but this leads to considerable B-cell toxicity (73).
Acknowledgements Original work underlying this article was supported by the Deutsche Forschungsgemeinschaft (Bonn), the Bayerische Forschungsstiftung (Munchen), the Bundesministerium fur Bildung und Forschung (Bonn), the Johannes and Frieda Marohn-Stiftung, the Wilhelm-Sander-Stiftung (Neustadt/ Donau), and the EU (Shared Cost Action Project on immunoregulatory aspects of T-cell autoimmunity in multiple sclerosis). The authors thank Bernhard Fleckenstein for his continuous support.
References 1. Schneider, U., Schwenk, H. U., and Bornkamm, G. (1977). Int. J. Cancer, 19,621. 2. Broker, B. M., Tsygankov, A. Y., Muller-Fleckenstein, I., Guse, A. H., Chitaev, N. A., Biesinger, B., Fleckenstein, B., and Emmrich, F. (1993). J. Immunol, 151, 1184. 3. Faller, D. V., Crimmins, M. A., and Mentzer, S. J. (1988). J. Virol, 62,2942. 4. Miyoshi, I., Kubonishi, I., Yoshimoto, S., Akagi, T., Ohtsuki, Y., Shiraishi, Y., Nagata, K., and Hinuma, Y. (1981). Nature, 294,770. 5. Persaud, D., Munoz, J. L., Tarsis, S. L., Parks, E. S., and Parks, W. P. (1995). /. V(>0/.,69,6297. 6. Popovic, M., Lange Wantzin, G., Sarin, P. S., Mann, D., and Gallo, R. C. (1983). Proc. NatlAcad. Sci. USA, 80, 5402. 7. Yamamoto, N., Okada, M., Koyanagi, Y., Kannagi, M., and Hinuma, Y. (1982). Science, 217,737. 8. Yoshida, M., Miyoshi, I., and Hinuma, Y. (1982). Proc. Natl Acad. Sci. USA, 79, 2031. 9. Inatsuki, A., Yasukawa, M., and Kobayashi, Y. (1989). /. Immunol., 143,1327. 10. Yssel, H., de Waal Malefyt, R., Due Dodon, M. D., Blanchard, D., Gazzolo, L., de Vries, J. E., and Spits, H. (1989). /. Immunol., 142,2279. 11. Biesinger, B., Muller-Fleckenstein, L, Simmer, B., Lang, G., Wittmann, S., Platzer, E., Desrosiers, R. C., and Fleckenstein, B. (1992). Proc. NatlAcad. Sci. USA, 89, 3116. 12. Meinl, E., Hohlfeld, R., Wekerle, H., and Fleckenstein, B. (1995). Immunol. Today, 16, 55. 13. Fickenscher, H. and Fleckenstein, B. (1998). In Methods in microbiology, Vol. 25, p. 573. Eds. S. H. E. Kaufmann and D. Kabelite. Academic Press, San Diego. 14. Nilsson, K. and Klein, G. (1982). Adv. Cancer Res., 37,319. 15. Tosato, G. (1997). In Current protocols in immunology (ed. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober), p. 7.22.1. Wiley, NY. 71
Edgar Meinl and Helmut Fickenscher 16. Melendez, L. V., Daniel, M. D., Hunt, R. D., and Garcia, F. G. (1968). Lab. Anim. Care, 18,374. 17. Roizman, B., Desrosiers, R. C., Fleckenstein, B., Lopez, C., Minson, A. C., and Studdert, M. J. (1992). Arch. Virol, 123,425. 18. Albrecht, J. C., Nicholas, J., Biller, D., Cameron, K. R., Biesinger, B., Newman, C., Wittmann, S., Craxton, M. A., Coleman, H., Fleckenstein, B., and Honess, R. W. (1992). /. Virol., 66,5047. 19. Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., and Moore, P. S. (1994). Science, 266,1865. 20. Falk, L. A., Wolfe, L. G, and Deinhardt, F. (1972). /. Natl Cancer Inst., 48, 1499. 21. Wright, J., Falk, L. A., Collins, D., and Deinhardt, F. (1976). J. Natl Cancer Inst., 57, 959. 22. Ablashi, D. V., Schirm, S., Fleckenstein, B., Faggioni, A., Dahlberg, J., Rabin, H., Loeb, W., Armstrong, G., Peng, J. W., Aulahk, G., and Torrisi, W. (1985). / Virol, 55, 623. 23. Duboise, S. M., Guo, J., Czajak, S., Desrosiers, R. C., and Jung, J. U. (1998). /. Virol, 72,1308. 24. Fleckenstein, B. and Desrosiers, R. C. (1982). In The herpesviruses (ed. B. Roizman), p. 253. Plenum, NY. 25. Knappe, A., Thurau, M., Niphuis, H., Killer, C., Wittmann, S., Kuhn, E.-M., Rosenwirth, B., Fleckenstein, B., Heeney, J., and Fickenscher, H. (1998). / Virol., 72,3469. 26. Knappe, A., Miller, C., Niphuis, H., Fossiez, F., Thurau, M., Wittmann, S., Kuhn, E.-M., Lebecque, S., Banchereau, J., Rosenwirth, B., Fleckenstein, B., Heeney, J., and Fickenscher, H. (1998). /. Virol. 72,5797. 27. Medveczky, M. M., Szomolanyi, E., Hesselton, R., DeGrand, D., Geek, P., and Medveczky, P. G. (1989). /. Virol., 63,3601. 28. Medveczky, P., Szomolanyi, E., Desrosiers, R. C., and Mulder, C. (1984). /. Virol., 52, 938. 29. Biesinger, B., Trimble, J. J., Desrosiers, R. C., and Fleckenstein, B. (1990). Virology, 176,505. 30. Chou, C. S., Medveczky, M. M., Geek, P., Vercelli, D., and Medveczky, P. G. (1995). Virology, 208,418. 31. Desrosiers, R. C., Silva, D. P., Waldron, L. M., and Letvin, N. L. (1986). J. Virol., 57,701. 32. Kiyotaki, M., Desrosiers, R. C., and Letvin, N. L. (1986). /. Exp. Med., 164,926. 33. Knappe, A., Hiller, C., Thurau, M., Wittmann, S., Hofmann, H., Fleckenstein, B., and Fickenscher, H. (1997). /. Virol., 71,9124. 34. Schirm, S., Miiller, I., Desrosiers, R. C., and Fleckenstein, B. (1984). J. Virol, 49, 938. 35. Szomolanyi, E., Medveczky, P, and Mulder, C. (1987). J. Virol, 61,3485. 36. Meinl, E., Fickenscher, H., Hoch, R. M., de Waal Malefyt, R., 't Hart, B. A., Wekerle, H., Hohlfeld, R., and Fleckenstein, B. (1997). Virology, 229,175. 37. Feldmann, G., Fickenscher, H., Bodemer, W., Spring, M., Nisslein, T., Hunsmann, G., and Dittmer, U. (1997). Virology, 229,106. 38. Akari, H., Mori, K., Terao, K., Otani, I., Fukasawa, M., Mukai, R., and Yoshikawa, Y. (1996). Virology, 218,382. 72
3: Viral transformation of lymphocytes 39. Alexander, L., Du, Z., Rosenzweig, M., Jung, J. U., and Desrosiers, R. C. (1997). J. ViroL, 71,6094. 40. Simmer, B., Alt, M., Buckreus, L, Berthold, S., Fleckenstein, B., Platzer, E., and Grassmann, R. (1991). J. Gen. Virol, 72,1953. 41. Daniel, M. D., Silva, D., Jackman, D., Sehgal, P., Baggs, R. B., Hunt, R. D., King, N. W., and Melendez, L. V. (1975). Bibl. Haematol., 43,392. 42. Daniel, M. D., Melendez, L. V., and Barahona, H. H. (1972). J. Natl Cancer Inst., 49,239. 43. Desrosiers, R. C. and Falk, L. A. (1982). J. Virol., 43, 352. 44. Fleckenstein, B., Muller, L, and Werner, J. (1977). Int. J. Cancer, 19,546. 45. Berend, K. R., Jung, J. U., Boyle, T. J., DiMaio, J. M., Mungal, S. A., Desrosiers, R. C., and Lyerly, H. K. (1993). J. Virol., 67,6317. 46. Fickenscher, H., Meinl, E., Knappe, A., Wittmann, S., and Fleckenstein, B. (1996). Immunologist, 4,41. 47. Saadawi, A. M., L'Faqihi, F., Diab, B. Y., Sol, M. A., Enault, G., Coppin, H., Cantagrel, A., Biesinger, B., Fleckenstein, B., and Thomsen, M., (1997). Tissue Antigens, 49,431. 48. Fickenscher, H., Biesinger, B., Knappe, A., Wittmann, S., and Fleckenstein, B. (1996).J. Virol, 70, 6012. 49. Fickenscher, H., Bokel, C., Knappe, A., Biesinger, B., Meinl, E., Fleischer, B., Fleckenstein, B., and Broker, B. M. (1997). J. Virol, 71,2252. 50. Klein, J. L., Fickenscher, H., Holliday, J. E., Biesinger, B., and Fleckenstein, B. (1996). J. ImmunoL, 156,2754. 51. Pacheco Castro, A., Marquez, C., Toribio, M. L., Ramiro, A. R., Trigueros, C., and Regueiro, J. R. (1996). Int. ImmunoL, 8,1797. 52. Yasukawa, M., Inoue, Y., Kimura, N., and Fujita, S. (1995). /. Virol., 69, 8114. 53. Nick, S., Fickenscher, H., Biesinger, B., Born, G., Jahn, G., and Fleckenstein, B. (1993). Virology, 194,875. 54. O'Donnell Tormey, J., Nathan, C. F., Lanks, K., DeBoer, C. J., and de la Harpe, J. (1987). J. Exp. Med., 165,500. 55. Medveczky, M. M., Geek, P., Sullivan, J. L., Serbousek, D., Djeu, J. Y., and Medveczky, P. G., (1993). Virology, 196,402. 56 Mittriicker, H. W., Muller-Fleckenstein, L, Fleckenstein, B., and Fleischer, B. (1992). J. Exp. Med., 176, 909. 57. Saha, K., Sova, P., Chao, W., Chess, L., and Volsky, D. J. (1996). Nature Med., 2, 1272. 58. De Carli, M., Berthold, S., Fickenscher, H., Muller-Fleckenstein, L, D'Elios, M. M., Gao, Q., Biagiotti, R., Giudizi, M. G., Kalden, J. R., Fleckenstein, B., Romagnani, S., and Del Prete, G. (1993). J. ImmunoL, 151, 5022. 59. Mittriicker, H. W., Muller-Fleckenstein, L, Fleckenstein, B., and Fleischer, B. (1993). Int. ImmunoL, S, 985. 60. Weber, F., Meinl, E., Drexler, K., Czlonkowska, A., Huber, S., Fickenscher, H., Muller-Fleckenstein, L, Fleckenstein, B., Wekerle, H., and Hohlfeld, R. (1993). Proc. NatlAcad. Sci. USA,9Q, 11049. 61. Kraft, M. S., Henning, G., Fickenscher, H., Lengenfelder, D., Tschopp, J., Fleckenstein, B., and Meinl, E. (1998). /. Virol., 72,3138. 62. Broker, B. M., Kraft, M. S., Klauenberg, U., Le Deist, F., de Villartay, J.-P., Fleckenstein, B., Fleischer, B., and Meinl, E. (1997). Eur. J. ImmunoL, 27,2774. 73
Edgar Meinl and Helmut Fickenscher 63. Meuer, S. C., Hussey, R. E., Fabbi, M., Fox, D., Acuto, O., Fitzgerald, K. A., Hodgdon, J. C., Protentis, J. P., Schlossman, S. F., and Reinherz, E. L. (1984). Cell, 36, 897. 64. Gardella, T., Medveczky, P., Sairenji, T., and Mulder, C. (1984). J. Viral, 50, 248. 65. Broker, B. M., Tsygankov, A. Y., Fickenscher, H., Chitaev, N. A., Schulze-Koops, H., Muller-Fleckenstein, L, Fleckenstein, B., Bolen, J. B., and Emmrich, F. (1994). Eur. J. Immunol., 24, 843. 66. Bankier, A. T., Dietrich, W., Baer, R., Barrell, B. G., Colbere Garapin, F., Fleckenstein, B., and Bodemer, W. (1985). J. ViroL, 55,133. 67. Knappe, A., Feldmann, G., Dittmer, U., Meinl, E., Nisslein, T., Wittmann, S., Kirchner, T., Matz-Rensing, K., Bodemer, W., and Fickenscher, H. (1999). (Submitted for publication). 68. Nutman, T. B. (1997). In Current protocols in immunology (ed. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober), p. 7.20.1. Wiley, NY. 69. Sugden, B. and Mark, W. (1977). J. ViroL, 23, 503. 70. Luka, J, Lindahl, T., and Klein, G. (1978). J. ViroL, 27, 604. 71. Falk, L., Deinhardt, F., Nonoyama, M., Wolfe, L. G., and Bergholz, C. (1976). Int. J. Cancer, 18,798. 72. Rabin, H., Neubauer, R. H., Hopkins, R. F., Dzhikidze, E. K., Shevtsova, Z. V., and Lapin, B. A. (1977). Intervirology, 8, 240. 73. Voss, G., Nick, S., Stahl Hennig, C., Ritter, K., and Hunsmann, G. (1992). J. ViroL Methods, 39,185. 74. Rangan, S. R., Martin, L. N., Bozelka, B. E., Wang, N., and Gormus, B. J. (1986). Int. J. Cancer, 38,425.
74
4
B- and T-cell hybridomas JUDY M. BASTIN
1. Introduction In 1975, Kohler and Milstein (1) described details of a powerful method in which B cells secreting antibody of one specificity could be fused with a continuously growing plasmacytoma. The fusion product is called a hybridoma, and it will express the immunoglobulin genes from both the normal antibodyforming B cell and the plasmacytoma. It will inherit the potential for unlimited growth from the continuously growing plasmacytoma parent and the genetic material determining a given antibody specificity from the antibodysecreting parent. The methods used to generate T-cell hybridomas are essentially the same as for B-cell hybridomas, and in 1978 Kontiainen et al. (2) and Taniguchi and Miller (3) isolated the first T-cell hybrid clones. Antigenspecific normal T cells are fused to a T-cell tumour line. The production of B- and T-cell hybridomas has become routine in many laboratories. Once the need for these reagents has been established those laboratories that are inexperienced in this area may have to decide whether to devote resources to establishing the technology or to approach commercial groups to make the hybridomas for them. The aim of this chapter is to help the reader make the right decision. The chapter does not attempt a complete review of methodology; the intention is to provide the reader with a broad understanding of the techniques and equipment needed to make hybridomas and to give advice on any problems they might encounter.
2. Methods for generating B- and T-cell hybridomas and the principles of hybridoma culture No two laboratories use exactly the same technique and many of these variations are based on empirical observations. This implies that there is much potential for flexibility in the methods. However, at first it is better to follow protocols exactly to avoid difficulties. The first question to ask is whether Bor T-cell hybridomas are appropriate for the problem being addressed. Conventional antisera or continuous cultures of T-cell clones may be equally
JudyM. Bastin good or even preferable to hybridomas. For example, the monoclonal antibodies raised may be of the wrong isotype to fix complement, may recognize an unwanted epitope away from the part of the antigen being studied, or may produce a low-affinity reagent. Also, although T-cell clones can be difficult to maintain, they may be more physiologically relevant than an artificial fusion product.
2.1 Tissue culture Making hybridomas requires experience in cell culture, and a good sterile technique is essential in tissue culture laboratories. The reader is referred to the principles outlined in the first chapter, or a basic cell-culture methods' manual (4). Realistically, the production of hybridomas may require months of tissue culture work. The sequence of events in making hybridomas is shown below and the reader will be taken through each of these step by step. (a) preparation of antigen; (b) development of a screening test; (c) immunization of the animals; (d) screening animal sera; (e) fusion protocol; (f) screening supernatants; (g) cloning and cryopreservation; (h) screening colonies from cloning plates; (i) cryopreserving, recloning, and retesting; (j) final cryopreservation of hybridomas. At each point cryopreservation is emphasized, as it is the only insurance against the loss of useful cultures.
2.2 Materials The equipment needed for the production of hybridomas is listed below and is likely to be available in most laboratories. All the materials can be purchased from commercial suppliers, e.g. Sigma or Gibco BRL. Routine cell-culture media is used, such as RPMI-1640 supplemented with fetal calf serum (PCS). Batches of PCS should be screened for their ability to support hybridoma growth, and pre-screened batches are available commercially. There are a number of calf sera variants available. For example, agamma (Ig-depleted) calf serum has been shown to produce twice as much immunoglobulin as standard PCS, both in human and mouse hybridoma lines (5), and the subsequent purification of a monoclonal antibody is easier if there is no bovine IgG present. Medium containing hypoxanthine, aminopterin, and thymidine (HAT) is 76
4: B- and T-cell Hybridomas used for the selective growth of hybrids after fusion (see Section 2.3): HAT supplement (100 x) is available from Sigma. Polyethylene glycol (PEG) is the fusion-inducing agent. Batches of PEG vary in their toxicity and ability to induce fusions (6), so screening batches for their suitability is worthwhile. A sterile 50% solution of PEG in serum-free RPMI is used. The pH of the solution should be between 7.2 and 8.0. The following equipment is needed for the generation of hybridomas: • • • • • • • • •
carbon-dioxide 37 °C incubator; class-II, tissue culture hood; inverted phase-contrast microscope; liquid-nitrogen storage facilities; centrifuge; access to a good animal facility; sterile tissue culture plasticware and pipettes; 37 °C water bath; relevant fusion-partner for B- or T-cell hybridomas.
2.3 Selection procedures When fusing two different cell types, the frequency of fusion is low (about 1 in 104). The potential of the neoplastic plasmacytoma or T-cell tumour lines for continuous growth means they will rapidly outcompete the minority hybridomas, so a strategy is necessary to eliminate the non-fused cells. The method most commonly in use was developed by Littlefield (7), and relies on the initial generation of mutant plasmacytomas lacking the enzymes responsible for the incorporation of purines and pyrimidines into DNA and RNA. Cells with mutations resulting in the functional absence of the enzymes thymidine kinase (TK) or hypoxanthine guanine phosphoribosyl transferase (HGPRT) will be the only cells to survive when these toxic base analogues are incorporated into the growth medium. Once these mutant lines have been isolated it is possible to select against the growth of the enzyme-deficient lines by forcing them to use the salvage pathway for DNA synthesis. Aminopterin blocks the normal pathway for purine and pyrimidine synthesis, and when it is added to the growth medium the plasmacytoma is forced to use the salvage pathway and cannot survive in HAT medium. Spleen cells fused to the HGPRT- or TK- plasmacytoma cells during hybrid formation enable the hybridomas to survive in the HAT medium. The unfused T or B cells do not proliferate in vitro, and will eventually die.
2.4 Immunizations Once the decision to make hybridomas has been made it is advisable to start the immunization protocol as soon as possible, as the whole procedure will 77
Judy M. Bastin take many weeks. The protocols for the immunization of animals are many and varied. However, in general, spleens are taken from hyperimmunized mice or rats 3 or 4 days after the last injection. Soluble antigen is best delivered with an adjuvant: complete Freund's adjuvant (CFA) is still a popular and efficient choice, but can cause some side-effects for the animals. Other newer adjuvants have been released which are said to be as good as CFA, but with fewer side-effects (8, 9). A secondary booster is given at a variable time after the primary injection, but never in CFA because of the risk of anaphylactic shock to the animal. It may be given in incomplete Freund's adjuvant (ICFA), which lacks the mycobacteria present in the complete form. Live allogeneic and xenogeneic cells are highly immunogenic and are injected intraperitoneally (see Protocol 1 for details of immunization procedures). We have recently used transgenic mice for making a monoclonal antibody to a non-classical HLA class-I protein (10). The aim was to make an antibody capable of distinguishing between classical HLA class-I proteins and the very similar, but less common, non-classical HLA class-I protein HFE. We decided to immunize an HLA B27 class-I transgenic mouse, which should be incapable of making an antibody to that molecule or closely related classical class-I molecules. A specific antibody that recognized HFE protein only and not classical class-I or other non-classical proteins was readily achieved by immunizing with recombinant refolded HFE protein, according to Protocol 1. It is clear that other transgenic animals could be used in this way to make antibodies to proteins that have very similar structures to the transgene product. Protocol 1. Immunization procedures Equipment and reagents • Complete Freund's adjuvant (CFA) • Incomplete Freund's adjuvant (ICFA) . Phosphate-buffered saline (PBS), pH 7.0
A. 1. 2. 3. 4.
• Sterile syringes and needles • Blood collection containers
Soluble antigens Day 1: Inject 50-100 ug of the antigen in CFA subcutaneously. Day 14: Repeat. Day 28: Repeat and test bleed. Inject 50 ug of the antigen in ICFA intravenously 4-5 days before fusion.
B. Cellular antigens 1. Day 1: Inject 5 x 106 washed cells (spin at 300 g for 10 min at room temperature) in PBS intraperitoneally. 2. Day 28: Repeat and test bleed. 3. Repeat with the same number of cells 4—5 days before fusion. 78
4: B- and T-cell Hybridomas
2.5 Fusion partners A number of myeloma or T-cell tumour lines are available for fusion. In the mouse, where there is the greatest choice and experience for antibody production, there is no apparent reason, apart from ready availability, for using a line that retains the ability to code for its own Ig light or heavy chains, since this might complicate the process of monoclonal hybridoma selection. However, both non-secretor and secretor myelomas have been used successfully. Some commonly used mouse myeloma lines used for hybridoma antibody production are: SP2/0-Agl4 (11), P3-X63-Ag8.653 (12), P3-NSl/l-Ag4-l (13), and NSO, a non-secreting clone of P3X63 Ag8 (14). Besides the ability to efficiently yield functional and stable hybridomas, the tumour lines must possess a drug marker that makes it easy to select hybrids. The most common murine T lymphoma is the AKR thymoma BW5147. Other T-cell tumour cell lines are another AKR thymoma, AKR-A, or EL-4 a C57BL/6 lymphoma. The maintenance and health of the fusion partner is of paramount importance in the eventual success of the fusion. Myeloma cells that have been growing for a long time or that have become overgrown are less successful at producing hybridomas than freshly grown cells. It is best to thaw myeloma cells from liquid nitrogen just days prior to the fusion procedure. It is almost impossible to yield successful hybridomas from mycoplasma-infected cells. Mycoplasma infection will reduce the efficiency of fusion and markedly affect the antibody secretion of the few hybridomas formed. Regular mycoplasma screening of all cell lines is therefore an essential part of hybridoma production, and it is better not to start a fusion protocol if cells have not been screened. The HAT sensitivity of the myelomas or thymomas to be used as fusion partners should be checked periodically by attempting to grow a subculture in HAT medium; if growth occurs, a stock culture should be grown in the presence of 10-4 M 8-azaguanine or discarded.
2.6 Fusion protocol There are many variations of the 'standard' fusion protocol. The one described in Protocol 2 has been used in the author's laboratory to produce monoclonal antibodies against a variety of antigens, ranging from cell-surface antigens to soluble proteins. In addition to using PEG as an agent to induce membrane fusion, there are less frequently used alternatives, such as electroporation, that are useful when low numbers of B cells are available for fusion. It is helpful to go through a checklist (see Protocol 2, Equipment and reagents list) and assemble all the reagents before starting the fusion protocol (Protocol 2).
79
Judy M. Bastin Protocol 2.
Fusion
Equipment and reagents Immunized mouse NSI or other fusion-partner cells (107) One sterile Petri dish Eight 24 x 2-ml or ten 96 x 0.2-ml well plates Plastic centrifuge tubes Sterile 1 ml and 10 ml pipettes Sterile Pasteur pipettes Sterile dissecting instruments
. RPMI-1640 at 37 °C . FCS at 37 °C . 37 °C water bath • Humidified 5% CO2-air incubator • 2 x hypoxanthine, aminopterin, thymidine (HAT) . Sterile 50% PEG in RPMI-1640 at 37°C • Timer
Method 1. Kill the mouse in a C02 chamber by cervical dislocation. 2. Soak the mouse in ethanol and open the skin. 3. Use sterile scissors and forceps to open the peritoneum and remove the spleen. 4. Place the spleen in a Petri dish containing 5 ml of serum-free medium (usually RPMI-1640) and cut it in half. Tease the cells out using sterile instruments. 5. Pipette these cells into a sterile plastic tube and allow the clumps to settle over 5 min. 6. Transfer the cells to a second plastic tube and centrifuge at 300 g for 10 min at room temperature. 7. Take 107 fusion-partner cells, wash them free of medium, and pellet by centrifugation (as step 6). 8. Resuspend the two pellets in 5 ml of serum-free medium, mix together, and centrifuge at 300 g for 10 min. Mix the splenic lymphocytes and fusion-partner cells at a ratio of 10:1.a 9. Gently tap the tube to disrupt the pellet and place the tube in a 37°C water bath. 10. Add 1 ml of a 50% PEG and medium mixture at 37°C dropwise to the cell pellet over 1 min. 11. Add 2 ml of pre-warmed serum-free medium, starting immediately, dropwise over 2 min; then add 8 ml over a further 3 min. 12. Spin the cells at 300 g for 10 min. Gentlyb resuspend the cells in the required volume of RPMI-1640 with 20% FCS and plate out.c 13. Place the plates at 37°C in a humidified 5% CO2-air incubator. 14. Add, 24 h later, an equal volume (100 ul for a microtitre plate or 1 ml for a 2-ml well plate) of RPMI-1640/20% FCS supplemented with 2 X HAT to each well. 80
4: B- and T-cell Hybridomas 15. Leave the plates to stand in the incubator until colonies appear (between 7 and 10 days). * For more accuracy you may want to count the spleen cells after lysing the red cells and adjust the number of fusion-partner cells accordingly. bBe very gentle at this stage because the cell-fusion products are susceptible to damage by shear forces. cVarious plating-out procedures are favoured by different workers, e.g. microtitre wells or larger 2 ml wells or a combination of the two. The smaller wells have the advantage that most wells in which cultures grow will contain only one colony (often equivalent to a clone) of hybrid cells, but the disadvantage is that the volume of supernatant available for assay is small.
2.7 Growth of hybridomas Following the plating out of cells in the HAT medium, the cells should be left for at least 7 days. After this time small colonies may appear. As the colonies grow, remove some supernatant and test for antibody or specific T-cell activity in the screening assay. We usually screen only those with single colonies. Obviously, this policy means that some hybridomas will be undetected, so if time allows screening can be extended to wells containing two or three colonies. However, if you do this you will have to separate and clone any positive colonies immediately. This can be a very busy time, and the benefits of a rapid, reliable screening assay cannot be overemphasized! Improved yields of hybridomas are obtained by the addition of feeder cells or various growth factors. The active ingredient of 'hybridoma growth factor' is interleukin-6 (IL-6), the addition of which can increase the yield of monoclonal antibodies. A variant of the Sp2/0 myeloma transfected so that it produces IL-6 is reported to improve hybridoma yields by up to 15-fold (15) In the absence of IL-6 or the Sp2/0 variant, add feeder cells (106/ml): these are usually spleen cells from a non-immunized mouse. It is very easy to lose valuable hybridomas at this vulnerable stage, and great care in cell-culture technique is required.
2.8 Screening assays It is of paramount importance to decide on, and test in good time, a suitable assay to screen hybridoma culture supernatants or T-cell hybridomas: this really cannot be overemphasized. The need to test the animal sera before fusion provides the ideal opportunity to optimize the assay. It is important to include normal mouse sera as a control. The more specific and simple the screening test, the better the chance of quickly and easily obtaining the desired hybridoma, but the procedure for screening for B-cell hybridomas is very different from that for T-cell hybridomas. The nature of the antigen will often dictate the screening assay. For example, hybridomas producing antibodies to cell-surface antigens can be examined quickly and easily by immunofluorescence, while immunoenzyme 81
Judy M. Bastin techniques are more suitable for tissue sections and enzyme-linked immunosorbent assays (ELISAs) for soluble antigens. The screening method chosen should reflect the techniques in which you want to use the antibody. Antibodies that react against fixed tissue will not necessarily react with fresh tissue; some antibodies work very well in one assay but not in another. It is important to have purified antigen for the assay, since antibodies against impurities in the immunizing material will react if the screening material contains the same impurities. It is also quite important to discover the isotype of the monoclonal antibody before the final choice of hybridoma is made. Some isotypes, e.g. IgG1, do not fix complement. IgM antibodies are difficult to store without loss of specificity. IgG3 antibodies are very useful for double-labelling studies as the majority of monoclonal markers are IgG1. The reader is referred to ref. 16 for details of the basic immunological methods mentioned in this section. The screening of T-cell hybridomas will depend on the T-cell phenotype. Thus, antigen-specific suppressor hybridomas are isolated by their ability to bind to antigen-coated plates (a panning procedure) or antigen-coated erythrocytes (a rosetting technique). Antigen-specific helper hybridomas are screened by examining their lymphokine-producing capability in an antigen-specific and MHC-restricted manner. Cytotoxic T-cell hybridomas are selected by a standard CTL assay using an appropriate target (as described in Chapter 7) In essence, the assay chosen must be specific, sensitive, and allow the rapid screening of large numbers of samples.
2.9 Cloning hybridomas Once the screening assay indicates that a well contains a hybridoma of interest, the contents of the well should be cloned as soon as possible. There are several reasons for cloning, the main one being to ensure that a monoclonal reagent is produced. However, it is also important to clone positive wells to prevent them being overgrown by non-specific cells. The most common cloning method is that of limiting dilution, in which wells are plated out from a starting culture into a number of individual wells so that the most likely number of cells in any given well is one. Poisson's distribution then predicts that 37% of wells will end up without cells. However, because the cloning efficiency may be low, it is advisable to clone at predicted frequencies of both one and three cells per well, and to plate out a minimum of 96 wells per concentration. Details of the cloning method used is shown in Protocol 3. Protocol 3. Cloning hybridomas Equipment and reagents • • • •
Non-immunized mouse Non-sterile and sterile scissors and forceps 96-well microtitre plates RPMI-1640 medium
82
• RPMI-1640 supplemented with HAT (see Protocol 2} • Sterile Pasteur pipettes • Liquid nitrogen
4: B- and T-cell Hybridomas Method 1. Kill a non-immunized mouse and remove the spleen aseptically (see Protocol 2). Make a single-cell suspension (see Protocol 2, steps 4-6) to provide the feeder layer for cloning. 2. If there is a single colony present in a well, transfer this to a new well.a 3. After removing cells for cloning, feed the cells remaining in the well with medium and feeder cells (106/ml). Allow the cells to proliferate, then freeze into liquid nitrogen as soon as possible to act as a back-up if the cloned cells do not survive. 4. Count the cells in the well and prepare suspensions at 30 and 10 cells/ ml in 20 ml HAT medium. Add feeder cells to a final concentration of 2 x 105/ml. Plate the mixture into 96-well microtitre plates at 200 ul/well. 5. After 7-21 days test the supernatant from wells containing single colonies and, if positive, expand the cultures and freeze in liquid nitrogen. aUsually, however, a single colony cannot be distinguished. In this case mix the contents of the well by gentle pipetting and transfer the contents to a new well in a microtitre plate).
2.10 Cryopreserving and thawing cells Preserving cells in liquid nitrogen is the only means of ensuring the long-term availability of hybridomas. Cells should be frozen down as soon as possible and their details recorded. The methods used for both freezing and thawing cells are shown in Protocol 4. Protocol 4. Freezing and thawing hybridomas Equipment and reagents « • • • •
• RPMI-1640 supplemented with HAT • RPMI-1640 medium supplemented with HAT, 50% FCS, 20% DMSO (freezing medium) • Polystyrene container with >1-cm thick walls
-80 °C freezer Cryotubes Liquid nitrogen 37 °C water bath Culture flasks or flat-bottomed microtitre plates
?-well
A. Freezinga 1. Take the cells from culture, spin at 300 g for 10 min at room temperature, and resuspend them at about 5 x 106/ml in HAT medium with 50% FCS and 20% dimethyl sulfoxide (DMSO). Gently mix the suspension and dispense into commercially available cryotubes. 2. After sealing and labelling the tubes, place them in the polystyrene container. 83
Judy M. Bastin Protocol 4.
Continued
3. Put this container into a -80°C freezer for 24 h. Then transfer it into liquid nitrogen. B. Thawing 1. Remove a vial from liquid nitrogen and warm it in your hand or in a 37°C water bath. 2. Remove the vial when the ice has just melted and dilute the cell suspension by the dropwise addition of an equal volume of HAT medium. Add another equal volume of medium and leave for 5 min. 3. Centrifuge the cells at 300 g for 5 min. at room temperature. 4. Resuspend the cells in a 5 ml millilitres of freezing medium and add either to a culture flask or a flat-bottomed 96 well plate. Add feeder cells (5 x 105/ml) and IL-6 (10U/ml) if the cells are slow to recover. aWhere possible a controlled-rate freezing system is preferable for very valuable hybridomas.
2.11 Large-scale production of hybridomas Recently, medium- to large-scale in vitro methods of antibody production have become more accessible to most research laboratories; hence, the use and justification for using ascitic fluid has decreased. The generation of peritoneal tumours in mice has been banned in some countries, including the United Kingdom. Monoclonal antibodies can be produced in dialysis tubing, where the antibody yields are up to 1 mg/ml (standard culture supernatant is up to 5 ug/ml). A high concentration of cells (107/ml) in 10 ml of medium supplemented with 10% FCS is placed in a dialysis tube (pore size 12000-14000) and then into an 800-ml tissue culture flask The flask is fed with RPMI-1640 medium containing 2% FCS and 2% primatone (Kraft, Norwich, NY, USA) and placed in a rotator in a CO2 incubator (17). A similar system using dialysis tubing fixed inside a roller bottle was described by Pannell and Milstein in 1992 (18). The yield of 1-2 mg/ml obtained with this method is good. The reader is referred to Andersen and Gruenberg (19) and von Wedel (20) for more information on other largescale production methods.
2.12 Purification There are numerous methods available for purifying monoclonal antibodies, but the method selected should reflect the intended use of the antibody. Sometimes the culture supernatant may be of sufficient purity for use. It is clear from the vast amount of literature on optimized purification procedures 84
4: B- and T-cell Hybridomas that no one procedure is suitable for all monoclonal antibodies, and the reader is referred to ref. 16 for a review of methods. The single, most useful purification procedure for monoclonal antibodies is affinity purification on protein G. It is simple and has the additional advantage of concentrating the antibodies, which can be particularly useful when dealing with large volumes of culture supernatant containing low concentrations of antibody (see Protocol 5 for details). At between pH 6.0 and pH 8.0, the Fc portions of all subclasses of IgG are bound to the protein G matrix. Once all the crude antibody has been applied to the column and washed with a number of column volumes of loading buffer, the purified antibody can be eluted from the column with buffers ranging from pH 4 to pH 2. An important early step is to determine the least acidic pH at which the antibody can be eluted. This will minimize any possible denaturing of the antibody. The protein G can be packed into a 5-ml syringe barrel with a glass-wool plug at the bottom. Protocol 5. Protein G purification Equipment and reagents • Protein G column (e.g. 5 ml syringe barrel with a glass-wool plug at the bottom) • Loading buffer: 0.02 sodium phosphate pH 7.4
• 5 ml collection tubes • Elution buffer: 0.1 M glycine HCI at the previously determined pH (see text above) • Neutralizing agent: 1 M Tris HCI, pH 9.0
Method 1. Wash the column with a 5 column volumes of the loading buffer. 2. Load the sample at a flow rate of less than 1 ml per min. 3. Once all the sample has been loaded, wash through with three column volumes of loading buffer or until the optical density at 280 nm is back to baseline levels. 4. Apply the elution buffer and collect the antibody fraction in a 5 ml tube containing 0.5 ml of the neutralizing agent. 5. Determine the antibody concentration using a spectrophotometer.
2.13 Human hybridomas To produce unaltered human antibodies or to obtain large numbers of human T cells it is necessary to immortalize human B or T lymphocytes. The generation of human antibody-secreting B-cell hybridoma lines was initially very encouraging (21, 22), but subsequently results have been inconsistent. One should remember that the antibodies from immortalized human B cells will not necessarily exactly reflect the human antibody repertoire. The 85
Judy M. Bastin monoclonal antibodies developed may present a biased selection, depending on the source of the B cells and the subsequent manipulations of the cells in vitro. Human B-cell hybridomas are generally stable, but not all B cells fuse equally well. In recent years, research has focused on the source of B cells for fusion, the choice of fusion partners, and the mechanism of fusion. For details of this research refer to ref. 23. There is now a large number of available human antigen-specific B hybridomas. The resultant monoclonal antibodies have made unique contributions to the development of diagnostic and therapeutic reagents. These include analysis of the human B-cell repertoire, which has led to significant insights into the origins of autoimmunity; the search for specific and therapeutic antibodies against human tumours, e.g. melanoma (24), and infectious pathogens continues. The situation for T-cell hybridomas is different. The essential method of production is to fuse PHA-activated human peripheral blood lymphocytes with a fusion partner, e.g. acute lymphatic leukaemia cells (CEM). Several experimental problems have made these cells less useful than continuous cultures of T-cell clones. T-cell hybridomas, particularly human hybrids, show a greater tendency to be functionally unstable during prolonged culture (see Section 2.15). Although human hybridomas were used in the past to study Tcell products such as interferon (25) or lymphokines (26), current literature suggests that T-cell hybridomas have been largely replaced as a research tool by continuous cultures of human T-cell clones.
2.14 Antibody production by chemical and genetic engineering The antigen-binding properties of a particular monoclonal antibody may be ideal in terms of its specificity and affinity, but its usefulness as a reagent may be limited by its isotype—such that certain effector functions cannot be harnessed in vivo, or Fc receptors on the antigen interfere with specific reactions. It may be necessary to alter the antibody by fragmentation and to change or remove the Fc region, or perhaps combine fragments of other antibody specificities to make bispecific reagents. This can be done by chemical means, e.g. proteolytic enzyme digestion to remove the Fc portion, or by genetic manipulation. The essential failure of the hybridoma method to reliably produce human monoclonal antibodies suitable for therapy has coincided with many technological advances in molecular biology. The use of transgenic mice to manipulate the production of a specific B- or T-cell parent has already been mentioned (Section 2.4) but this still yields a rodent hybridoma. The definition of antibody gene sequences led the way, via genetic manipulation, to 'humanize' what started as rodent antibodies so that they would resemble the human equivalent without losing specificity. This approach renders the reagent more 86
4: B- and T-cell Hybridomas clinically useful as there is less danger of rejection. The isolation of antibody genes enables the fine-tuning of the desired characteristics (e.g. specificity or binding affinity), which cannot be achieved by the conventional hybridoma method. The reader is referred to ref. 23 for details of this area of research. One can imagine that in the future the antibody required could be designed by computer and selected from a family of antibody gene libraries.
2.15 Disadvantages of hybridomas The general disadvantages of B-cell hybridomas over conventional antisera have already been mentioned. The specific disadvantage of the IgM isotype is that IgG antibodies are more stable and can be more easily isolated and purified. However, a high number of IgG-producing hybrids are obtained when lymph node cells are used instead of splenocytes for the fusion. The disadvantages of T-cell hybridomas are even greater. Several experimental problems with T-cell hybridomas have made them less useful than continuously growing T-cell clones. T-cell hybridomas, particularly human hybrids, show a greater tendency to functional instability during culture. This may be due to rapid chromosome loss or somatic mutations. In a study of more than 600 mouse and human hybridomas, most of the lymphocytederived chromosomes were lost (27). Therefore, it is best to keep good stocks of cloned hybridomas in frozen storage, and to redone established hybridoma lines when they have been grown continuously for long periods (more than 6 months). Another problem to be aware of is that T-cell hybridomas are not necessarily going to behave like normal antigen-specific T cells. Studies of pairs of cloned T cells and the hybridoma cells derived from them (i.e. fusion products of established T-cell clones and tumour cells) show a number of differences in activation requirements, affinity, use of CD4 molecules, lymphokine secretion, and effector functions. Possible explanations may include the use of different T-cell receptor genes from the tumour fusion partner, different gene regulation in the hybridomas, or differences in the screening methods used in their preparation. As a consequence, great care must be taken in interpreting the experimental data obtained from T-cell hybridomas.
2.16 Conclusions The aim of this section has been to provide a basic understanding of T- and Bcell hybridomas and how they are made. These days, many monoclonal antibodies are commercially available in purified form or can be supplied with a variety of enzyme or fluorescent labels attached, but these are often very expensive. It may be possible to obtain the original hybridoma and purify the antibody in-house. The time and effort involved in generating a monoclonal reagent from scratch should not be underestimated. 87
Judy M. Bastin
3. Applications of hybridoma technology 3.1 B-cell hybridomas The first B-cell hybridomas were produced in an attempt to study immunoglobulin gene expression, and have led to a much greater understanding of the genetic mechanisms of the generation of antibody diversity. The first antibodies with a particular application (those to histocompatibility antigens) were made in 1977 (28). The potential use of monoclonal antibodies as reagents was soon widely appreciated leading to a rapid growth in the field, and a whole area of the biotechnology industry developed around monoclonal antibodies. There are now entire areas of research and diagnosis that would be impossible without monoclonal antibodies, such as the detailed analysis of leucocyte phenotype (29). Many of the major applications of monoclonal antibodies in immunological studies are described elsewhere in this book. 3.1.1 Diagnostic applications of monoclonal antibodies Monoclonal antibodies have been a great success as in vitro and diagnostic reagents. They are used widely in medicine and biology to measure hormones, to identify contaminants in the food industry, to purify proteins, and to identify pathogens in human, veterinary, or plant pathology, where they have largely replaced polyclonal antisera. The reaction between an antibody and its antigen can be directly observed in vitro when an immunoprecipitate is seen at equivalent concentrations: this is the basis of antigen detection. Greater sensitivity can be attained by the use of radioimmunoassay (RIA) techniques, particularly in situations where the antibody itself is labelled with a radioisotope. Even better performance can be obtained when the radioactive label is replaced by a non-radioactive alternative such as a chemiluminescent molecule. This use of monoclonal antibodies is the basis of many diagnostic services in clinical immunology laboratories. 3.1.2 Immunolocalization using monoclonal antibodies Using the technique of immunocytochemistry, antigens can be localized within cells or tissues by the application of antibodies specific for the antigen under investigation, as described in Chapter 2. This permits the precise location of antigens implicated in diseases: one recent example is the human tissue distribution of HFE, a non-classical MUC class I protein, which is associated with hereditary haemochromatosis, a disorder of iron metabolism (10). The antigen-antibody complex can be visualized by applying various labels or markers. The reader is referred to Chapter 2 and ref. 30 for different methods of specimen preparation, both for light and electron microscopy, together with the choices of antibody and label most appropriate. 88
4: B- and T-cell Hybridomas The molecular size of an antigen can be ascertained using immunoblotting techniques (Western blots) on various tissue lysates (16). However, not all antibodies will work for this method and the need for a range of different functional antibodies of the same specificity should be appreciated. 3.1.3 Therapeutic applications of monoclonal antibodies Murine monoclonal antibodies are now the mainstay of virtually all routine diagnostic work in clinical laboratories, where they work well. However, their use in human therapy has been mainly limited by the immune response of the host to the foreign protein, known as the human anti-mouse antibody (HAMA) response, which can be minimized by humanizing the original rodent antibody. Recent developments in human recombinant antibody construction has made available a whole new range of antibody specificities, which may increase their therapeutic applications. An antibody may be used as a specific means of delivering a toxin, radiolabel, or enzymatic prodrug to its target, or to block interactions with receptors and adhesion molecules. However, it is important to remember that a monoclonal reagent may not necessarily be monospecific, since its target epitope may also be present in different antigens or cell types. Unexpected cross-reactions arise fairly frequently and have the potential to reduce clinical efficacy or cause pathological problems (31). Different specific antibodies may have different effects on the target, such as neutralization, lysis, opsonization, or antibody-dependent cytotoxicity. The most useful antibodies for therapy are those that are specific for tumour cellsurface markers, or those that can inactivate infectious agents or manipulate the immune system. The first monoclonal antibody to be approved for therapy was OKT3 in 1986 (32): this recognizes the human T-lymphocyte CD3 complex of the T-cell receptor, causing shedding of their surface T-cell receptor complexes. OKT3 has been a particularly useful immunosuppressive agent against T cell-mediated rejection of solid organ transplants. Similarly, anti CD-4 monoclonal antibody treatment has reduced synovial inflammation in patients with early rheumatoid arthritis (33) and has also been used to treat Crohn's disease (34). Humanized antibodies are made by replacing the constant regions of the rodent antibody with the human equivalent components. This technique has been extended so that just the antigen-binding CDR loops of the rodent antibody are grafted into the human framework. The first example of a fully humanized CDR-grafted antibody of therapeutic potential was CAMPATH1H (35). This was derived from a series of rat monoclonal antibodies specific for the differentiation antigen CD52, which is strongly expressed on virtually all human lymphocytes and monocytes, but not on other blood cells— including haemopoietic stem cells. This antibody has therapeutic potential for the treatment of various lymphoid malignancies, the control of graft versus host disease (GVHD) in bone-marrow transplantation, and the prevention of 89
Judy M. Bastin bone-marrow and organ rejection. Clinical results using this humanized antibody have been very encouraging (36). Monoclonal antibody treatment of lymphoid malignancies has brought some success. There is a humanized antibody against a form of the interleukin-2 receptor (IL-2R alpha) that is absent from resting T cells but present on abnormal T cells in some leukaemias and lymphomas, and on effector T cells involved in GVHD and allograft rejection. In clinical trials, a significant proportion of patients had partial or complete remissions without an antiglobulin response (37). More recently, use of a chimeric antibody directed against the B-cell specific antigen CD20 expressed on non-Hodgkin's lymphomas have been encouraging (38). The treatment of solid tumours has been less successful, although human monoclonal antibodies have been produced against melanomas (24), carcinomas of the colon (39), ovary (40), breast (41), and lung (42). There are few reports of the clinical use of solid tumour-specific antibodies, but recent preliminary data suggests that an antibody specific for an antigen (HER2/neu) expressed in an aggressive form of breast cancer, conjugated with a T-cell costimulatory molecule, B7.1, can improve the outcome for some patients (43).
3.2 T-cell hybridomas The uses of T-cell hybridomas are definitely more limited, particularly now that there are better methods for maintaining continuous T-cell cultures. Nevertheless, T-cell hybridomas can be useful when studies on more physiologically relevant T-cell populations are impossible. 3.2.1 Antigen presentation One of the most useful applications of T-cell hybridomas is in the study of antigen presentation. Antigen-specific CD4+ T-cell hybridomas will produce cytokines after specific stimulation, and this technique has been used in studies of the mechanisms of protection in diabetes (44) and the characterization of immunodominant and protective influenza haemagglutinin epitopes (45). Similarly, acetylcholine receptor-specific T-cell hybridomas have been used to study the autoimmune disorder myasthenia gravis (46, 47). Allergenspecific T-cell hybridomas have been used to study IL-5 production in cells from asthma patients (48), and hybridomas generated from lamina propria lymphocytes have been studied to examine the regulation of interleukin release by prostaglandin E2 in intestinal lymphocyte populations (49, 50). 3.2.2 Apoptosis T-cell hybridomas were used in the initial identification of the cell-surface molecules Fas and Fas-ligand involved in apoptosis (51). The inhibition of Fas-ligand upregulation in HIV-infected individuals (52), and the regulation of Fas and Fas-ligand by cyclosporin (53) were both studied using T-cell hybridomas. 90
4: B- and T-cell Hybridomas 3.2.3 Metastasis and adhesion T-cell hybridomas are highly metastatic, which can be demonstrated by the extent of their invasiveness in fibroblast cultures: this process depends on the activation of LFA-1. Activation of G proteins induces LFA 1-mediated adhesion of T-cell hybridoma cells to the intercellular adhesion molecule ICAM-1 by signal pathways that differ from those involved in phorbol esterinduced adhesion (54). The same author has used T-cell hybridomas to study metastasis reduction (55). In other studies, T-cell hybridomas were used to study the modulation of T-cell endothelial adhesion by astrocyte-conditioned medium (56), thus providing some insights into the physiological properties of the blood-brain barrier. 3.2.4 Other uses of T-cell hybridomas Some interesting applications of T-cell hybridomas include looking at the role of non-anchor residues of Db restricted peptides in class I binding and TCR triggering (57), studies of T-cell tolerance (58), vaccine design (59, 60), T-cell receptors, and superantigens (61). The use of a T-cell hybridoma to study mechanisms of antigen processing and presentation by a murine myoblast cell line (62) led to the increasing use of DNA constructs as a means of vaccination. Thus the original discovery of Kohler and Milstein back in 1975 has led to the distinctive and exciting discipline of hybridoma technology as it is today. These monoclonal reagents will undoubtedly continue to contribute to many areas of medical research.
References 1. Kohler, G. and Milstein, C. (1975). Nature, 256,495. 2. Kontianen, S., Simpson, E., Bohrer, S., Beverley, P. C. L., Herzenberg, L. A., Fitzpatrick, W. C., Vogt, P., Torano, A., McKenzie, I. F. C., and Feldman, M. (1978). Nature, 274,477. 3. Taniguchi, M. and Miller, J. F. A. P. (1978). J. Exp. Med., 148, 373. 4. Freshney, R. I. (1983). Culture of animal cells. A manual of basic technique. Alan R. Liss Inc., New York. 5. Torres, A. R., Healey, M. C., Johnston, A. V., and McKnight, M. E. (1992). Hum. Antibod. Hybridomas, 3, 206. 6. Lane, D., Crissman, R., and Lachman, M. (1984). J. Immunol. Methods, 72,71. 7. Littlefield, J. W. (1964). Science, 145, 709. 8. Bennett, B., Check, I. J., Olsen, M. R., and Hunter, R. L. (1992). J. Immunol. Methods, 153, 31. 9. Kenney, J. S, Hughes, B. W., Masada, M. P., and Allison, A. C. (1984). /. Immunol. Methods, 121, 157. 10. Bastin, J. M., Jones, M., O'Callaghan, C., Schimanski, L., Mason, D., and Townsend, A. (1998). Brit. J. HaemotoL, 103, 931. 91
Judy M. Bastin 11. Shulman, M., Wilde, C. D., and Kohler, G. (1978). Nature, 276, 269. 12. Kearney, J. F., Radbruch, A., Liesegang, B., and Rajewsky, K. (1979). /. Immunol., 123, 1548. 13. Kohler, G., Howe, S. C., and Milstein, C. (1976). Eur. J. Immunol., 6,292. 14. Galfre, G. and Milstein, C. (1981). Methods in enzymology, Vol. 73B, 3. 15. King, L. B. and Ashwell, J. D. (1993). Curr. Opin. Immunol., 5,368. 16. Coligan, J., Kruisbeck, A., Marguiles, D., Shevach, E., and Strober, W. (1994). Current protocols in immunology. National Institutes of Health, USA. John Wiley & Sons Inc. 17. Sjogren-Jansson, E. and Jeansson, S. (1985). J. Immunol. Methods, 84, 359. 18. Pannell, R. and Milstein, C. (1992). J. Immunol. Methods, 146, 43. 19. Andersen, B. G. and Gruenberg, M. L. (1987). In Commercial production of monoclonal antibodies: a guide for scale-up (ed. S. S. Seaver), p. 175. Marcel Dekker, NY. 20. von Wedel, R. J. (1987). In Commercial production of monoclonal antibodies., a guide for scale-up (ed. S. S. Seaver), p. 159. Marcel Decker, NY. 21. Croce, C. M., Linnenbach, A., Hall, W., Steplewski, Z., and Koprowski, H. (1980). Nature, 288, 488. 22. Olsson, L. and Kaplan, H. S. (1980). Proc. Natl Acad. Sci. USA, 77, 5429. 23. Zola, H. (1995). Monoclonal antibodies the second generation. Bios Scientific Publishers Ltd., Oxford. 24. Yielding, N. M., Gerstner, C., and Kirkwood, J. M. (1992). Int. J. Cancer, 52, 967. 25. Le, J., Vilcek, J., Saxinger, C., and Prensky, W. (1982). Proc. Natl. Acad. Sci. USA, 79,7857. 26. Kobayashi, Y., Asada, M., Higuchi, M., and Osawa, T. (1982). J. Immunol., 128, 2714. 27. Gravekamp, C., Santoli, D., Vreudenhil, R., Collard, J. G., and Bolhuis, R. L. (1987). Hybridoma, 6,121. 28. Galfre, G., Howe, S. C., Milstein, C., Butcher, G. W., and Howard, J. C. (1977). Nature, 266, 550. 29. Schlossman, S. F. (1993). Proceedings of Fifth International Workshop on White Cell Differentiation Antigens. 3-7 Nov. 1993. Oxford University Press. Boston, USA. 30. Beesley, J. E. (ed.) (1993). Immunocytochemistry: a practical approach. IRL Press. Oxford. 31. Ghosh, S. and Campbell, A. M. (1986). Immunol. Today, 7, 217. 32. Ortho Multi Centre Study Group (1985). N. Engl. J. Med., 313, 337. 33. Tak, P. P., Van der Lubbe, P. A., Cauli, A., Daha, M. R., Smeets, T. J. M., Kluin, P. M., Meinders, A. E., Yanni, G., Panayi, G. S., and Breedveld, F. C. (1997). Arthritis Rheum., 38, 1457. 34. Stronkhorst, A., Radema, S., Yong, S. L., Bijl, H., Ten Berge, I. J. M., Tytgat, G. N. J., and van Deventer, S. J. H. (1997). Gut, 40, 320. 35. Reichmann, L., Clark, M., and Waldmann, H. (1988). Nature, 332, 323. 36. Lockwood, C. M., Thiru, S., Stewart, S., Hale, G., Isaacs, J., Wraight, P., Elliott, J., and Waldmann, H. (1996). Q. J. Med., 89, 903. 37. Queen, C., Schneider, W. P., and Waldmann, T. A. (1993). In Protein engineering of antibody molecules for prophylactic and therapeutic applications in man (ed. M. Clark), p. 159. Academic Titles, Nottingham. 92
4: B- and T-cell Hybridomas 38. Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T. M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., and Levy, R. (1997). Blood, 90, 2188. 39. Yagyu, T., Monden, T., and Baba, M. (1993). Jpn. J. Cancer Res., 84, 75. 40. Gallagher, G., al-Azzawi, R, Walsh, L. P, and Wilson, G. (1991). Clin. Exp. Immunol., S3, 92. 41. Imam, S. A., Mills, L. A., and Taylor, C. R. (1991). Br. J. Cancer, 64, 1001. 42. Kato, M., Mochezuki, K., Hashizume, S., Tachibana, H., Shirahata, S., and Murakami, H. (1993). Hum. Antibod. Hybridomas, 4, 9. 43. Challlita Eid, P. M., Penichet, M. L., Shin, S. U., Poles, T., Mosammaparast, N., Mahmood, K., Slamon, D. J., Morrison, S., and Rosenblatt, J. D. (1998). /. Immunol, 160, 3419. 44. Ludher, F., Katz, J., Benoist, C., and Mathis, D. (1998). /. Exp. Med., 187, 379. 45. Rajnavolgyi, E., Horvath, A., Gogolak, P., Toth, G. K., Fazekas, G., Fridkin, M., and Pecht, I. (1997). Eur. J. Immunol., 27, 3105, 46. Yang, B., Mclntosh, K. R., and Drachman, D. B. (1998). Clin. Immunol. Immunopathol., 86, 45. 47. Kraig, E., Pierce, J. L., Clarkin, K. Z., Standifer, N. E., Currier, P., Wall, K. A., and Infante, A. J. (1996). /. NeuroimmunoL, 71, 87. 48. Mori, A., Kaminuma, O., Suko, M., Mikami, T., Nishizaki, Y., et al. (1997). J. Allergy Clin. Immunol., 100,56. 49. Barrera, S., Lai, J., Fiocchi, C., and Roche, J. K. (1996). /. Cell. Physiol, 166,130. 50. Kimachi, K., Croft, M., and Grey, H. M. (1997). Eur. J. Immunol, 27, 3310. 51. Suda, T. and Nagata, S. (1994). J. Exp. Med., 179,873. 52. Yang, Y., Liu, Z. H., Ware, C. F., and Ashwell, J. D. (1997). Blood, 89, 550. 53. Brunner, T., Yoo, N. J., Laface, D., Ware, C. F., and Green, D. R. (1996). Int. Immun., 8,1017. 54. Driessens, M. H. E., Van Hulten, P. E. M., Van Rijthoven, E. A. M., Soede, R. D. M. and Roos, E. (1997). Exp. Cell Res., 231, 242. 55. Driessens, M. H. E., Van Rijthoven, E. A. M., La Riviere, G., and Roos, E. (1996). Blood, 88, 3116. 56. Joseph, J., Lublin, F. D., and Knobler, R. L. (1997). Glia, 21, 408. 57. Sigal, L. J. and Wylie, D. E. (1996). Mol. Immunol, 33, 1323. 58. Faure, M., Sanchez, P., Cazenave, P. A., and Rueff-Juy, D. (1997). Cell. Immunol, 180, 84. 59. Lang, T., Prina, E., Sibthorpe, D., and Blackwell, J. M. (1997). Infect. Immun., 65, 380. 60. Sela, M. and Zisman, E. (1997). FASEB J., 11, 449. 61. Fleisher, B., Necker, A., Leget, C., Malissen, B., and Romagne, F. (1996). Infect. Immun., 64, 987. 62. Garlepp, M. J., Chen, W., Tabaris, H., Baines, M., Brooks, A., and McCluskey, J. (1995). Clin. Exp. Immunol., 102, 614.
93
This page intentionally left blank
5 Murine T-cell culture KINGSTON H. G. MILLS
1. Introduction The development of techniques for propagating and cloning T cells has had a dramatic impact on the field of immunology. Indeed, the study of cellular immunology, and many aspects of molecular immunology, are now almost totally dependent on cell-culture techniques. T cells cultured from blood, spleen, lymph nodes, or other lymphoid organs have been successfully used to establish that CD4+ and CD8+ T-cell responses recognize antigen in association with major histocompatibility complex (MHC) class I or class II gene products (1, 2) and that functionally distinct T-cell subtypes can be discriminated on the basis of cytokine secretion (3). The ability to clone antigen-specific T cells has also allowed the definitive identification and functional analysis of distinct T-cell subpopulations, and has provided the ideal tools for studies on the mechanisms of antigen processing, presentation, and T-cell receptor interaction with peptide-MHC complexes. Furthermore, the study of T-cell subtypes in vitro has provided valuable information for manipulating the induction and function of these cells in vivo, and this has important implications for future developments in immunotherapy and vaccines (4).
1.1 T-cell subtypes and their role in protective immunity T cells play a major role in protection against foreign pathogens. CD8+ cytotoxic T lymphocytes (CTLs) kill target cells infected with viruses or bacteria. CD4+ T helper (Th) cells provide help for B cells in antibody production, as well as secreting a range of cytokines that are involved in a variety of immunoregulatory functions or have a direct effect on invading microorganisms (3, 5, 6). CD4+ T cells can also be divided into two subpopulations on the basis of their function and cytokine secretion (3). Th1 cells secrete interleukin (IL)-2, interferon (IFN)--y, and tumour necrosis factor (TNF)-B. They are also involved in delayed-type hypersensitivity and inflammatory responses and display CTL activity in vitro. An important function of the Th1 population in the immunological defence mechanisms in vivo is the activation of macrophages, which are stimulated to take up and kill
Kingston H. G. Mills invading microorganisms. In contrast, Th2 cells, which secrete IL-4, IL-5, IL6, and IL-10, are considered to be the true helper T cells; their secreted cytokines play a crucial role in immunoglobulin (Ig) class switching and B-cell differentiation, in particular for IgE, IgA, and IgGl antibody production (7). Although it was initially considered that cellular and humoral immunity were mediated by Th1 and Th2 subtypes, respectively, it is now clear that TH1 cells can also provide helper function for specific IgG subclasses, especially those involved in opsonization and virus neutralization (8, 9). Furthermore, the Th1 and Th2 subpopulations are reciprocally regulated through a range of cytokines such as IFN-y, IL-4, IL-10, IL-12, and IL-18 secreted by T cells or by cells of the innate immune system (8, 10).
1.2 Strategies for the induction of distinct T-cell subtypes CD4+ and CD8+ T cells respond to antigens that are processed and presented by antigen-presenting cells (APCs) using distinct mechanisms (11-13). CD4+ T cells recognize exogenous antigen in association with MHC class II molecules. Internalized antigens are processed in endosomes into short fragments or peptides which bind to the MHC class II molecules, and Tcell receptors of CD4+ T cells specific for that T-cell epitope interact with the peptide-MHC complex, following expression on the surface of APCs (12, 13). In contrast, CD8+ T cells recognize endogenous antigen in association with MHC class I molecules (1, 13). Therefore CD4+ T cells are readily generated following immunization with killed bacteria, viruses, or purified antigens, whereas the induction of CD8+ T cells normally requires the antigen to be synthesized in the APC, for example a viral antigen in a virus-infected cell. The use of live attenuated microorganisms as vectors, such as the expression of the foreign antigen in a vaccinia virus or attenuated salmonella, provides an alternative means of allowing the induction of CD8+ T-cell responses. The induction of CD8+ class I-restricted T-cell responses is more difficult with non-replicating pathogens or purified recombinant proteins. However, it has been demonstrated that live or killed bacteria or purified antigens, presented in adjuvant formulations based on particles, emulsions, or lipids, can allow exogenous antigen to gain access to the endogenous processing route for presentation to class I-restricted T cells (14, 15). The nature of the antigen, dose, choice of adjuvant, route of immunization, and number of inoculations are all known to affect the strength, duration, and repertoire of T-cell responses (4). The choice of live virulent, live attenuated, or killed whole virus or bacteria, as well as a purified native subunit, live or purified recombinants, or naked DNA as the immunogen considerably influence the induction of T-cell responses in both qualitative and quantitative terms. In general, the longer the immune system is exposed to an antigen, the stronger and more persistent is the T-cell response. Immunization with soluble proteins, including purified native or recombinant antigens, results in 96
5: Murine T-cell culture weak and transient T-cell responses, and when given by a mucosal route (e.g. oral or intranasal) it can result in a state of immunological tolerance. A variety of experimental adjuvants and delivery systems can be used to boost the immune response to the injected antigen. These work by a number of mechanisms, such as: • maintaining the antigen at the site of inoculation for longer; • enhancing antigen uptake through particle formation; • by including components, such as bacterial products, that stimulate innate immune responses. Freund introduced the classical adjuvant for experimental use over 50 years ago. It consists of water in a mineral-oil emulsion containing killed whole mycobacteria. Although this adjuvant is highly effective for inducing antibody and T-cell responses, it is highly toxic and unsuitable for human use. Aluminium salts (aluminium hydroxide and aluminium phosphate) were first used in the 1920s and are still the adjuvants of choice for human immunization. Although used with success in a number of current vaccines (e.g. diphtheria, tetanus, and pertussis; hepatitis B; and killed poliovirus), this adjuvant often induces weak, transient immune responses, especially with soluble, non-particulate protein antigens, thus favouring the induction of Th2 cells in mice (15, 16). The addition of heat-killed Bordetella pertussis has been used experimentally to boost the immune response to alum-adsorbed antigens. This appears to function through the adjuvant effect of lipopolysaccharide (LPS) and pertussis toxin (17, 18). A number of new generation adjuvants and antigen-presenting systems that encompass the properties of Freund's complete adjuvant or alum have recently been developed. Liposomes, immunostimulating complexes (ISCOMs), biocompatible microparticles, or metabolizable oil in water emulsions (4) can replace the particulate nature of the toxic mineral-oil emulsion of Freund's adjuvant. Furthermore, the crude killed bacteria have been replaced by non-toxic bacterial derivatives, such as muramyl dipeptide or monophosphoryl lipid A, or non-toxic mutants of bacterial toxins (16, 18). These molecules enhance acquired immunity by stimulating innate immune responses, such as IL-12 production and B7 expression by APCs (16-18). These approaches can also be used for the selective stimulation of Th1 or Th2 cells, an important consideration in the generation of T-cell clones. Injection of antigen by a systemic route (subcutaneous, intraperitoneal, or intramuscular) is most commonly used and generates the most potent circulating antibody and T-cell responses. We have demonstrated that immunization by the intraperitoneal route favours the induction of Th1 cells, while the subcutaneous route favours Th2 cells (15, 19). However, the majority of infectious pathogens enter the body by a mucosal route, where local immune responses may be an important first line of defence. The role of 97
Kingston H. G. Mills secretory IgA, induced by immunization at any of the common sites of the mucosal system, is well documented against a variety of human pathogen (20). However, the role of local T cells and their induction has been more difficult to evaluate. Nevertheless, there is evidence that immunization at mucosal sites can induce local and systemic T-cell responses (15). It appears that immunization at mucosal surfaces may favour the induction of Th2 cells, and this is consistent with the role of IL-4 and IL-5 in class-switching to IgA.
1.3 Techniques for detecting T-cell responses Once a T-cell response is induced in vivo, the response can be detected in vitro using a variety of laboratory assays. One of the simplest and most routinely used techniques to detect T-cell responses is the proliferation assay. However, this method is relatively crude, and in its simplest form cannot discriminate between T cells of different phenotypes or functions—or even between T cells and B cells, which can also proliferate in response to foreign antigen. More recently, the detection of T-cell responses has encompassed a sophisticated range of assays that can discriminate between the responding population on the basis of their function or cytokine production. Semi-purified mononuclear leucocyte preparations can be used ex vivo for many of the assays used to detect T-cell responses. Since almost all assays involve T-cell recognition of antigen as the first step, a source of APCs as well as T cells is necessary. Unseparated spleen or lymph node cells and densitygradient separated peripheral blood mononuclear cells are rich sources of lymphocytes and also contain sufficient monocytes/macrophages, and other cells, that can function as APCs without further additions. Although contaminated with relatively small numbers of polymorphs and red blood cells, spleen cells can be used for many of the T-cell assays without further separation. Where necessary, the contaminating cells can be removed by density-gradient centrifugation. Although these relatively crude mononuclear cell preparations, which include T cells, B cells, monocytes, dendritic cells, natural killer (NK) cells, and other non-conventional lymphoid cells, can be used for most assays, they do not allow discrimination of the responding T-cell subpopulation. Furthermore, for the assays of T-cell function (e.g. helper or CTL assays) purified T cells, CD4+ or CD8+ T-cell subpopulations, B cells, or APCs are required. A range of methods can be used to purify and separate lymphocyte subpopulations. T cells can be enriched from density-gradient purified mononuclear cells by passage through a nylon-wool column, resetting with ox erythrocytes coupled with anti-mouse IgG (21), or by depletion of B cells on Ig-coated pla